published_papers "タイトル(日本語)","タイトル(英語)","著者(日本語)","著者(英語)","担当区分","概要(日本語)","概要(英語)","出版者・発行元(日本語)","出版者・発行元(英語)","出版年月","誌名(日本語)","誌名(英語)","巻","号","開始ページ","終了ページ","記述言語","査読の有無","招待の有無","掲載種別","国際・国内誌","国際共著","DOI","ISSN","eISSN","URL","URL2","主要な業績かどうか","公開の有無" "Cross-Sectional and Longitudinal Associations between Skin Autofluorescence and Tubular Injury Defined by Urinary Excretion of Liver-Type Fatty Acid-Binding Protein in People with Type 2 Diabetes.","Cross-Sectional and Longitudinal Associations between Skin Autofluorescence and Tubular Injury Defined by Urinary Excretion of Liver-Type Fatty Acid-Binding Protein in People with Type 2 Diabetes.","Hiroki Yamagami, Tomoyo Hara, Saya Yasui, Minae Hosoki, Taiki Hori, Yousuke Kaneko, Yukari Mitsui, Kiyoe Kurahashi, Takeshi Harada, Sumiko Yoshida, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe, Ken-ichi Aihara","Hiroki Yamagami, Tomoyo Hara, Saya Yasui, Minae Hosoki, Taiki Hori, Yousuke Kaneko, Yukari Mitsui, Kiyoe Kurahashi, Takeshi Harada, Sumiko Yoshida, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe, Ken-ichi Aihara","null","= 0.026). In conclusion, SAF is positively correlated with uL-FABP but not with uACR in people with T2D. Thus, there is a possibility that SAF can serve as a novel predictor for the development of diabetic tubular injury.","= 0.026). In conclusion, SAF is positively correlated with uL-FABP but not with uACR in people with T2D. Thus, there is a possibility that SAF can serve as a novel predictor for the development of diabetic tubular injury.","null","null","2023-11-10","Biomedicines","Biomedicines","Vol.11","No.11","null","null","eng","true","null","scientific_journal","null","null","10.3390/biomedicines11113020","2227-9059","null","null","null","null","null" "Dehydroepiandrosterone Sulfate, an Adrenal Androgen, Is Inversely Associated with Prevalence of Dynapenia in Male Individuals with Type 2 Diabetes.","Dehydroepiandrosterone Sulfate, an Adrenal Androgen, Is Inversely Associated with Prevalence of Dynapenia in Male Individuals with Type 2 Diabetes.","Saya Yasui, Yousuke Kaneko, Hiroki Yamagami, Minae Hosoki, Taiki Hori, Akihiro Tani, Tomoyo Hara, Kiyoe Kurahashi, Takeshi Harada, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Hiroyasu Mori, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Takeshi Soeki, Ken-ichi Aihara","Saya Yasui, Yousuke Kaneko, Hiroki Yamagami, Minae Hosoki, Taiki Hori, Akihiro Tani, Tomoyo Hara, Kiyoe Kurahashi, Takeshi Harada, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Hiroyasu Mori, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Takeshi Soeki, Ken-ichi Aihara","null","Dehydroepiandrosterone sulfate (DHEAS) is thought to be associated with life expectancy and anti-aging. Although skeletal muscle disorders are often found in diabetic people, the clinical significance of DHEAS in skeletal muscle remains unclear. Therefore, we aimed to determine whether DHEAS is associated with the development of skeletal muscle disorders in individuals with type 2 diabetes (T2D). A cross-sectional study was conducted in 361 individuals with T2D. Serum DHEAS levels, skeletal muscle mass index (SMI), handgrip strength (HS), and gait speed (GS) were measured in the participants. Pre-sarcopenia, sarcopenia, and dynapenia were defined according to the definitions of the AWGS 2019 criteria. DHEAS level was positively associated with HS but not with SMI or GS after adjustment of confounding factors. Multiple logistic regression analyses in total subjects showed that DHEAS level had an inverse association with the prevalence of dynapenia but not with the prevalence of pre-sarcopenia or sarcopenia. Furthermore, a significant association between DHEAS level and dynapenia was found in males but not in females. ROC curve analysis indicated that cutoff values of serum DHEAS for risk of dynapenia in males was 92.0 μg/dL. Therefore, in male individuals with T2D who have low serum levels of DHEAS, adequate exercise might be needed to prevent dynapenia.","Dehydroepiandrosterone sulfate (DHEAS) is thought to be associated with life expectancy and anti-aging. Although skeletal muscle disorders are often found in diabetic people, the clinical significance of DHEAS in skeletal muscle remains unclear. Therefore, we aimed to determine whether DHEAS is associated with the development of skeletal muscle disorders in individuals with type 2 diabetes (T2D). A cross-sectional study was conducted in 361 individuals with T2D. Serum DHEAS levels, skeletal muscle mass index (SMI), handgrip strength (HS), and gait speed (GS) were measured in the participants. Pre-sarcopenia, sarcopenia, and dynapenia were defined according to the definitions of the AWGS 2019 criteria. DHEAS level was positively associated with HS but not with SMI or GS after adjustment of confounding factors. Multiple logistic regression analyses in total subjects showed that DHEAS level had an inverse association with the prevalence of dynapenia but not with the prevalence of pre-sarcopenia or sarcopenia. Furthermore, a significant association between DHEAS level and dynapenia was found in males but not in females. ROC curve analysis indicated that cutoff values of serum DHEAS for risk of dynapenia in males was 92.0 μg/dL. Therefore, in male individuals with T2D who have low serum levels of DHEAS, adequate exercise might be needed to prevent dynapenia.","null","null","2023-11-03","Metabolites","Metabolites","Vol.13","No.11","null","null","eng","true","null","scientific_journal","null","null","10.3390/metabo13111129","2218-1989","null","null","null","null","null" "Albuminuria and Serum Tumor Necrosis Factor Receptor Levels in Patients with Type 2 Diabetes on SGLT2 Inhibitors: A Prospective Study.","Albuminuria and Serum Tumor Necrosis Factor Receptor Levels in Patients with Type 2 Diabetes on SGLT2 Inhibitors: A Prospective Study.","Toshiki Otoda, Akiko Sekine, Ryoko Uemoto, Seijiro Tsuji, Tomoyo Hara, Motoyuki Tamaki, Tomoyuki Yuasa, Toshiaki Tamaki, Munehide Matsuhisa, Ken-ichi Aihara","Toshiki Otoda, Akiko Sekine, Ryoko Uemoto, Seijiro Tsuji, Tomoyo Hara, Motoyuki Tamaki, Tomoyuki Yuasa, Toshiaki Tamaki, Munehide Matsuhisa, Ken-ichi Aihara","null","(interquartile range (IQR) 23.1-28.9), and the median HbA1c level was 7.3% (IQR 6.9-8.3). After SGLT2i administration, the uACR declined from 19.2 mg/gCr (IQR 7.1-48.7) to 13.3 mg/gCr (IQR 7.5-31.6), whereas the uL-FABPCR was not influenced. In univariate analysis, the change in log-transformed uACR due to SGLT2i administration showed a positive correlation with the change in serum TNFR1 level (R = 0.244, p < 0.01). Multivariate regression analysis, including confounding factors, showed that the changes in serum TNFR1 level were independently associated with the changes in the log-transformed uACR (independent t = 2.102, p < 0.05).","UMIN000031947.","null","null","2023-10-26","Diabetes therapy : research, treatment and education of diabetes and related disorders","Diabetes therapy : research, treatment and education of diabetes and related disorders","Vol.15","No.1","127","143","eng","true","null","scientific_journal","null","null","10.1007/s13300-023-01488-0","1869-6953","null","null","null","null","null" "Impact of COVID-19 pandemic on behavioral changes and glycemic control and a survey of telemedicine in patients with diabetes: A multicenter retrospective observational study.","Impact of COVID-19 pandemic on behavioral changes and glycemic control and a survey of telemedicine in patients with diabetes: A multicenter retrospective observational study.","Ryotaro Bouchi, Takehiro Sugiyama, Atsushi Goto, Mitsuru Ohsugi, Narihito Yoshioka, Hideki Katagiri, Tomoya Mita, Yushi Hirota, Hiroshi Ikegami, Munehide Matsuhisa, Eiichi Araki, Hiroki Yokoyama, Masae Minami, Katsuya Yamazaki, Hideaki Jinnouchi, Hiroki Ikeda, Hitomi Fujii, Miyuki Nogawa, Masahiro Kaneshige, Kengo Miyo, Kohjiro Ueki","Ryotaro Bouchi, Takehiro Sugiyama, Atsushi Goto, Mitsuru Ohsugi, Narihito Yoshioka, Hideki Katagiri, Tomoya Mita, Yushi Hirota, Hiroshi Ikegami, Munehide Matsuhisa, Eiichi Araki, Hiroki Yokoyama, Masae Minami, Katsuya Yamazaki, Hideaki Jinnouchi, Hiroki Ikeda, Hitomi Fujii, Miyuki Nogawa, Masahiro Kaneshige, Kengo Miyo, Kohjiro Ueki","null","The HbA1c levels were comparable between 2019 (7.27 ± 0.97%), 2020 (7.28 ± 0.92%), and 2021 (7.25 ± 0.94%) without statistical difference between each of those 3 years. Prescriptions for diabetes medications increased during the period. The frequency of eating out was drastically reduced (51.7% in 2019; 30.1% in 2020), and physical activity decreased during the pandemic (48.1% in 2019; 41.4% in 2020; 43.3% in 2021). Both patients and physicians cited increased convenience and reduced risk of infection as their expectations for telemedicine, while the lack of physician-patient interaction and the impossibility of consultation and examination were cited as sources of concern.","Our data suggest that glycemic control did not deteriorate during the COVID-19 pandemic with appropriate intensification of diabetes treatment in patients with diabetes who continued to attend specialized diabetes care facilities, and that patients and physicians shared the same expectations and concerns about telemedicine.","null","null","2023-05-15","Journal of Diabetes Investigation","Journal of Diabetes Investigation","Vol.14","No.8","994","1004","eng","true","null","scientific_journal","null","null","10.1111/jdi.14027","2040-1124","null","null","null","null","null" "Vascular Endothelial Function Is Associated with eGFR Slope in Female and Non-Smoking Male Individuals with Cardiovascular Risk Factors: A Pilot Study on the Predictive Value of FMD for Renal Prognosis.","Vascular Endothelial Function Is Associated with eGFR Slope in Female and Non-Smoking Male Individuals with Cardiovascular Risk Factors: A Pilot Study on the Predictive Value of FMD for Renal Prognosis.","Shiho Masuda, Tomoyo Hara, Hiroki Yamagami, Yukari Mitsui, Kiyoe Kurahashi, Sumiko Yoshida, Takeshi Harada, Toshiki Otoda, Tomoyuki Yuasa, Shingen Nakamura, Akio Kuroda, Itsuro Endo, Toshio Matsumoto, Munehide Matsuhisa, Masahiro Abe, Ken-ichi Aihara","Shiho Masuda, Tomoyo Hara, Hiroki Yamagami, Yukari Mitsui, Kiyoe Kurahashi, Sumiko Yoshida, Takeshi Harada, Toshiki Otoda, Tomoyuki Yuasa, Shingen Nakamura, Akio Kuroda, Itsuro Endo, Toshio Matsumoto, Munehide Matsuhisa, Masahiro Abe, Ken-ichi Aihara","null","In individuals with cardiovascular risk factors, evaluation of vascular endothelial function enables prediction of renal prognosis in females and non-smoking males.","In individuals with cardiovascular risk factors, evaluation of vascular endothelial function enables prediction of renal prognosis in females and non-smoking males.","null","null","2023-04-19","Journal of Atherosclerosis and Thrombosis","Journal of Atherosclerosis and Thrombosis","null","null","null","null","eng","true","null","scientific_journal","null","null","10.5551/jat.63987","1880-3873","null","null","null","null","null" "Phase angle and extracellular water-to-total body water ratio estimated by bioelectrical impedance analysis are associated with levels of hemoglobin and hematocrit in patients with diabetes.","Phase angle and extracellular water-to-total body water ratio estimated by bioelectrical impedance analysis are associated with levels of hemoglobin and hematocrit in patients with diabetes.","Taiki Hori, Shingen Nakamura, Hiroki Yamagami, Saya Yasui, Minae Hosoki, Tomoyo Hara, Yukari Mitsui, Shiho Masuda, Kiyoe Kurahashi, Sumiko Yoshida, Takeshi Harada, Akio Kuroda, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe, Ken-ichi Aihara","Taiki Hori, Shingen Nakamura, Hiroki Yamagami, Saya Yasui, Minae Hosoki, Tomoyo Hara, Yukari Mitsui, Shiho Masuda, Kiyoe Kurahashi, Sumiko Yoshida, Takeshi Harada, Akio Kuroda, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe, Ken-ichi Aihara","null","PhA and ECW/TBW but not SMI were associated with levels of Hgb and Hct in patients with diabetes. Therefore, aberrant values of PhA and ECW/TBW suggest a risk of anemia in diabetic patients.","PhA and ECW/TBW but not SMI were associated with levels of Hgb and Hct in patients with diabetes. Therefore, aberrant values of PhA and ECW/TBW suggest a risk of anemia in diabetic patients.","null","null","2023-03-21","Heliyon","Heliyon","Vol.9","No.4","null","null","eng","true","null","scientific_journal","null","null","10.1016/j.heliyon.2023.e14724","2405-8440","null","null","null","null","null" "Use of iGlarLixi for the Management of Type2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study.","Use of iGlarLixi for the Management of Type2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study.","Hideaki Miyoshi, Munehide Matsuhisa, Daisuke Yabe, Yoko Takahashi, Yukiko Morimoto, Yasuo Terauchi","Hideaki Miyoshi, Munehide Matsuhisa, Daisuke Yabe, Yoko Takahashi, Yukiko Morimoto, Yasuo Terauchi","null","In participants with suboptimal glycaemic control on various regimens, 6 months of iGlarLixi treatment improved HbA1c in all but one prior treatment subgroup (GLP-1 RA + BI), and was generally well tolerated.","UMIN-CTR Trials Registry, UMIN000044126; registered 10 May 2021.","null","null","2023-02-21","Diabetes Therapy","Diabetes Therapy","Vol.14","No.4","671","689","eng","true","null","scientific_journal","null","null","10.1007/s13300-023-01373-w","1869-6953","null","null","null","null","null" "Umami taste sensitivity is associated with food intake and oral environment in subjects with diabetes","Umami taste sensitivity is associated with food intake and oral environment in subjects with diabetes","川上 歩花, 板東 美香, 髙士 友恵, 杉内 美月, Mizusa Hyodo, 三島 優奈, Masashi Kuroda, 森 博康, 黒田 暁生, 湯本 浩通, 松久 宗英, 阪上 浩, 堤 理恵","Ayuka Kawakami, Mika Bandou, Tomoe Takashi, Mizuki Sugiuchi, Mizusa Hyodo, Yuna Mishima, Masashi Kuroda, Hiroyasu Mori, Akio Kuroda, Hiromichi Yumoto, Munehide Matsuhisa, Hiroshi Sakaue, Rie Tsutsumi","null","Dysgeusia is a serious problem in patients with diabetes because it often leads to overeating, which is associated with disease progression. This study aimed to investigate the association between taste sensitivity, eating habits, and the oral environment. In this cross-sectional study of 75 subjects with diabetes, gustatory function was assessed using the whole-mouth method, and lingual taste receptor gene expression was measured by real-time PCR. Food intake was evaluated using a food frequency questionnaire based on food groups. The oral environment was assessed using xerostomia and periodontal comprehensive examination. In total, 45.3%, 28.0%, and 18.7% of subjects showed lower umami taste sensitivity, low sweet taste sensitivity, and low salt taste sensitivity, respectively. Lower umami sensitivity correlated with lower estimated glomerular filtration rate and higher energy-source food intake. Subjects with diabetes with higher plaque control record showed significantly higher T1R3 gene expression than those with lower plaque control record. Reduced umami taste sensitivity is associated with decreased renal function and high energy food intake in diabetes. Subjects with diabetes with higher plaque control record showed significantly higher T1R3 gene expression, suggesting that the oral environment affects taste gene expression. J. Med. Invest. 70 : 241-250, February, 2023.","Dysgeusia is a serious problem in patients with diabetes because it often leads to overeating, which is associated with disease progression. This study aimed to investigate the association between taste sensitivity, eating habits, and the oral environment. In this cross-sectional study of 75 subjects with diabetes, gustatory function was assessed using the whole-mouth method, and lingual taste receptor gene expression was measured by real-time PCR. Food intake was evaluated using a food frequency questionnaire based on food groups. The oral environment was assessed using xerostomia and periodontal comprehensive examination. In total, 45.3%, 28.0%, and 18.7% of subjects showed lower umami taste sensitivity, low sweet taste sensitivity, and low salt taste sensitivity, respectively. Lower umami sensitivity correlated with lower estimated glomerular filtration rate and higher energy-source food intake. Subjects with diabetes with higher plaque control record showed significantly higher T1R3 gene expression than those with lower plaque control record. Reduced umami taste sensitivity is associated with decreased renal function and high energy food intake in diabetes. Subjects with diabetes with higher plaque control record showed significantly higher T1R3 gene expression, suggesting that the oral environment affects taste gene expression. J. Med. Invest. 70 : 241-250, February, 2023.","null","null","2023-02-05","The Journal of Medical Investigation : JMI","The Journal of Medical Investigation : JMI","Vol.70","No.1.2","241","250","jpn","true","null","scientific_journal","null","null","10.2152/jmi.70.241","1349-6867","null","null","null","null","null" "Chronic Intake of a Meal Including Alaska Pollack Protein Increases Skeletal Muscle Mass and Strength in Healthy Older Women: A Double-Blind Randomized Controlled Trial","Chronic Intake of a Meal Including Alaska Pollack Protein Increases Skeletal Muscle Mass and Strength in Healthy Older Women: A Double-Blind Randomized Controlled Trial","Hiroyasu Mori, Yasunobu Tokuda, Eriko Yoshida, Kenji Uchida, Munehide Matsuhisa","Hiroyasu Mori, Yasunobu Tokuda, Eriko Yoshida, Kenji Uchida, Munehide Matsuhisa","null","In animal studies, a meal containing Alaska pollack protein (APP) induces fast-twitch muscle hypertrophy. To our knowledge, no interventional studies have examined the benefits of APP intake on muscle mass and muscle weakness and the prevention of sarcopenia in older individuals. We evaluated the effects of APP intake on skeletal muscle mass, muscle strength, and physical performance among healthy community-dwelling older Japanese women. In this double-blind randomized controlled trial, healthy women 65 y old were allocated to an APP or whey protein control (CON) group. Participants ingested test protein meals (5.0-5.1 g protein/serving) daily for 24 wk. Between-group differences in the change of skeletal muscle mass index (SMI) as the primary outcome and muscle strength as a secondary outcome were tested using multifrequency BIA and a handheld dynamometer, respectively, at baseline, and 4, 12, and 24 wk. The mean changes in the measured primary and secondary outcome variables from baseline to 4, 12, and 24 wk were compared using unpaired t tests. There were no between-group differences in nutritional status, food intake, or total energy and protein intakes at baseline, 12 wk, or 24 wk. The change in SMI was 0.12 kg/m2 (95% CI: 0.01, 0.23 kg/m2) and 0.11 kg/m2 (95% CI: 0.03, 0.19 kg/m2) greater in the APP group than in the CON group at 12 wk and 24 wk (P 0.03) and knee extension strength was 0.07 Nm/kg BW (95% CI: 0.02, 0.12 Nm/kg BW) and 0.05 Nm/kg BW (95% CI: 0.00, 0.09 Nm/kg BW) higher in the APP group than in the CON group at these times (P 0.015), respectively. The groups did not differ at 4 wk. Daily intake of a meal containing APP compared with whey protein increases skeletal muscle mass and lower-extremity muscle strength in healthy older women, suggesting that an APP-containing meal may be useful in the prevention of sarcopenia in this group.This trial was registered at as UMIN000035718.","In animal studies, a meal containing Alaska pollack protein (APP) induces fast-twitch muscle hypertrophy. To our knowledge, no interventional studies have examined the benefits of APP intake on muscle mass and muscle weakness and the prevention of sarcopenia in older individuals. We evaluated the effects of APP intake on skeletal muscle mass, muscle strength, and physical performance among healthy community-dwelling older Japanese women. In this double-blind randomized controlled trial, healthy women 65 y old were allocated to an APP or whey protein control (CON) group. Participants ingested test protein meals (5.0-5.1 g protein/serving) daily for 24 wk. Between-group differences in the change of skeletal muscle mass index (SMI) as the primary outcome and muscle strength as a secondary outcome were tested using multifrequency BIA and a handheld dynamometer, respectively, at baseline, and 4, 12, and 24 wk. The mean changes in the measured primary and secondary outcome variables from baseline to 4, 12, and 24 wk were compared using unpaired t tests. There were no between-group differences in nutritional status, food intake, or total energy and protein intakes at baseline, 12 wk, or 24 wk. The change in SMI was 0.12 kg/m2 (95% CI: 0.01, 0.23 kg/m2) and 0.11 kg/m2 (95% CI: 0.03, 0.19 kg/m2) greater in the APP group than in the CON group at 12 wk and 24 wk (P 0.03) and knee extension strength was 0.07 Nm/kg BW (95% CI: 0.02, 0.12 Nm/kg BW) and 0.05 Nm/kg BW (95% CI: 0.00, 0.09 Nm/kg BW) higher in the APP group than in the CON group at these times (P 0.015), respectively. The groups did not differ at 4 wk. Daily intake of a meal containing APP compared with whey protein increases skeletal muscle mass and lower-extremity muscle strength in healthy older women, suggesting that an APP-containing meal may be useful in the prevention of sarcopenia in this group.This trial was registered at as UMIN000035718.","null","null","2022-12","The Journal of Nutrition","The Journal of Nutrition","Vol.152","No.12","2761","2770","eng","true","null","scientific_journal","null","null","10.1093/jn/nxac219","0022-3166","null","null","null","null","null" "Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study.","Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study.","Munehide Matsuhisa, Hideaki Miyoshi, Daisuke Yabe, Yoko Takahashi, Yukiko Morimoto, Yasuo Terauchi","Munehide Matsuhisa, Hideaki Miyoshi, Daisuke Yabe, Yoko Takahashi, Yukiko Morimoto, Yasuo Terauchi","null","The full analysis set included 432 individuals, with data available at 6 months for 426. Of the 432 individuals, the mean (SD) age at baseline was 61.6 (12.8) years and the majority had a T2D duration of ≥ 10 years [mean (SD) 13.3 (10.4) years]. At 6 months, HbA1c had significantly decreased versus baseline ( -0.85%; P < 0.0001), with a greater decrease in those aged < 65 years, with a shorter duration of T2D and higher baseline HbA1c. A significant increase in the proportion of participants achieving age-specific HbA1c versus baseline was observed. Mean body weight decreased by 0.5 kg (P = 0.0034 versus baseline). There were few hypoglycemia and gastrointestinal events (in individuals with HbA1c data); no severe hypoglycemic events were reported.","UMIN-CTR Trials Registry, UMIN000044126; registered 10 May 2021.","null","null","2022-11-23","Diabetes Therapy","Diabetes Therapy","Vol.14","No.1","219","236","eng","true","null","scientific_journal","null","null","10.1007/s13300-022-01333-w","1869-6953","null","null","null","null","null" "Prevention of hypoglycemia by intermittent-scanning continuous glucose monitoring device combined with structured education in patients with type 1 diabetes mellitus: A randomized, crossover trial.","Prevention of hypoglycemia by intermittent-scanning continuous glucose monitoring device combined with structured education in patients with type 1 diabetes mellitus: A randomized, crossover trial.","Group Study ISCHIA, Munehide Matsuhisa, Akio Kuroda","Group Study ISCHIA, Munehide Matsuhisa, Akio Kuroda","null","The time below range was significantly reduced in the Intervention arm compared to the Control arm (2.42 ± 1.68 h/day [10.1 %±7.0 %] vs 3.10 ± 2.28 h/day [12.9 %±9.5 %], P = 0.012). The ratio of high-risk participants with low blood glucose index >5 was significantly reduced (8.6 % vs 23.7 %, P < 0.001).","The use of isCGM combined with structured education significantly reduced the time below range in patients with T1DM.","null","null","2022-11-14","Diabetes Research and Clinical Practice","Diabetes Research and Clinical Practice","Vol.195","null","110147","110147","eng","true","null","scientific_journal","null","null","10.1016/j.diabres.2022.110147","1872-8227","null","null","null","null","null" "Plasma Heparin Cofactor II Activity Is Inversely Associated with Hepatic Fibrosis of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus.","Plasma Heparin Cofactor II Activity Is Inversely Associated with Hepatic Fibrosis of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus.","Tomoyo Hara, Ryoko Uemoto, Akiko Sekine, Yukari Mitsui, Shiho Masuda, Hiroki Yamagami, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Yasumasa Ikeda, Itsuro Endo, Soichi Honda, Katsuhiko Yoshimoto, Akira Kondo, Toshiaki Tamaki, Toshio Matsumoto, Munehide Matsuhisa, Masahiro Abe, Ken-ichi Aihara","Tomoyo Hara, Ryoko Uemoto, Akiko Sekine, Yukari Mitsui, Shiho Masuda, Hiroki Yamagami, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Yasumasa Ikeda, Itsuro Endo, Soichi Honda, Katsuhiko Yoshimoto, Akira Kondo, Toshiaki Tamaki, Toshio Matsumoto, Munehide Matsuhisa, Masahiro Abe, Ken-ichi Aihara","null","Multiple regression analysis including confounding factors showed that plasma HCII activity independently contributed to decreases in FIB-4 index (p<0.001), NFS (p<0.001) and APRI (p=0.004). In addition, logistic regression analysis for the prevalence of advanced hepatic fibrosis defined by the cutoff points of the clinical scores showed that plasma HCII activity was the sole and common negative factor for prevalence of advanced hepatic fibrosis (FIB-4 index: p=0.002, NFS: p=0.026 and APRI: p=0.012).","Plasma HCII activity was inversely associated with clinical hepatic fibrosis indices including FIB-4 index, NFS and APRI and with the prevalence of advanced hepatic fibrosis in patients with T2DM. The results suggest that HCII can serve as a novel biomarker for assessment of hepatic fibrosis of NAFLD in patients with T2DM.","null","null","2022-10-14","Journal of Atherosclerosis and Thrombosis","Journal of Atherosclerosis and Thrombosis","null","null","null","null","eng","true","null","scientific_journal","null","null","10.5551/jat.63752","1880-3873","null","null","null","null","null" "Comparison of continuous subcutaneous insulin infusion treatment and multiple daily injection treatment on the progression of diabetic complications in Japanese patients with juvenile-onset type 1 diabetes mellitus.","Comparison of continuous subcutaneous insulin infusion treatment and multiple daily injection treatment on the progression of diabetic complications in Japanese patients with juvenile-onset type 1 diabetes mellitus.","Takafumi Masuda, Naoto Katakami, Naohiro Taya, Kazuyuki Miyashita, Mitsuyoshi Takahara, Ken Kato, Akio Kuroda, Munehide Matsuhisa, Iichiro Shimomura","Takafumi Masuda, Naoto Katakami, Naohiro Taya, Kazuyuki Miyashita, Mitsuyoshi Takahara, Ken Kato, Akio Kuroda, Munehide Matsuhisa, Iichiro Shimomura","null","To evaluate whether continuous subcutaneous insulin infusion attenuates the progression of diabetic complications, we retrospectively extracted data from 35 individuals who had developed type 1 diabetes mellitus aged ≤20 years and whose treatment had been changed from multiple daily injections to continuous subcutaneous insulin infusion. The annual changes in estimated glomerular filtration rate, urinary albumin excretion rate, carotid intima-media thickness and brachial-ankle pulse wave velocity during each treatment period were calculated. Although mean glycated hemoglobin under the continuous subcutaneous insulin infusion treatment was lower than that under the multiple daily injection treatment, there were no significant differences in annual changes in diabetic nephropathy and atherosclerosis between the two treatment periods. This pilot study showed that, in Japanese patients with juvenile-onset type 1 diabetes mellitus, there was no significant difference in the progression of diabetic nephropathy and atherosclerosis, at least in the early stage, between the two treatments.","To evaluate whether continuous subcutaneous insulin infusion attenuates the progression of diabetic complications, we retrospectively extracted data from 35 individuals who had developed type 1 diabetes mellitus aged ≤20 years and whose treatment had been changed from multiple daily injections to continuous subcutaneous insulin infusion. The annual changes in estimated glomerular filtration rate, urinary albumin excretion rate, carotid intima-media thickness and brachial-ankle pulse wave velocity during each treatment period were calculated. Although mean glycated hemoglobin under the continuous subcutaneous insulin infusion treatment was lower than that under the multiple daily injection treatment, there were no significant differences in annual changes in diabetic nephropathy and atherosclerosis between the two treatment periods. This pilot study showed that, in Japanese patients with juvenile-onset type 1 diabetes mellitus, there was no significant difference in the progression of diabetic nephropathy and atherosclerosis, at least in the early stage, between the two treatments.","null","null","2022-04-27","Journal of Diabetes Investigation","Journal of Diabetes Investigation","null","null","null","null","eng","true","null","scientific_journal","null","null","10.1111/jdi.13819","2040-1124","null","null","null","null","null" "Novel method utilizing bisulfite conversion with dual amplification-refractory mutation system polymerase chain reaction to detect circulating pancreatic β-cell cfDNA.","Novel method utilizing bisulfite conversion with dual amplification-refractory mutation system polymerase chain reaction to detect circulating pancreatic β-cell cfDNA.","Asami Okada, Misuzu Yamada-Yamashita, Yukari Tominaga, Kyoka Jo, Hiroyasu Mori, Reiko Suzuki, Masashi Ishizu, Motoyuki Tamaki, Yuko Akehi, Yuichi Takashi, Daisuke Koga, Eisuke Shimokita, Fuminori Tanihara, Kiyoe Kurahashi, Sumiko Yoshida, Yukari Mitsui, Shiho Masuda, Itsuro Endo, Ken-ichi Aihara, Shoji Kagami, Masahiro Abe, Kevin Ferreri, Yoshio Fujitani, Munehide Matsuhisa, Akio Kuroda","Asami Okada, Misuzu Yamada-Yamashita, Yukari Tominaga, Kyoka Jo, Hiroyasu Mori, Reiko Suzuki, Masashi Ishizu, Motoyuki Tamaki, Yuko Akehi, Yuichi Takashi, Daisuke Koga, Eisuke Shimokita, Fuminori Tanihara, Kiyoe Kurahashi, Sumiko Yoshida, Yukari Mitsui, Shiho Masuda, Itsuro Endo, Ken-ichi Aihara, Shoji Kagami, Masahiro Abe, Kevin Ferreri, Yoshio Fujitani, Munehide Matsuhisa, Akio Kuroda","null","We developed a novel method for detecting unmethylated insulin DNA in circulation that can be performed using a conventional real-time PCR system. This method would be useful for analyzing dynamic profiles of β-cells in human disease such as type 1 diabetes.","We developed a novel method for detecting unmethylated insulin DNA in circulation that can be performed using a conventional real-time PCR system. This method would be useful for analyzing dynamic profiles of β-cells in human disease such as type 1 diabetes.","null","null","2022-04-09","Journal of Diabetes Investigation","Journal of Diabetes Investigation","Vol.13","No.7","1140","1148","eng","true","null","scientific_journal","null","null","10.1111/jdi.13806","2040-1124","null","null","null","null","null" "Effectiveness of a Diabetes Oral Nursing Program Including a Modified Diabetes Oral Health Assessment Tool for Nurses (M-DiOHAT©): A 12-Month Follow-Up Intervention Study","Effectiveness of a Diabetes Oral Nursing Program Including a Modified Diabetes Oral Health Assessment Tool for Nurses (M-DiOHAT©): A 12-Month Follow-Up Intervention Study","Yumi Kuwamura, Sumiko Yoshida, Kiyoe Kurahashi, Masuko Sumikawa, Hiromichi Yumoto, Hirokazu Uemura, Munehide Matsuhisa","Yumi Kuwamura, Sumiko Yoshida, Kiyoe Kurahashi, Masuko Sumikawa, Hiromichi Yumoto, Hirokazu Uemura, Munehide Matsuhisa","null","This study aimed to evaluate the effectiveness of a diabetes oral nursing intervention program for individuals with diabetes. Fifty-six participants with diabetes underwent a diabetes oral nursing intervention program. The program's effect was evaluated through questionnaires and small interviews. The modified diabetes oral health assessment tool (M-DiOHAT©) was used to assess and educate four factors;oral conditions, behaviors, perceptions and knowledge about diabetes and periodontal disease, and health information-sharing, among participants at baseline, 3, 6, and 12 months later. Primary outcomes included changes in the M-DiOHAT© total scores. Secondary outcomes included scores on the motivation stage of changes in oral health behaviors' scales, dental visits, number of present teeth, hemoglobin A1c (HbA1c), and participants' comments. The M-DiOHAT© total score and the motivation stage score significantly improved with the narrative comment of ""being motivated to practice oral health behaviors"" between the baseline and 12 months later. Eight participants visited the dentist, whereas no differences were observed in the number of present teeth or HbA1c. This program improved participants' M-DiOHAT© total score, motivation stage score, and dental visits. These results suggest the program improved oral health perceptions and behaviors among individuals with diabetes. J. Med. Invest. 69 : 86-96, February, 2022.","This study aimed to evaluate the effectiveness of a diabetes oral nursing intervention program for individuals with diabetes. Fifty-six participants with diabetes underwent a diabetes oral nursing intervention program. The program's effect was evaluated through questionnaires and small interviews. The modified diabetes oral health assessment tool (M-DiOHAT©) was used to assess and educate four factors;oral conditions, behaviors, perceptions and knowledge about diabetes and periodontal disease, and health information-sharing, among participants at baseline, 3, 6, and 12 months later. Primary outcomes included changes in the M-DiOHAT© total scores. Secondary outcomes included scores on the motivation stage of changes in oral health behaviors' scales, dental visits, number of present teeth, hemoglobin A1c (HbA1c), and participants' comments. The M-DiOHAT© total score and the motivation stage score significantly improved with the narrative comment of ""being motivated to practice oral health behaviors"" between the baseline and 12 months later. Eight participants visited the dentist, whereas no differences were observed in the number of present teeth or HbA1c. This program improved participants' M-DiOHAT© total score, motivation stage score, and dental visits. These results suggest the program improved oral health perceptions and behaviors among individuals with diabetes. J. Med. Invest. 69 : 86-96, February, 2022.","null","null","2022-03-28","The Journal of Medical Investigation : JMI","The Journal of Medical Investigation : JMI","Vol.69","No.1,2","86","96","eng","true","null","scientific_journal","null","null","10.2152/jmi.69.86","1349-6867","null","https://www.jstage.jst.go.jp/article/jmi/69/1.2/69_86/_article","null","null","null" "Basal insulin requirement in patients with type 1 diabetes depends on the age and body mass index.","Basal insulin requirement in patients with type 1 diabetes depends on the age and body mass index.","Yukari Mitsui, Akio Kuroda, Masashi Ishizu, Hiroyasu Mori, Kiyoe Kurahashi, Takeshi Kondo, Sumiko Yoshida, Yuko Akehi, Ken-ichi Aihara, Itsuro Endo, Masahiro Abe, Munehide Matsuhisa","Yukari Mitsui, Akio Kuroda, Masashi Ishizu, Hiroyasu Mori, Kiyoe Kurahashi, Takeshi Kondo, Sumiko Yoshida, Yuko Akehi, Ken-ichi Aihara, Itsuro Endo, Masahiro Abe, Munehide Matsuhisa","null","T","T","null","null","2022-02","Journal of Diabetes Investigation","Journal of Diabetes Investigation","Vol.13","No.2","292","298","eng","true","null","scientific_journal","null","null","10.1111/jdi.13547","2040-1124","null","null","null","null","null" "Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study","Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study","Kenya Kusunose, H Yoshida, A Tanaka, H Teragawa, Y Akasaki, Y Fukumoto, K Eguchi, H Kamiya, K Kario, Hirotsugu Yamada, Masataka Sata, K Node, Munehide Matsuhisa","Kenya Kusunose, H Yoshida, A Tanaka, H Teragawa, Y Akasaki, Y Fukumoto, K Eguchi, H Kamiya, K Kario, Hirotsugu Yamada, Masataka Sata, K Node, Munehide Matsuhisa","null","null","null","null","null","2022-01","Hypertension Research","Hypertension Research","Vol.45","No.1","106","115","eng","true","null","scientific_journal","null","null","10.1038/s41440-021-00752-9","1348-4214","null","null","null","null","null" "Taste receptor gene expression is associated with decreased eGFR in patients with diabetes.","Taste receptor gene expression is associated with decreased eGFR in patients with diabetes.","Kana Beppu, Ayuka Kawakami, Yuna Mishima, Rie Tsutsumi, Masashi Kuroda, Hiroyasu Mori, Akio Kuroda, Munehide Matsuhisa, Hiroshi Sakaue","Kana Beppu, Ayuka Kawakami, Yuna Mishima, Rie Tsutsumi, Masashi Kuroda, Hiroyasu Mori, Akio Kuroda, Munehide Matsuhisa, Hiroshi Sakaue","null","Dysgeusia is not only associated with zinc deficiency but also with certain drugs or diseases, including diabetes and renal failure. It often lowers the patient's quality of life and hinders access to proper nutrition. The underlying mechanism is unclear and there is a lack of awareness among patients. Here, we focused on lingual taste receptor gene expression in diabetes and elucidated the relationship between taste receptor gene expression and renal function. Forty-seven patients with diabetes and 10 healthy subjects (control group) were enrolled. Lingual foliate papillae were scraped and the derived cDNA was quantified by real-time polymerase chain reaction. Dysgeusia was assessed using SALSAVE?. All statistical analyses were performed using JMP? software 13. The expression of T1R1 and T1R2 was significantly upregulated in type 2 diabetes patients as compared with that in healthy subjects (P<0.01) but did not change in type 1 diabetes patients. T1R3 expression positively correlated and Scnn1 expression negatively correlated with estimated glomerular filtration rate, suggesting that altered taste receptor gene expression could reflect impaired renal function. Thus, alterations in T1R3 and Scnn1 expression in diabetes correlated with renal function. Taste receptor gene expression dysregulation could indicate dysgeusia associated with impaired renal function in patients with diabetes. J. Med. Invest. 69 : 120-126, February, 2022.","Dysgeusia is not only associated with zinc deficiency but also with certain drugs or diseases, including diabetes and renal failure. It often lowers the patient's quality of life and hinders access to proper nutrition. The underlying mechanism is unclear and there is a lack of awareness among patients. Here, we focused on lingual taste receptor gene expression in diabetes and elucidated the relationship between taste receptor gene expression and renal function. Forty-seven patients with diabetes and 10 healthy subjects (control group) were enrolled. Lingual foliate papillae were scraped and the derived cDNA was quantified by real-time polymerase chain reaction. Dysgeusia was assessed using SALSAVE?. All statistical analyses were performed using JMP? software 13. The expression of T1R1 and T1R2 was significantly upregulated in type 2 diabetes patients as compared with that in healthy subjects (P<0.01) but did not change in type 1 diabetes patients. T1R3 expression positively correlated and Scnn1 expression negatively correlated with estimated glomerular filtration rate, suggesting that altered taste receptor gene expression could reflect impaired renal function. Thus, alterations in T1R3 and Scnn1 expression in diabetes correlated with renal function. Taste receptor gene expression dysregulation could indicate dysgeusia associated with impaired renal function in patients with diabetes. J. Med. Invest. 69 : 120-126, February, 2022.","null","null","2022","The Journal of Medical Investigation : JMI","The Journal of Medical Investigation : JMI","Vol.69","No.1.2","120","126","eng","true","null","scientific_journal","null","null","10.2152/jmi.69.120","1349-6867","null","null","null","null","null" "循環血中遊離 DNA を用いた膵β細胞傷害の新規検出法の確立","循環血中遊離 DNA を用いた膵β細胞傷害の新規検出法の確立","岡田 朝美, 山田 美鈴, 森 博康, 明比 祐子, 倉橋 清衛, 吉田 守美子, 遠藤 逸朗, 粟飯原 賢一, 松久 宗英, 黒田 暁生","Asami Okada, Misuzu Yamada, Hiroyasu Mori, 明比 祐子, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa, Akio Kuroda","null","In people with type1 diabetes(T1D), biomarkers that can sensitively and quantitatively evaluate injury of pancreatic beta cell are required in order to predict the onset of the disease at an early stage and to provide interventions to prevent the progression of the disease. We developed a new method for quantifying pancreatic beta cell-derived insulin DNA in circulation that combines bisulfite conversion and Amplification Refractory Mutation System(ARMS)PCR, which can be performed using a conventional real-time PCR system. We applied this method to T1D patients and healthy adults, both could be detected in about 30% of cases. The results in healthy adults indicate that this method may have sensitivity to detect the turnover of pancreatic beta cells at physiological conditions. In post-onset T1D patients, there were many negatives because the amount of residual pancreatic beta cells was extremely small. However, in some cases with a short duration of the disease, pancreatic beta cell-derived insulin DNA was detected in negative correlation between the duration of the disease, that suggested the residual pancreatic beta cells continue to be slowly destroyed. It was demonstrated that the time course of pathophysiology in T1D could be understood using this method.","In people with type1 diabetes(T1D), biomarkers that can sensitively and quantitatively evaluate injury of pancreatic beta cell are required in order to predict the onset of the disease at an early stage and to provide interventions to prevent the progression of the disease. We developed a new method for quantifying pancreatic beta cell-derived insulin DNA in circulation that combines bisulfite conversion and Amplification Refractory Mutation System(ARMS)PCR, which can be performed using a conventional real-time PCR system. We applied this method to T1D patients and healthy adults, both could be detected in about 30% of cases. The results in healthy adults indicate that this method may have sensitivity to detect the turnover of pancreatic beta cells at physiological conditions. In post-onset T1D patients, there were many negatives because the amount of residual pancreatic beta cells was extremely small. However, in some cases with a short duration of the disease, pancreatic beta cell-derived insulin DNA was detected in negative correlation between the duration of the disease, that suggested the residual pancreatic beta cells continue to be slowly destroyed. It was demonstrated that the time course of pathophysiology in T1D could be understood using this method.","null","null","2021-12-25","四国医学雑誌","Shikoku Acta Medica","Vol.77","No.5,6","249","245","jpn","true","null","scientific_journal","null","null","null","0037-3699","null","http://repo.lib.tokushima-u.ac.jp/117138","null","null","null" "TIA様症状を契機に診断されたインスリノーマの1例","TIA様症状を契機に診断されたインスリノーマの1例","吉川 紘平, 金子 遥祐, 辻 誠士郎, 河田 沙紀, 川原 綾香, 森 建介, 遠藤 ふうり, 原 倫世, 倉橋 清衛, 吉田 守美子, 黒田 暁生, 明比 祐子, 遠藤 逸朗, 船木 真理, 福本 誠二, 安倍 正博, 松久 宗英","吉川 紘平, 金子 遥祐, 辻 誠士郎, 河田 沙紀, 川原 綾香, 森 建介, 遠藤 ふうり, Tomoyo Hara, Kiyoe Kurahashi, Sumiko Yoshida, Akio Kuroda, 明比 祐子, Itsuro Endo, Makoto Funaki, Seiji Fukumoto, Masahiro Abe, Munehide Matsuhisa","null","We report the case of a67-year-old woman who had symptoms suggestive of a transient ischemic attack(TIA), such as lightheadedness and transient visual changes before meals for 4 months. She experienced altered consciousness before lunch and was taken to the emergency room2weeks ago. She had repeated hypoglycemia with a blood glucose level of 31 mg/dL. Insulin secretion was not suppressed, with an immunoreactive insulin level of 14.0 μU/mL and connecting peptide immunoreactivity of 1.83 ng/mL for occasional blood glucose levels of 49 mg/dL. Dynamic CT revealed a 17‐mm mass enhanced during the arterial phase in the pancreatic uncinate process, suggestive of a pancreatic neuroendocrine tumor. A selective arterial secretagogue(calcium)injection test revealed the localization of insulinoma in the head of the pancreas. Therefore, pancreatoduodenectomy was performed. Hyperglycemia occurred after the surgery, and it was judged that the insulinoma was resected. This case showed TIA-like symptoms without signs of sympathetic overdrive associated with hypoglycemia. Thus, the diagnosis was delayed. Insulinoma may present with symptoms of neuroglycopenia but not autonomic activity due to hypoglycemia. Insulinoma should be distinguished in patients with unknown neurological symptoms since neuroglycopenia caused by insulinoma is diverse.","We report the case of a67-year-old woman who had symptoms suggestive of a transient ischemic attack(TIA), such as lightheadedness and transient visual changes before meals for 4 months. She experienced altered consciousness before lunch and was taken to the emergency room2weeks ago. She had repeated hypoglycemia with a blood glucose level of 31 mg/dL. Insulin secretion was not suppressed, with an immunoreactive insulin level of 14.0 μU/mL and connecting peptide immunoreactivity of 1.83 ng/mL for occasional blood glucose levels of 49 mg/dL. Dynamic CT revealed a 17‐mm mass enhanced during the arterial phase in the pancreatic uncinate process, suggestive of a pancreatic neuroendocrine tumor. A selective arterial secretagogue(calcium)injection test revealed the localization of insulinoma in the head of the pancreas. Therefore, pancreatoduodenectomy was performed. Hyperglycemia occurred after the surgery, and it was judged that the insulinoma was resected. This case showed TIA-like symptoms without signs of sympathetic overdrive associated with hypoglycemia. Thus, the diagnosis was delayed. Insulinoma may present with symptoms of neuroglycopenia but not autonomic activity due to hypoglycemia. Insulinoma should be distinguished in patients with unknown neurological symptoms since neuroglycopenia caused by insulinoma is diverse.","null","null","2021-12-25","四国医学雑誌","Shikoku Acta Medica","Vol.77","No.5-6","275","280","jpn","true","null","scientific_journal","null","null","null","0037-3699","null","http://repo.lib.tokushima-u.ac.jp/116831","null","null","null" "歩行不能だったが,多職種の高度な連携と患者特性に配慮したケアにより自宅生活可能となった高度肥満症の一例","歩行不能だったが,多職種の高度な連携と患者特性に配慮したケアにより自宅生活可能となった高度肥満症の一例","川原 綾香, 倉橋 清衛, 工藤 千晶, 鎌田 基夢, 加藤 真介, 富岡 有紀子, 辻本 賀美, 安井 沙耶, 遠藤 ふうり, 桝田 志保, 三井 由加里, 吉田 守美子, 粟飯原 賢一, 遠藤 逸朗, 福本 誠二, 松久 宗英, 安倍 正博","川原 綾香, Kiyoe Kurahashi, 工藤 千晶, 鎌田 基夢, Shinsuke Katoh, Yukiko Tomioka, 辻本 賀美, 安井 沙耶, 遠藤 ふうり, 桝田 志保, 三井 由加里, Sumiko Yoshida, Ken-ichi Aihara, Itsuro Endo, Seiji Fukumoto, Munehide Matsuhisa, Masahiro Abe","null","A 48-year-old man who weighed 216 kg was significantly overweight with a body mass index (BMI)of 75.6kg/m2, and was unable to walk due to disuse syndrome. Because of the psychological and social problems in the background, a psychological examination was performed and the staff took time to build a trusting relationship with the patient, taking into account his characteristics. With diet and rehabilitation, he was able to lose weight to 124kg and BMI 43.9kg/m2 over 600 days, and was able to walk with assistive devices and defecate by himself. The patient was discharged from our hospital after a series of multidisciplinary meetings with medical, nursing, welfare, and governmental agencies to create an environment for home recuperation. The reasons for the improvement to enable him to be discharged from the hospital were due to the multi-disciplinary meetings among the staff inside and outside the hospital, information sharing and advanced coordination, and smooth communication with the patient by taking into account his characteristics from a psychological standpoint.","A 48-year-old man who weighed 216 kg was significantly overweight with a body mass index (BMI)of 75.6kg/m2, and was unable to walk due to disuse syndrome. Because of the psychological and social problems in the background, a psychological examination was performed and the staff took time to build a trusting relationship with the patient, taking into account his characteristics. With diet and rehabilitation, he was able to lose weight to 124kg and BMI 43.9kg/m2 over 600 days, and was able to walk with assistive devices and defecate by himself. The patient was discharged from our hospital after a series of multidisciplinary meetings with medical, nursing, welfare, and governmental agencies to create an environment for home recuperation. The reasons for the improvement to enable him to be discharged from the hospital were due to the multi-disciplinary meetings among the staff inside and outside the hospital, information sharing and advanced coordination, and smooth communication with the patient by taking into account his characteristics from a psychological standpoint.","null","null","2021-10","四国医学雑誌","Shikoku Acta Medica","Vol.76","No.1","317","322","jpn","true","null","scientific_journal","null","null","null","0037-3699","null","http://repo.lib.tokushima-u.ac.jp/115801","null","null","null" "Characterisation of Ppy-lineage cells clarifies the functional heterogeneity of pancreatic beta cells in mice.","Characterisation of Ppy-lineage cells clarifies the functional heterogeneity of pancreatic beta cells in mice.","Takahiro Fukaishi, Yuko Nakagawa, Ayako Fukunaka, Takashi Sato, Akemi Hara, Keiko Nakao, Michiko Saito, Kenji Kohno, Takeshi Miyatsuka, Motoyuki Tamaki, Munehide Matsuhisa, Taka-Aki Matsuoka, Tetsuya Yamada, Hirotaka Watada, Yoshio Fujitani","Takahiro Fukaishi, Yuko Nakagawa, Ayako Fukunaka, Takashi Sato, Akemi Hara, Keiko Nakao, Michiko Saito, Kenji Kohno, Takeshi Miyatsuka, Motoyuki Tamaki, Munehide Matsuhisa, Taka-Aki Matsuoka, Tetsuya Yamada, Hirotaka Watada, Yoshio Fujitani","null","The single-cell RNA sequence (scRNA-seq) analysis datasets generated in this study have been deposited in the Gene Expression Omnibus (GEO) under the accession number GSE166164 ( www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE166164 ).","The single-cell RNA sequence (scRNA-seq) analysis datasets generated in this study have been deposited in the Gene Expression Omnibus (GEO) under the accession number GSE166164 ( www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE166164 ).","null","null","2021-09-09","Diabetologia","Diabetologia","Vol.64","No.12","2803","2816","eng","true","null","scientific_journal","null","null","10.1007/s00125-021-05560-x","1432-0428","null","null","null","null","null" "情報を活かし地域に沿った腎症重症化予防策「行政・医療機関の情報を活用したヒューマンネットワークによる糖尿病重症化」","情報を活かし地域に沿った腎症重症化予防策「行政・医療機関の情報を活用したヒューマンネットワークによる糖尿病重症化」","松久 宗英, 森 博康, 谷口 諭, 玉木 悠, 黒田 暁生","Munehide Matsuhisa, Hiroyasu Mori, Satoshi Taniguchi, Yuu Tamaki, Akio Kuroda","null","null","null","null","null","2021-08","日本糖尿病情報学会誌 18: 43-49, 2021.8.31","日本糖尿病情報学会誌 18: 43-49, 2021.8.31","Vol.18","null","43","49","jpn","true","null","scientific_journal","null","null","null","null","null","null","null","null","null" "Skeletal FGFR1 signaling is necessary for regulation of serum phosphate level by FGF23 and normal life span.","Skeletal FGFR1 signaling is necessary for regulation of serum phosphate level by FGF23 and normal life span.","Yuichi Takashi, Shun Sawatsubashi, Itsuro Endo, Yukiyo Ohnishi, Masahiro Abe, Munehide Matsuhisa, Daiji Kawanami, Toshio Matsumoto, Seiji Fukumoto","Yuichi Takashi, Shun Sawatsubashi, Itsuro Endo, Yukiyo Ohnishi, Masahiro Abe, Munehide Matsuhisa, Daiji Kawanami, Toshio Matsumoto, Seiji Fukumoto","null","Fibroblast growth factor (FGF) 23 produced by the bone is the principal hormone to regulate serum phosphate level. Serum FGF23 needs to be tightly regulated to maintain serum phosphate in a narrow range. Thus, we hypothesized that the bone has some phosphate-sensing mechanism to regulate the production of FGF23. Previously we showed that extracellular phosphate induces the phosphorylation of FGF receptor 1 (FGFR1) and FGFR1 signaling regulates the expression of , whose product works to increase FGF23 production . In this study, we show the significance of FGFR1 in the regulated FGF23 production and serum phosphate level . We generated late-osteoblast/osteocyte-specific -knockout mice ( ) by crossing the and the floxed mouse lines. We evaluated serum phosphate and FGF23 levels, the expression of in the bone, the body weight and life span. A selective ablation of aborted the increase of serum active full-length FGF23 and the enhanced expression of in the bone by a high phosphate diet. These mice showed more pronounced hyperphosphatemia compared with control mice. In addition, these mice fed with a control diet showed body weight loss after 23 weeks of age and shorter life span. These results reveal a novel significance of FGFR1 signaling in the phosphate metabolism and normal life span.","Fibroblast growth factor (FGF) 23 produced by the bone is the principal hormone to regulate serum phosphate level. Serum FGF23 needs to be tightly regulated to maintain serum phosphate in a narrow range. Thus, we hypothesized that the bone has some phosphate-sensing mechanism to regulate the production of FGF23. Previously we showed that extracellular phosphate induces the phosphorylation of FGF receptor 1 (FGFR1) and FGFR1 signaling regulates the expression of , whose product works to increase FGF23 production . In this study, we show the significance of FGFR1 in the regulated FGF23 production and serum phosphate level . We generated late-osteoblast/osteocyte-specific -knockout mice ( ) by crossing the and the floxed mouse lines. We evaluated serum phosphate and FGF23 levels, the expression of in the bone, the body weight and life span. A selective ablation of aborted the increase of serum active full-length FGF23 and the enhanced expression of in the bone by a high phosphate diet. These mice showed more pronounced hyperphosphatemia compared with control mice. In addition, these mice fed with a control diet showed body weight loss after 23 weeks of age and shorter life span. These results reveal a novel significance of FGFR1 signaling in the phosphate metabolism and normal life span.","null","null","2021-08-17","Biochemistry and Biophysics Reports","Biochemistry and Biophysics Reports","Vol.27","null","101107","101107","eng","true","null","scientific_journal","null","null","10.1016/j.bbrep.2021.101107","2405-5808","null","null","null","null","null" "A low serum IGF-1 is correlated with sarcopenia in subjects with type 1 diabetes mellitus: Findings from a post-hoc analysis of the iDIAMOND study.","A low serum IGF-1 is correlated with sarcopenia in subjects with type 1 diabetes mellitus: Findings from a post-hoc analysis of the iDIAMOND study.","Sonyun Hata, Hiroyasu Mori, Tetsuyuki Yasuda, Yoko Irie, Tsunehiko Yamamoto, Yutaka Umayahara, Kayoko Ryomoto, Kazutomi Yoshiuchi, Sumiko Yoshida, Iichiro Shimomura, Akio Kuroda, Munehide Matsuhisa","Sonyun Hata, Hiroyasu Mori, Tetsuyuki Yasuda, Yoko Irie, Tsunehiko Yamamoto, Yutaka Umayahara, Kayoko Ryomoto, Kazutomi Yoshiuchi, Sumiko Yoshida, Iichiro Shimomura, Akio Kuroda, Munehide Matsuhisa","null","The z-score of serum IGF-1 was significantly lower in the subjects with T1DM than that in those without diabetes (p < 0.001). Among subjects with T1DM, the z-score of serum IGF-1 was significantly lower in sarcopenic subjects than in non-sarcopenic subjects. The multivariable logistic regression analysis showed that the serum IGF-1 z-score was an independent determinant of sarcopenia and a low skeletal muscle mass index, but not low grip strength nor slow gait speed in subjects with T1DM.","A low serum IGF-1 level is correlated with sarcopenia and low skeletal muscle mass in subjects with T1DM.","null","null","2021-08-11","Diabetes Research and Clinical Practice","Diabetes Research and Clinical Practice","Vol.179","null","null","null","eng","true","null","scientific_journal","null","null","10.1016/j.diabres.2021.108998","1872-8227","null","null","null","null","null" "Protocol for a Randomized, Crossover Trial to Decrease Time in Hypoglycemia by Combined Intervention of the Usage of Intermittent-Scanning Continuous Glucose Monitoring Device and the Structured Education Regarding its Usage: Effect of Intermittent-Scanning Continuous Glucose Monitoring to Glycemic Control Including Hypoglycemia and Quality of Life of Patients with Type 1 Diabetes Mellitus Study (ISCHIA Study).","Protocol for a Randomized, Crossover Trial to Decrease Time in Hypoglycemia by Combined Intervention of the Usage of Intermittent-Scanning Continuous Glucose Monitoring Device and the Structured Education Regarding its Usage: Effect of Intermittent-Scanning Continuous Glucose Monitoring to Glycemic Control Including Hypoglycemia and Quality of Life of Patients with Type 1 Diabetes Mellitus Study (ISCHIA Study).","Shota Suzuki, Atsuhito Tone, Takashi Murata, Kunihiro Nishimura, Yoshihiro Miyamoto, Naoki Sakane, Noriko Satoh-Asahara, Masao Toyoda, Yushi Hirota, Munehide Matsuhisa, Akio Kuroda, Ken Kato, Ryuji Kouyama, Junnosuke Miura, Akiko Suganuma, Tsutomu Tomita, Michio Noguchi, Cheol Son, Masato Kasahara, Yukie Ito, Shu Kasama, Kiminori Hosoda","Shota Suzuki, Atsuhito Tone, Takashi Murata, Kunihiro Nishimura, Yoshihiro Miyamoto, Naoki Sakane, Noriko Satoh-Asahara, Masao Toyoda, Yushi Hirota, Munehide Matsuhisa, Akio Kuroda, Ken Kato, Ryuji Kouyama, Junnosuke Miura, Akiko Suganuma, Tsutomu Tomita, Michio Noguchi, Cheol Son, Masato Kasahara, Yukie Ito, Shu Kasama, Kiminori Hosoda","null","The ISCHIA study will contribute to the standardization of patient education regarding the prevention of hypoglycemia by using isCGM.","The ISCHIA study will contribute to the standardization of patient education regarding the prevention of hypoglycemia by using isCGM.","null","null","2021-07-20","The Tokai Journal of Experimental and Clinical Medicine","The Tokai Journal of Experimental and Clinical Medicine","Vol.46","No.2","59","68","eng","true","null","scientific_journal","null","null","null","2185-2243","null","null","null","null","null" "先進糖尿病治療の進歩","先進糖尿病治療の進歩","松久 宗英, 黒田 暁生","Munehide Matsuhisa, Akio Kuroda","null","null","null","null","null","2021-06-01","糖尿病","Journal of the The Japan Diabetes Society","Vol.13","No.6","62","68","jpn","true","null","scientific_journal","null","null","null","0021-437X","null","null","null","null","null" "High prevalence and clinical impact of dynapenia and sarcopenia in Japanese patients with type 1 and type 2 diabetes: Findings from the Impact of Diabetes Mellitus on Dynapenia study.","High prevalence and clinical impact of dynapenia and sarcopenia in Japanese patients with type 1 and type 2 diabetes: Findings from the Impact of Diabetes Mellitus on Dynapenia study.","Hiroyasu Mori, Akio Kuroda, Sumiko Yoshida, Tetsuyuki Yasuda, Yutaka Umayahara, Sayoko Shimizu, Kayoko Ryomoto, Kazutomi Yoshiuchi, Tsunehiko Yamamoto, Taka-Aki Matsuoka, Iichiro Shimomura, Munehide Matsuhisa","Hiroyasu Mori, Akio Kuroda, Sumiko Yoshida, Tetsuyuki Yasuda, Yutaka Umayahara, Sayoko Shimizu, Kayoko Ryomoto, Kazutomi Yoshiuchi, Tsunehiko Yamamoto, Taka-Aki Matsuoka, Iichiro Shimomura, Munehide Matsuhisa","null","Sarcopenia and dynapenia were more frequent in patients with type 1 diabetes and type 2 diabetes than in individuals without diabetes, which might contribute to their impaired quality of life and incidental falls.","Sarcopenia and dynapenia were more frequent in patients with type 1 diabetes and type 2 diabetes than in individuals without diabetes, which might contribute to their impaired quality of life and incidental falls.","null","null","2021-06","Journal of Diabetes Investigation","Journal of Diabetes Investigation","Vol.12","No.6","1050","1059","eng","true","null","scientific_journal","null","null","10.1111/jdi.13436","2040-1124","null","null","null","null","null" "Plasma Heparin Cofactor II Activity Is Inversely Associated with Albuminuria and Its Annual Deterioration in Patients with Diabetes.","Plasma Heparin Cofactor II Activity Is Inversely Associated with Albuminuria and Its Annual Deterioration in Patients with Diabetes.","Tomoyo Hara, Ryoko Uemoto, Akiko Sekine, Yukari Mitsui, Shiho Masuda, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Yasumasa Ikeda, Itsuro Endo, Soichi Honda, Katsuhiko Yoshimoto, Akira Kondo, Toshiaki Tamaki, Toshio Matsumoto, Munehide Matsuhisa, Masahiro Abe, Ken-ichi Aihara","Tomoyo Hara, Ryoko Uemoto, Akiko Sekine, Yukari Mitsui, Shiho Masuda, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Yasumasa Ikeda, Itsuro Endo, Soichi Honda, Katsuhiko Yoshimoto, Akira Kondo, Toshiaki Tamaki, Toshio Matsumoto, Munehide Matsuhisa, Masahiro Abe, Ken-ichi Aihara","null","The plasma HCII activity was inversely and specifically associated with glomerular injury in patients with diabetes. The results suggest that HCII can serve as a novel predictive factor for early-stage DKD development, as represented by albuminuria.","The plasma HCII activity was inversely and specifically associated with glomerular injury in patients with diabetes. The results suggest that HCII can serve as a novel predictive factor for early-stage DKD development, as represented by albuminuria.","null","null","2021-05-27","Journal of Diabetes Investigation","Journal of Diabetes Investigation","null","null","null","null","eng","true","null","scientific_journal","null","null","10.1111/jdi.13602","2040-1124","null","null","null","null","null" "Glycemic control status, diabetes management patterns, and clinical characteristics of adults with type 1 diabetes in Japan: Study of Adults Glycemia in T1DM subanalysis","Glycemic control status, diabetes management patterns, and clinical characteristics of adults with type 1 diabetes in Japan: Study of Adults Glycemia in T1DM subanalysis","Abiru Norio, Shimada Akira, Nishimura Rimei, Munehide Matsuhisa, Ozaki Asuka ·, Ikegam Hiroshi","Abiru Norio, Shimada Akira, Nishimura Rimei, Munehide Matsuhisa, Ozaki Asuka ·, Ikegam Hiroshi","null","null","null","null","null","2021-04-25","Diabetology International","Diabetology International","Vol.12","No.4","460","473","eng","true","null","scientific_journal","null","null","10.1007/s13340-021-00504-7","2190-1686","null","null","null","null","null" "先進糖尿病治療の進歩","Progression of the advanced technology and therapy for diabetes mellitus","松久 宗英, 黒田 暁生","Munehide Matsuhisa, Akio Kuroda","null","null","null","null","null","2021-03-10","日本内科学会雑誌","The Journal of the Japanese Society of Internal Medicine","Vol.110","No.3","420","426","jpn","true","null","scientific_journal","null","null","null","0021-5384","null","https://ci.nii.ac.jp/naid/40022515659/","null","null","null" "Urinary adiponectin excretion is an early predictive marker of the decline of the renal function in patients with diabetes mellitus.","Urinary adiponectin excretion is an early predictive marker of the decline of the renal function in patients with diabetes mellitus.","Masashi Ishizu, Hiroyasu Mori, Mami Ohishi, Akio Kuroda, Y Akehi, Sumiko Yoshida, Ken-ichi Aihara, M Aiba, T Kawano, Seiichi Hashida, Munehide Matsuhisa","Masashi Ishizu, Hiroyasu Mori, Mami Ohishi, Akio Kuroda, Y Akehi, Sumiko Yoshida, Ken-ichi Aihara, M Aiba, T Kawano, Seiichi Hashida, Munehide Matsuhisa","null","Since diabetes-associated kidney complication changes from diabetic nephropathy to diabetic kidney disease (DKD), more suitable biomarkers than urinary albumin are required. It has been hypothesized that urinary adiponectin (u-ADPN) is associated with the progression of DKD. We therefore evaluated the effectiveness of u-ADPN in predicting the decline of the renal function in patients with diabetes prior to end-stage renal disease. An ultrasensitive immune complex transfer enzyme immunoassay (ICT-EIA) was used to measure total and high molecular weight (HMW) adiponectin separately. We evaluated the relationships between the creatinine-adjusted urinary total-ADPN and HMW-ADPN, albumin (UACR) and liver-type fatty acid binding protein (L-FABP) at baseline and the 2-year change of the estimated glomerular filtration rate (ΔeGFR). This 2-year prospective observational study included 201 patients with diabetes. These patients were divided into three groups according to their ΔeGFR: ≤-10 mL/min/1.73m, >-10 and ≤0 mL/min/1.73m, and >0 mL/min/1.73m. Jonckheere-Terpstra test showed that lower ΔeGFR was associated with higher u-HMW-ADPN (p = 0.045). In logistic regression analysis, u-HMW-ADPN was associated with ΔeGFR after adjusted age, sex, and basal eGFR. Urinary HMW-ADPN could predict a declining renal function in patients with diabetes.","Since diabetes-associated kidney complication changes from diabetic nephropathy to diabetic kidney disease (DKD), more suitable biomarkers than urinary albumin are required. It has been hypothesized that urinary adiponectin (u-ADPN) is associated with the progression of DKD. We therefore evaluated the effectiveness of u-ADPN in predicting the decline of the renal function in patients with diabetes prior to end-stage renal disease. An ultrasensitive immune complex transfer enzyme immunoassay (ICT-EIA) was used to measure total and high molecular weight (HMW) adiponectin separately. We evaluated the relationships between the creatinine-adjusted urinary total-ADPN and HMW-ADPN, albumin (UACR) and liver-type fatty acid binding protein (L-FABP) at baseline and the 2-year change of the estimated glomerular filtration rate (ΔeGFR). This 2-year prospective observational study included 201 patients with diabetes. These patients were divided into three groups according to their ΔeGFR: ≤-10 mL/min/1.73m, >-10 and ≤0 mL/min/1.73m, and >0 mL/min/1.73m. Jonckheere-Terpstra test showed that lower ΔeGFR was associated with higher u-HMW-ADPN (p = 0.045). In logistic regression analysis, u-HMW-ADPN was associated with ΔeGFR after adjusted age, sex, and basal eGFR. Urinary HMW-ADPN could predict a declining renal function in patients with diabetes.","null","null","2021-01-07","Journal of Diabetes and its Complications","Journal of Diabetes and its Complications","Vol.35","No.4","107848","107848","eng","true","null","scientific_journal","null","null","10.1016/j.jdiacomp.2021.107848","1873-460X","null","null","null","null","null" "ICTがもたらす地域医療連携と糖尿病診療の未来","ICTがもたらす地域医療連携と糖尿病診療の未来","松久 宗英","Munehide Matsuhisa","null","null","null","null","null","2020","大阪府内科医会会誌","大阪府内科医会会誌","Vol.29","No.1-2","20","27","jpn","true","null","scientific_journal","null","null","null","1881-669X","null","null","null","null","null" "Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients.","Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients.","Yuichi Takashi, Shu Wakino, Hitoshi Minakuchi, Masashi Ishizu, Akio Kuroda, Hisato Shima, Manabu Tashiro, Keiko Miya, Kazuyoshi Okada, Jun Minakuchi, Shu Kawashima, Munehide Matsuhisa, Toshio Matsumoto, Seiji Fukumoto","Yuichi Takashi, Shu Wakino, Hitoshi Minakuchi, Masashi Ishizu, Akio Kuroda, Hisato Shima, Manabu Tashiro, Keiko Miya, Kazuyoshi Okada, Jun Minakuchi, Shu Kawashima, Munehide Matsuhisa, Toshio Matsumoto, Seiji Fukumoto","null","Fibroblast growth factor (FGF) 23 is a bone-derived hormone regulating serum inorganic phosphate (Pi) concentration. FGF23 is also involved in the development of chronic kidney disease (CKD)-mineral and bone disorder. Serum FGF23 concentration begins to increase early in the progression of CKD and can be remarkably high in hemodialysis patients with end-stage renal disease. It has been reported that high FGF23 concentration is a risk factor for cardiac dysfunction, atherosclerosis, infection or systemic inflammation in CKD patients. FGF23 was also shown to induce cardiac hypertrophy directly acting on cardiomyocytes. However, it is still controversial whether high FGF23 is causing cardiac dysfunction, atherosclerosis, infection or systemic inflammation in CKD patients. In the current study, we investigated whether FGF23 concentration is associated with cardiac dysfunction, atherosclerosis, infection or systemic inflammation in Japanese hemodialysis patients. We recruited 119 hemodialysis patients and examined the association between serum FGF23 concentration and several parameters concerning mineral metabolism, cardiac dysfunction, atherosclerosis, infection, and systemic inflammation. Serum FGF23 concentration was independently associated with serum calcium and Pi concentration (β = 0.276, p < 0.001; β = 0.689, p < 0.001). However, serum FGF23 concentration was not associated with parameters of cardiac dysfunction, atherosclerosis, infection, and systemic inflammation, either. Our results do not support the hypothesis that high FGF23 in dialysis patients is the cause of cardiac dysfunction, atherosclerosis, infection or systemic inflammation.","Fibroblast growth factor (FGF) 23 is a bone-derived hormone regulating serum inorganic phosphate (Pi) concentration. FGF23 is also involved in the development of chronic kidney disease (CKD)-mineral and bone disorder. Serum FGF23 concentration begins to increase early in the progression of CKD and can be remarkably high in hemodialysis patients with end-stage renal disease. It has been reported that high FGF23 concentration is a risk factor for cardiac dysfunction, atherosclerosis, infection or systemic inflammation in CKD patients. FGF23 was also shown to induce cardiac hypertrophy directly acting on cardiomyocytes. However, it is still controversial whether high FGF23 is causing cardiac dysfunction, atherosclerosis, infection or systemic inflammation in CKD patients. In the current study, we investigated whether FGF23 concentration is associated with cardiac dysfunction, atherosclerosis, infection or systemic inflammation in Japanese hemodialysis patients. We recruited 119 hemodialysis patients and examined the association between serum FGF23 concentration and several parameters concerning mineral metabolism, cardiac dysfunction, atherosclerosis, infection, and systemic inflammation. Serum FGF23 concentration was independently associated with serum calcium and Pi concentration (β = 0.276, p < 0.001; β = 0.689, p < 0.001). However, serum FGF23 concentration was not associated with parameters of cardiac dysfunction, atherosclerosis, infection, and systemic inflammation, either. Our results do not support the hypothesis that high FGF23 in dialysis patients is the cause of cardiac dysfunction, atherosclerosis, infection or systemic inflammation.","null","null","2020","Journal of Bone and Mineral Metabolism","Journal of Bone and Mineral Metabolism","Vol.38","No.1","70-77","70-77","eng","true","null","scientific_journal","null","null","10.1007/s00774-019-01027-7","1435-5604","null","null","null","null","null" "多職種連携と患者特性に配慮したケアを行った高度肥満症の一例","A case of severe obesity who had been unable to walk but became able to live at home thanks to a high level of coordination and patient-specific care by a multidisciplinary team","川原 綾香, 倉橋 清衛, 鎌田 基夢, 加藤 真介, 富岡 有紀子, 辻本 賀美, 安井 沙耶, 遠藤 ふうり, 桝田 志保, 三井 由加里, 吉田 守美子, 粟飯原 賢一, 遠藤 逸朗, 福本 誠二, 松久 宗英, 安倍 正博","川原 綾香, Kiyoe Kurahashi, 鎌田 基夢, Shinsuke Katoh, Yukiko Tomioka, 辻本 賀美, 安井 沙耶, 遠藤 ふうり, 桝田 志保, 三井 由加里, Sumiko Yoshida, Ken-ichi Aihara, Itsuro Endo, Seiji Fukumoto, Munehide Matsuhisa, Masahiro Abe","null","A 48-year-old man who weighed 216 kg was significantly overweight with a body mass index (BMI)of 75.6kg/m2, and was unable to walk due to disuse syndrome. Because of the psychological and social problems in the background, a psychological examination was performed and the staff took time to build a trusting relationship with the patient, taking into account his characteristics. With diet and rehabilitation, he was able to lose weight to 124kg and BMI 43.9kg/m2 over 600 days, and was able to walk with assistive devices and defecate by himself. The patient was discharged from our hospital after a series of multidisciplinary meetings with medical, nursing, welfare, and governmental agencies to create an environment for home recuperation. The reasons for the improvement to enable him to be discharged from the hospital were due to the multi-disciplinary meetings among the staff inside and outside the hospital, information sharing and advanced coordination, and smooth communication with the patient by taking into account his characteristics from a psychological standpoint.","A 48-year-old man who weighed 216 kg was significantly overweight with a body mass index (BMI)of 75.6kg/m2, and was unable to walk due to disuse syndrome. Because of the psychological and social problems in the background, a psychological examination was performed and the staff took time to build a trusting relationship with the patient, taking into account his characteristics. With diet and rehabilitation, he was able to lose weight to 124kg and BMI 43.9kg/m2 over 600 days, and was able to walk with assistive devices and defecate by himself. The patient was discharged from our hospital after a series of multidisciplinary meetings with medical, nursing, welfare, and governmental agencies to create an environment for home recuperation. The reasons for the improvement to enable him to be discharged from the hospital were due to the multi-disciplinary meetings among the staff inside and outside the hospital, information sharing and advanced coordination, and smooth communication with the patient by taking into account his characteristics from a psychological standpoint.","null","null","2020-12-25","四国医学雑誌","Shikoku Acta Medica","Vol.76","No.5-6","317","322","jpn","true","null","scientific_journal","null","null","null","0037-3699","null","http://repo.lib.tokushima-u.ac.jp/115801","null","null","null" "Risk of hypoglycemia in Japanese people with type 2 diabetes mellitus who initiated or switched to insulin glargine 300 U/mL: A subgroup analysis of 12-month post-marketing surveillance study (X-STAR study).","Risk of hypoglycemia in Japanese people with type 2 diabetes mellitus who initiated or switched to insulin glargine 300 U/mL: A subgroup analysis of 12-month post-marketing surveillance study (X-STAR study).","Takahisa Hirose, Masato Odawara, Munehide Matsuhisa, Ryusuke Koshida, Masayuki Senda, Yasushi Tanaka, Yasuo Terauchi","Takahisa Hirose, Masato Odawara, Munehide Matsuhisa, Ryusuke Koshida, Masayuki Senda, Yasushi Tanaka, Yasuo Terauchi","null","We examined data from 4621 people with T2D (1227 insulin-naïve and 3394 insulin-experienced) of the X-STAR study, a prospective, observational, 12-month study conducted from December 2015 to August 2018 in Japan. Participants were stratified by age (<65, 65 to <75, and ≥75 years) and estimated glomerular filtration rate (eGFR) (≥90, 60 to <90, 30 to <60, and <30 mL/min/1.73 m","Our study found no apparent increase in the hypoglycemia risk in people with older age and renal impairment who were administered Gla-300. These results would provide reassuring information on Gla-300 use.","null","null","2020-12-24","Diabetes Research and Clinical Practice","Diabetes Research and Clinical Practice","Vol.172","null","null","null","eng","true","null","scientific_journal","null","null","10.1016/j.diabres.2020.108647","1872-8227","null","null","null","null","null" "糖尿病患者の口腔保健行動アセスメントツールを用いた看護支援プログラムの評価","糖尿病患者の口腔保健行動アセスメントツールを用いた看護支援プログラムの評価","桑村 由美, 吉田 守美子, 倉橋 清衛, 澄川 真珠子, 坂本 英次郎, 黒田 暁生, 粟飯原 賢一, 船木 真理, 湯本 浩通, 上村 浩一, 岡本 美鈴, 大和 光, 松久 宗英, 遠藤 逸朗, 岸田 佐智","Yumi Kuwamura, Sumiko Yoshida, Kiyoe Kurahashi, 澄川 真珠子, Eijiro Sakamoto, Akio Kuroda, Ken-ichi Aihara, Makoto Funaki, Hiromichi Yumoto, Hirokazu Uemura, 岡本 美鈴, 大和 光, Munehide Matsuhisa, Itsuro Endo, Sachi Kishida","null","null","null","null","null","2020-10-05","糖尿病","Journal of the The Japan Diabetes Society","Vol.63","No.Supplement","S117","S117","jpn","true","null","scientific_journal","null","null","null","0021-437X","null","null","null","null","null" "Development of fully automated and ultrasensitive assays for urinary adiponectin and their application as novel biomarkers for diabetic kidney disease.","Development of fully automated and ultrasensitive assays for urinary adiponectin and their application as novel biomarkers for diabetic kidney disease.","Toshihiro Watanabe, Yuki Fujimoto, Aya Morimoto, Mai Nishiyama, Akinori Kawai, Seiki Okada, Motohiro Aiba, Tomoharu Kawano, Mina Kawahigashi, Masashi Ishizu, Hiroyasu Mori, Munehide Matsuhisa, Akiko Hata, Makoto Funaki, Seiichi Hashida","Toshihiro Watanabe, Yuki Fujimoto, Aya Morimoto, Mai Nishiyama, Akinori Kawai, Seiki Okada, Motohiro Aiba, Tomoharu Kawano, Mina Kawahigashi, Masashi Ishizu, Hiroyasu Mori, Munehide Matsuhisa, Akiko Hata, Makoto Funaki, Seiichi Hashida","null","Glomerular filtration rate (GFR) and urinary albumin excretion rate (UAER) are used to diagnose and classify the severity of chronic kidney disease. Total adiponectin (T-AN) and high molecular weight adiponectin (H-AN) assays were developed using the fully automated immunoassay system, HI-1000 and their significance over conventional biomarkers were investigated. The T-AN and H-AN assays had high reproducibility, good linearity, and sufficient sensitivity to detect trace amounts of adiponectin in the urine. Urine samples after gel filtration were analyzed for the presence of different molecular isoforms. Low molecular weight (LMW) forms and monomers were the major components (93%) of adiponectin in the urine from a diabetic patient with normoalbuminuria. Urine from a microalbuminuria patient contained both high molecular weight (HMW) (11%) and middle molecular weight (MMW) (28%) adiponectin, although the LMW level was still high (52%). The amount of HMW (32%) and MMW (42%) were more abundant than that of LMW (24%) in a diabetic patient with macroalbuminuria. T-AN (r = - 0.43) and H-AN (r = - 0.38) levels showed higher correlation with estimated GFR (eGFR) than UAER (r = - 0.23). Urinary levels of both T-AN and H-AN negatively correlated with renal function in diabetic patients and they may serve as new biomarkers for diabetic kidney disease.","Glomerular filtration rate (GFR) and urinary albumin excretion rate (UAER) are used to diagnose and classify the severity of chronic kidney disease. Total adiponectin (T-AN) and high molecular weight adiponectin (H-AN) assays were developed using the fully automated immunoassay system, HI-1000 and their significance over conventional biomarkers were investigated. The T-AN and H-AN assays had high reproducibility, good linearity, and sufficient sensitivity to detect trace amounts of adiponectin in the urine. Urine samples after gel filtration were analyzed for the presence of different molecular isoforms. Low molecular weight (LMW) forms and monomers were the major components (93%) of adiponectin in the urine from a diabetic patient with normoalbuminuria. Urine from a microalbuminuria patient contained both high molecular weight (HMW) (11%) and middle molecular weight (MMW) (28%) adiponectin, although the LMW level was still high (52%). The amount of HMW (32%) and MMW (42%) were more abundant than that of LMW (24%) in a diabetic patient with macroalbuminuria. T-AN (r = - 0.43) and H-AN (r = - 0.38) levels showed higher correlation with estimated GFR (eGFR) than UAER (r = - 0.23). Urinary levels of both T-AN and H-AN negatively correlated with renal function in diabetic patients and they may serve as new biomarkers for diabetic kidney disease.","null","null","2020-09-28","Scientific Reports","Scientific Reports","Vol.10","No.1","15869","15869","eng","true","null","scientific_journal","null","null","10.1038/s41598-020-72494-6","2045-2322","null","null","null","null","null" "Real-world data on the use of insulin glargine 300 U/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study).","Real-world data on the use of insulin glargine 300 U/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study).","Munehide Matsuhisa, Masato Odawara, Takahisa Hirose, Ryusuke Koshida, Masayuki Senda, Yasushi Tanaka, Yasuo Terauchi","Munehide Matsuhisa, Masato Odawara, Takahisa Hirose, Ryusuke Koshida, Masayuki Senda, Yasushi Tanaka, Yasuo Terauchi","null","Of 774 patients, mean (±standard deviation) HbA1c (%) and fasting plasma glucose (mg/dL) decreased from 8.27 ± 1.55 to 8.15 ± 1.35 (by -0.12 ± 1.30 [p = 0.013]) and 167.9 ± 92.6 to 153.9 ± 70.9 (by -13.9 ± 103.8 [p = 0.067]) from baseline to month 12, respectively. A total of 16.3% achieved HbA1c <7.0% at month 12. Gla-300 dose increased by 1.13 ± 3.18 U/day (0.02 ± 0.05 U/kg/day) (p < 0.001), with a + 0.22 ± 2.70 (p = 0.037) body-weight change (kg) from baseline 60.83 ± 12.81 to 12-month 61.06 ± 12.89. Adverse drug reactions (ADRs) and serious ADRs occurred in 9.82% and 0.78% of the patients, respectively. Hypoglycemia was the most common ADR (9.30%). In total, 88.9% adhered to Gla-300 administration schedules, whereas <40% adhered to exercise and dietary instructions, respectively.","Gla-300 showed no unprecedented safety concerns for insulin-experienced T1DM patients in Japanese clinical settings. Our results provide insights into strategies for blunted Gla-300 up-titration dose, despite insufficient HbA1c control and lifestyle modification.","null","null","2020-08-25","Expert Opinion on Pharmacotherapy","Expert Opinion on Pharmacotherapy","Vol.22","No.2","249","256","eng","true","null","scientific_journal","null","null","10.1080/14656566.2020.1810665","1744-7666","null","null","null","null","null" "Predictive Factors of the Adherence to Real-Time Continuous Glucose Monitoring Sensors: A Prospective Observational Study (PARCS STUDY).","Predictive Factors of the Adherence to Real-Time Continuous Glucose Monitoring Sensors: A Prospective Observational Study (PARCS STUDY).","Takashi Murata, Akio Kuroda, Munehide Matsuhisa, Masao Toyoda, Moritsugu Kimura, Yushi Hirota, Ken Kato, Hideaki Sawaki, Atsuhito Tone, Satoshi Kawashima, Akira Okada, Tomokazu Watanabe, Shinsuke Nirengi, Akiko Suganuma, Naoki Sakane","Takashi Murata, Akio Kuroda, Munehide Matsuhisa, Masao Toyoda, Moritsugu Kimura, Yushi Hirota, Ken Kato, Hideaki Sawaki, Atsuhito Tone, Satoshi Kawashima, Akira Okada, Tomokazu Watanabe, Shinsuke Nirengi, Akiko Suganuma, Naoki Sakane","null","= .102).","Higher adherence to CGM sensors may be associated with a heavier emotional burden of diabetes and a worse QOL in relation to CSII at baseline.","null","null","2020-08-07","Journal of Diabetes Science and Technology","Journal of Diabetes Science and Technology","null","null","null","null","eng","true","null","scientific_journal","null","null","10.1177/1932296820939204","1932-2968","null","null","null","null","null" "Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study).","Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study).","Masato Odawara, Munehide Matsuhisa, Takahisa Hirose, Ryusuke Koshida, Masayuki Senda, Yasushi Tanaka, Yasuo Terauchi","Masato Odawara, Munehide Matsuhisa, Takahisa Hirose, Ryusuke Koshida, Masayuki Senda, Yasushi Tanaka, Yasuo Terauchi","null","We identified 1,227 insulin-naïve and 3,394 insulin-experienced patients. Insulin-naïve group increased the Gla-300 starting dose by 2.80 U/day during 12 months (7.49 to 10.29 U/day). Mean HbA1c reduced by 1.99% (9.82 to 7.83%), and 28.4% showed HbA1c < 7.0%. Insulin-experienced group had a baseline insulin dose of 14.86 U/day, which increased by 0.73 U/day. Mean HbA1c reduced by 0.18% (7.99 to 7.81%), and 24.6% showed HbA1c < 7.0%. Adverse drug reactions occurred in 3.42% (insulin-naïve) and 4.45% (insulin-experienced); symptomatic hypoglycemia (2.93% and 3.86%, respectively) was the most common in both groups.","Gla-300, in clinical practice, provides an effective and safe therapy as HbA1c was reduced/maintained in insulin-naïve/experienced Japanese T2DM patients without new safety signal. This study provides insights into the current Japanese clinical practices where insulin use is delayed and conservative despite relatively low HbA1c achievement.","null","null","2020-07-22","Expert Opinion on Pharmacotherapy","Expert Opinion on Pharmacotherapy","null","null","1","10","eng","true","null","scientific_journal","null","null","10.1080/14656566.2020.1785430","1744-7666","null","null","null","null","null" "Ethics and practical mitigations for ongoing clinical trials during the COVID-19 pandemic.","Ethics and practical mitigations for ongoing clinical trials during the COVID-19 pandemic.","Shota Suzuki, Yukie Ito, Shu Kasama, Takashi Murata, Munehide Matsuhisa, Masato Kasahara","Shota Suzuki, Yukie Ito, Shu Kasama, Takashi Murata, Munehide Matsuhisa, Masato Kasahara","null","null","null","null","null","2020-06-19","Diabetology International","Diabetology International","Vol.11","No.3","240","241","eng","true","null","scientific_journal","null","null","10.1007/s13340-020-00449-3","2190-1678","null","null","null","null","null" "Lower Risk for Severe Hypoglycaemia with Insulin Glargine 300 U/mL vs Glargine 100 U/mL in Participants with Type 1 Diabetes: a Meta-Analysis of 6-Month Phase 3 Clinical Trials.","Lower Risk for Severe Hypoglycaemia with Insulin Glargine 300 U/mL vs Glargine 100 U/mL in Participants with Type 1 Diabetes: a Meta-Analysis of 6-Month Phase 3 Clinical Trials.","Thomas Danne, Munehide Matsuhisa, Christian Sussebach, Harmonie Goyeau, Felipe Lauand, Elisabeth Niemoeller, B Geremia Bolli","Thomas Danne, Munehide Matsuhisa, Christian Sussebach, Harmonie Goyeau, Felipe Lauand, Elisabeth Niemoeller, B Geremia Bolli","null","reductions were similar. Fewer participants experienced ≥1 SH event with Gla-300 (6.2%) than Gla-100 (9.3%). From baseline to Month 6, the risk of a first SH event was lower with Gla-300: hazard ratio, 0.65 (95% confidence interval [CI] 0.44-0.98; stratified log-rank test, P = 0.038). SH event rates (relative risk [95% CI]) were numerically lower with Gla-300 versus Gla-100 from baseline to Month 6 (0.80 [0.49-1.29; P = 0.356]) and baseline to Week 8 (0.73 [0.37-1.44; P = 0.369]). Thus, Gla-300 demonstrated similar glycaemic control with lower risk of SH versus Gla-100, particularly during the titration period. This article is protected by copyright. All rights reserved.","Severe hypoglycaemia (SH) remains a challenge to people with type 1 diabetes (T1DM) and new generation basal insulins may improve patient outcomes. This post-hoc meta-analysis explored the risk of SH with insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100) in a pooled population with T1DM from three randomised, multicentre, 6-month similarly designed phase 3 trials: EDITION 4, EDITION JP 1, and EDITION JUNIOR. Endpoints included incidence and time to first occurrence of SH. Among 629 and 626 participants randomised to Gla-300 and Gla-100, HbA","null","null","2020-06-09","Diabetes, Obesity & Metabolism","Diabetes, Obesity & Metabolism","null","null","null","null","eng","true","null","scientific_journal","null","null","10.1111/dom.14109","1463-1326","null","null","null","null","null" "Nasal glucagon as a viable alternative for treating insulin-induced hypoglycaemia in Japanese patients with type 1 or type 2 diabetes: A phase 3 randomized crossover study.","Nasal glucagon as a viable alternative for treating insulin-induced hypoglycaemia in Japanese patients with type 1 or type 2 diabetes: A phase 3 randomized crossover study.","Munehide Matsuhisa, Yasushi Takita, Risa Nasu, Yukiko Nagai, Kenji Ohwaki, Hirotaka Nagashima","Munehide Matsuhisa, Yasushi Takita, Risa Nasu, Yukiko Nagai, Kenji Ohwaki, Hirotaka Nagashima","null","Seventy-five patients with T1DM (n = 34) or T2DM (n = 41) were enrolled; 72 patients (50 men, 22 women) received ≥1 study drug dose (T1DM, n = 33; T2DM, n = 39). Sixty-eight patients completed the study and were evaluable. All NG- and IMG-treated patients achieved treatment success (treatment arm difference: 0%; upper limit of two-sided 95% CI 1.47%); NG met prespecified conditions defining non-inferiority versus IMG. Glucagon was rapidly absorbed after both nasal and intramuscular administration; PG profiles were similar between administration routes during the first 60 minutes post dose. Study drug-related treatment-emergent adverse events affecting >2 patients were rhinalgia, increased blood pressure, nausea, ear pain and vomiting in the NG group, and nausea and vomiting in the IMG group.","Nasal glucagon was non-inferior to IMG for successful treatment of insulin-induced hypoglycaemia in Japanese patients with T1DM/T2DM, supporting use of NG as a rescue treatment for severe hypoglycaemia.","null","null","2020-04-12","Diabetes, Obesity & Metabolism","Diabetes, Obesity & Metabolism","Vol.22","No.7","1167","1175","eng","true","null","scientific_journal","null","null","10.1111/dom.14019","1463-1326","null","null","null","null","null" "Predictive factors of posttransplant glucose intolerance in Japanese patients with type 1 diabetes after pancreas transplantation.","Predictive factors of posttransplant glucose intolerance in Japanese patients with type 1 diabetes after pancreas transplantation.","Yasumitsu Takahi, Kazuyuki Miyashita, Mitsuyoshi Takahara, Naoto Katakami, Akio Kuroda, Taka-Aki Matsuoka, Munehide Matsuhisa, Toshinori Ito, Iichiro Shimomura","Yasumitsu Takahi, Kazuyuki Miyashita, Mitsuyoshi Takahara, Naoto Katakami, Akio Kuroda, Taka-Aki Matsuoka, Munehide Matsuhisa, Toshinori Ito, Iichiro Shimomura","null","120 at the initial examination. In conclusion, insulinogenic index and iAUCR from OGTT performed in the early posttransplantation period were predictive factors of future glucose intolerance.","120 at the initial examination. In conclusion, insulinogenic index and iAUCR from OGTT performed in the early posttransplantation period were predictive factors of future glucose intolerance.","null","null","2019-09-07","Endocrine Journal","Endocrine Journal","Vol.66","No.12","1101","1112","eng","true","null","scientific_journal","null","null","10.1507/endocrj.EJ19-0180","1348-4540","null","null","null","null","null" "第42回徳島医学会賞受賞論文 糖尿病患者の在宅ケア向上をめざした徳島市糖尿病サポーター(TCDS)育成の試み","The Attempt to Develop the Tokushima City Certified Diabetes Supporter (TCDS) for the Advancement of the Quality of Home Medical Care for the Diabetic Patients","鶴尾 美穂, 住友 正治, 大島 康志, 小松 まち子, 鈴木 麗子, 粟飯原 賢一, 安藝 菜奈子, 坂東 智子, 高橋 保子, 丸岡 重代, 原田 和代, 若槻 真吾, 桜井 えつ, 井野口 卓, 白神 敦久, 豊崎 纏, 松久 宗英, 宇都宮 正登","鶴尾 美穂, 住友 正治, 大島 康志, 小松 まち子, 鈴木 麗子, Ken-ichi Aihara, 安藝 菜奈子, 坂東 智子, 高橋 保子, 丸岡 重代, 原田 和代, 若槻 真吾, 桜井 えつ, 井野口 卓, 白神 敦久, 豊崎 纏, Munehide Matsuhisa, 宇都宮 正登","null","The Tokushima City Medical Association has cultivated the talented persons of nursing care profession by both the education of diabetes and the instruction of medical treatments to secure the quality of home care for increasing diabetic patients. They are certified to be the Tokushima City Certified Diabetes Supporter(TCDS). In Tokushima Prefecture, the rate of aging and the certification rate of care need are ranked high in Japan, and the medical measures should be provided for the aged diabetic patients utilizing team nursing care as well as team medical care, because many of these patients are obliged to receive home medical care owing to the introduction of community-based integrated care systems. Tokushima Prefecture kept the worst of age-adjusted diabetes mortality and also the worst of crude diabetes mortality in recent years. Therefore, the program for the TCDS was arranged by the staffs composed of board certified fellows of the Japan Diabetes Society, certified diabetes physicians of Tokushima, and Tokushima local certified diabetes educators (Tokushima LCDEs). The program includes the lectures of diabetes and medical treatments, the practical training, and the group work by the World Café system collaborated with the medical staffs across many different fields, using the dramatic skit presented by the medical doctors and the LCDE staffs after narrating the scenario for the blood glucose control of diabetic patients to be treated. The persons who have completed the training course are certified as the TCDS by The Tokushima City Medical Association. The workshop is held twice a year and the certification is renewed every three years without examination. In conclusion, it is suggested that the development of TCDS leads to the improvement of the ability of nursing care staffs to support diabetic treatments and the advancement of the quality of home medical care for the aged diabetic patients.","The Tokushima City Medical Association has cultivated the talented persons of nursing care profession by both the education of diabetes and the instruction of medical treatments to secure the quality of home care for increasing diabetic patients. They are certified to be the Tokushima City Certified Diabetes Supporter(TCDS). In Tokushima Prefecture, the rate of aging and the certification rate of care need are ranked high in Japan, and the medical measures should be provided for the aged diabetic patients utilizing team nursing care as well as team medical care, because many of these patients are obliged to receive home medical care owing to the introduction of community-based integrated care systems. Tokushima Prefecture kept the worst of age-adjusted diabetes mortality and also the worst of crude diabetes mortality in recent years. Therefore, the program for the TCDS was arranged by the staffs composed of board certified fellows of the Japan Diabetes Society, certified diabetes physicians of Tokushima, and Tokushima local certified diabetes educators (Tokushima LCDEs). The program includes the lectures of diabetes and medical treatments, the practical training, and the group work by the World Café system collaborated with the medical staffs across many different fields, using the dramatic skit presented by the medical doctors and the LCDE staffs after narrating the scenario for the blood glucose control of diabetic patients to be treated. The persons who have completed the training course are certified as the TCDS by The Tokushima City Medical Association. The workshop is held twice a year and the certification is renewed every three years without examination. In conclusion, it is suggested that the development of TCDS leads to the improvement of the ability of nursing care staffs to support diabetic treatments and the advancement of the quality of home medical care for the aged diabetic patients.","null","null","2019-08-25","四国医学雑誌","Shikoku Acta Medica","Vol.75","No.3","97","102","jpn","true","null","scientific_journal","null","null","null","0037-3699","null","null","null","null","null" "Assessing the oral health of in-patients with diabetes using a clinical version of the diabetes oral health assessment tool© and its association with dental examinations","Assessing the oral health of in-patients with diabetes using a clinical version of the diabetes oral health assessment tool© and its association with dental examinations","Yumi Kuwamura, Eijiro Sakamoto, Masuko Sumikawa, Munehide Matsuhisa, Daisuke Hinode, Hirokazu Uemura, Sachi Kishida","Yumi Kuwamura, Eijiro Sakamoto, Masuko Sumikawa, Munehide Matsuhisa, Daisuke Hinode, Hirokazu Uemura, Sachi Kishida","null","null","null","null","null","2019-08-02","The Journal of Medical Investigation : JMI","The Journal of Medical Investigation : JMI","Vol.66","No.3,4","328","336","eng","true","null","scientific_journal","null","null","10.2152/jmi.66.328","1343-1420","null","https://www.jstage.jst.go.jp/article/jmi/66/3.4/66_328/_pdf/-char/en","null","null","null" "In vitro and in vivo effects of insulin-producing cells generated by xeno-antigen free 3D culture with RCP piece.","In vitro and in vivo effects of insulin-producing cells generated by xeno-antigen free 3D culture with RCP piece.","Tetsuya Ikemoto, Rui Feng, Shuichi Iwahashi, Shin-ichiro Yamada, Yu Saitou, Yuji Morine, Satoru Imura, Munehide Matsuhisa, Mitsuo Shimada","Tetsuya Ikemoto, Rui Feng, Shuichi Iwahashi, Shin-ichiro Yamada, Yu Saitou, Yuji Morine, Satoru Imura, Munehide Matsuhisa, Mitsuo Shimada","null","To establish widespread cell therapy for type 1 diabetes mellitus, we aimed to develop an effective protocol for generating insulin-producing cells (IPCs) from adipose-derived stem cells (ADSCs). We established a 3D culture using a human recombinant peptide (RCP) petaloid μ-piece with xeno-antigen free reagents. Briefly, we employed our two-step protocol to differentiate ADSCs in 96-well dishes and cultured cells in xeno-antigen free reagents with 0.1 mg/mL RCP μ-piece for 7 days (step 1), followed by addition of histone deacetylase inhibitor for 14 days (step 2). Generated IPCs were strongly stained with dithizone, anti-insulin antibody at day 21, and microstructures resembling insulin secretory granules were detected by electron microscopy. Glucose stimulation index (maximum value, 4.9) and MAFA mRNA expression were significantly higher in 3D cultured cells compared with conventionally cultured cells (P < 0.01 and P < 0.05, respectively). The hyperglycaemic state of streptozotocin-induced diabetic nude mice converted to normoglycaemic state around 14 days after transplantation of 96 IPCs under kidney capsule or intra-mesentery. Histological evaluation revealed that insulin and C-peptide positive structures existed at day 120. Our established xeno-antigen free and RCP petaloid μ-piece 3D culture method for generating IPCs may be suitable for clinical application, due to the proven effectiveness in vitro and in vivo.","To establish widespread cell therapy for type 1 diabetes mellitus, we aimed to develop an effective protocol for generating insulin-producing cells (IPCs) from adipose-derived stem cells (ADSCs). We established a 3D culture using a human recombinant peptide (RCP) petaloid μ-piece with xeno-antigen free reagents. Briefly, we employed our two-step protocol to differentiate ADSCs in 96-well dishes and cultured cells in xeno-antigen free reagents with 0.1 mg/mL RCP μ-piece for 7 days (step 1), followed by addition of histone deacetylase inhibitor for 14 days (step 2). Generated IPCs were strongly stained with dithizone, anti-insulin antibody at day 21, and microstructures resembling insulin secretory granules were detected by electron microscopy. Glucose stimulation index (maximum value, 4.9) and MAFA mRNA expression were significantly higher in 3D cultured cells compared with conventionally cultured cells (P < 0.01 and P < 0.05, respectively). The hyperglycaemic state of streptozotocin-induced diabetic nude mice converted to normoglycaemic state around 14 days after transplantation of 96 IPCs under kidney capsule or intra-mesentery. Histological evaluation revealed that insulin and C-peptide positive structures existed at day 120. Our established xeno-antigen free and RCP petaloid μ-piece 3D culture method for generating IPCs may be suitable for clinical application, due to the proven effectiveness in vitro and in vivo.","null","null","2019-07-24","Scientific Reports","Scientific Reports","Vol.9","No.1","null","null","eng","true","null","scientific_journal","null","null","10.1038/s41598-019-47257-7","2045-2322","null","null","null","null","null" "Clinical impact of sarcopenia and dynapenia on diabetes.","Clinical impact of sarcopenia and dynapenia on diabetes.","Hiroyasu Mori, Akio Kuroda, Munehide Matsuhisa","Hiroyasu Mori, Akio Kuroda, Munehide Matsuhisa","null","Sarcopenia as a progressive and generalized skeletal muscle disorder that is associated with an increased likelihood of adverse outcomes, including falls, fractures, physical disability, and mortality. On the other hand, an age-related decline in muscle strength prior to the reduction of muscle mass, is proposed to be ""dynapenia"". Sarcopenia and dynapenia have recently been recognized as a diabetic complications in type 2 diabetes. We firstly indicated that sarcopenia was frequently observed in 16.6% of patients with type 1 diabetes aged even over 40 years. Additionally, we recently reported that the prevalence rate of dynapenia was higher than sarcopenia in patients with type 2 diabetes. Chronic hyperglycemia accelerates accumulation of advanced glycation end products (AGEs), which causes diabetic vascular complications through oxidative stress and chronic inflammation. We also demonstrated that skin autofluorescence (AF) as a marker of AGEs, was the independent determinant for skeletal muscle mass and strength in patients with type 2 diabetes and muscle strength in type 1 diabetes. Therefore, the early diagnosis of muscle weakness is essential for patients with diabetes and sustained good glycemic control with exercise and dietary intervention might be beneficial to prevent the progression of muscle weakness in these patients.","Sarcopenia as a progressive and generalized skeletal muscle disorder that is associated with an increased likelihood of adverse outcomes, including falls, fractures, physical disability, and mortality. On the other hand, an age-related decline in muscle strength prior to the reduction of muscle mass, is proposed to be ""dynapenia"". Sarcopenia and dynapenia have recently been recognized as a diabetic complications in type 2 diabetes. We firstly indicated that sarcopenia was frequently observed in 16.6% of patients with type 1 diabetes aged even over 40 years. Additionally, we recently reported that the prevalence rate of dynapenia was higher than sarcopenia in patients with type 2 diabetes. Chronic hyperglycemia accelerates accumulation of advanced glycation end products (AGEs), which causes diabetic vascular complications through oxidative stress and chronic inflammation. We also demonstrated that skin autofluorescence (AF) as a marker of AGEs, was the independent determinant for skeletal muscle mass and strength in patients with type 2 diabetes and muscle strength in type 1 diabetes. Therefore, the early diagnosis of muscle weakness is essential for patients with diabetes and sustained good glycemic control with exercise and dietary intervention might be beneficial to prevent the progression of muscle weakness in these patients.","null","null","2019-06-19","Diabetology International","Diabetology International","Vol.10","No.3","183","187","eng","true","null","scientific_journal","null","null","10.1007/s13340-019-00400-1","2190-1678","null","null","null","null","null" "Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation","Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation","Yuichi Takashi, Hidetaka Kosako, Shun Sawatsubashi, Yuka Kinoshita, Nobuaki Ito, Maria K. Tsoumpra, Masaomi Nangaku, Masahiro Abe, Munehide Matsuhisa, Shigeaki Kato, Toshio Matsumoto, Seiji Fukumoto","Yuichi Takashi, Hidetaka Kosako, Shun Sawatsubashi, Yuka Kinoshita, Nobuaki Ito, Maria K. Tsoumpra, Masaomi Nangaku, Masahiro Abe, Munehide Matsuhisa, Shigeaki Kato, Toshio Matsumoto, Seiji Fukumoto","null","Fibroblast growth factor (FGF) 23 produced by bone is a hormone that decreases serum phosphate (Pi). Reflecting its central role in Pi control, serum FGF23 is tightly regulated by serum Pi alterations. FGF23 levels are regulated by the transcriptional event and posttranslational cleavage into inactive fragments before its secretion. For the latter, O-glycosylation of FGF23 by gene product prevents the cleavage, leading to an increase in serum FGF23. However, the molecular basis of Pi sensing in the regulation of serum FGF23 remains elusive. In this study, we showed that high Pi diet enhanced the skeletal expression of , but not , with expected increases in serum FGF23 and Pi in mice. induction by high Pi was further observed in osteoblastic UMR 106 cells, and this was mediated by activation of the extracellular signal-regulated kinase (ERK) pathway. Through proteomic searches for the upstream sensor for high Pi, we identified one subtype of the FGF receptor (FGFR1c), which was phosphorylated by high Pi in the absence of FGFs. The mode of unliganded FGFR activation by high Pi appeared different from that of FGFR bound to a canonical FGFR ligand (FGF2) when phosphorylation of the FGFR substrate 2α and ERK was monitored. Finally, we showed that an FGFR inhibitor and conditional deletion of in osteoblasts/osteocytes abrogated high Pi diet-induced increases in serum FGF23 and femoral expression in mice. Thus, these findings uncover an unrecognized facet of unliganded FGFR function and illustrate a Pi-sensing pathway involved in regulation of FGF23 production.","Fibroblast growth factor (FGF) 23 produced by bone is a hormone that decreases serum phosphate (Pi). Reflecting its central role in Pi control, serum FGF23 is tightly regulated by serum Pi alterations. FGF23 levels are regulated by the transcriptional event and posttranslational cleavage into inactive fragments before its secretion. For the latter, O-glycosylation of FGF23 by gene product prevents the cleavage, leading to an increase in serum FGF23. However, the molecular basis of Pi sensing in the regulation of serum FGF23 remains elusive. In this study, we showed that high Pi diet enhanced the skeletal expression of , but not , with expected increases in serum FGF23 and Pi in mice. induction by high Pi was further observed in osteoblastic UMR 106 cells, and this was mediated by activation of the extracellular signal-regulated kinase (ERK) pathway. Through proteomic searches for the upstream sensor for high Pi, we identified one subtype of the FGF receptor (FGFR1c), which was phosphorylated by high Pi in the absence of FGFs. The mode of unliganded FGFR activation by high Pi appeared different from that of FGFR bound to a canonical FGFR ligand (FGF2) when phosphorylation of the FGFR substrate 2α and ERK was monitored. Finally, we showed that an FGFR inhibitor and conditional deletion of in osteoblasts/osteocytes abrogated high Pi diet-induced increases in serum FGF23 and femoral expression in mice. Thus, these findings uncover an unrecognized facet of unliganded FGFR function and illustrate a Pi-sensing pathway involved in regulation of FGF23 production.","null","null","2019-05-16","Proceedings of the National Academy of Sciences of the United States of America","Proceedings of the National Academy of Sciences of the United States of America","Vol.116","No.23","11418","11427","eng","true","null","scientific_journal","null","null","10.1073/pnas.1815166116","1091-6490","null","null","null","null","null" "Circulating osteocalcin as a bone-derived hormone is inversely correlated with body fat in patients with type 1 diabetes.","Circulating osteocalcin as a bone-derived hormone is inversely correlated with body fat in patients with type 1 diabetes.","Yuichi Takashi, Masashi Ishizu, Hiroyasu Mori, Kazuyuki Miyashita, Fumie Sakamoto, Naoto Katakami, Taka-Aki Matsuoka, Tetsuyuki Yasuda, Seiichi Hashida, Munehide Matsuhisa, Akio Kuroda","Yuichi Takashi, Masashi Ishizu, Hiroyasu Mori, Kazuyuki Miyashita, Fumie Sakamoto, Naoto Katakami, Taka-Aki Matsuoka, Tetsuyuki Yasuda, Seiichi Hashida, Munehide Matsuhisa, Akio Kuroda","null","The objective of the present study was to investigate the correlations between serum undercarboxylated osteocalcin (ucOC) or osteocalcin (OC) concentrations and %body fat, serum adiponectin and free-testosterone concentration, muscle strength and dose of exogenous insulin in patients with type 1 diabetes. We recruited 73 Japanese young adult patients with childhood-onset type 1 diabetes. All participants were receiving insulin replacement therapy. The correlations between logarithmic serum ucOC or OC concentrations and each parameter were examined. Serum ucOC and OC concentrations were inversely correlated with %body fat (r = -0.319, P = 0.007; r = -0.321, P = 0.006, respectively). Furthermore, multiple linear regression analyses were performed to determine whether or not serum ucOC or OC concentrations were factors associated with %body fat. Serum ucOC and OC concentrations remained significant factors even after adjusting for gender, HbA1c, body weight-adjusted total daily dose of insulin and duration of diabetes (β = -0.260, P = 0.027; β = -0.254, P = 0.031, respectively). However, serum ucOC and OC concentrations were not correlated with serum adiponectin or free-testosterone concentrations, muscle strength or dose of exogenous insulin. In conclusion, our study demonstrates the inverse correlation between serum ucOC or OC concentrations and body fat in patients with type 1 diabetes.","The objective of the present study was to investigate the correlations between serum undercarboxylated osteocalcin (ucOC) or osteocalcin (OC) concentrations and %body fat, serum adiponectin and free-testosterone concentration, muscle strength and dose of exogenous insulin in patients with type 1 diabetes. We recruited 73 Japanese young adult patients with childhood-onset type 1 diabetes. All participants were receiving insulin replacement therapy. The correlations between logarithmic serum ucOC or OC concentrations and each parameter were examined. Serum ucOC and OC concentrations were inversely correlated with %body fat (r = -0.319, P = 0.007; r = -0.321, P = 0.006, respectively). Furthermore, multiple linear regression analyses were performed to determine whether or not serum ucOC or OC concentrations were factors associated with %body fat. Serum ucOC and OC concentrations remained significant factors even after adjusting for gender, HbA1c, body weight-adjusted total daily dose of insulin and duration of diabetes (β = -0.260, P = 0.027; β = -0.254, P = 0.031, respectively). However, serum ucOC and OC concentrations were not correlated with serum adiponectin or free-testosterone concentrations, muscle strength or dose of exogenous insulin. In conclusion, our study demonstrates the inverse correlation between serum ucOC or OC concentrations and body fat in patients with type 1 diabetes.","null","null","2019-05-03","PLoS ONE","PLoS ONE","Vol.14","No.5","null","null","eng","true","null","scientific_journal","null","null","10.1371/journal.pone.0216416","1932-6203","null","null","null","null","null" "Development of monoclonal mouse antibodies that specifically recognize pancreatic polypeptide.","Development of monoclonal mouse antibodies that specifically recognize pancreatic polypeptide.","Akemi Hara, Yuko Nakagawa, Keiko Nakao, Motoyuki Tamaki, Tetsuya Ikemoto, Mitsuo Shimada, Munehide Matsuhisa, Hiroki Mizukami, Nobuhiro Maruyama, Hirotaka Watada, Yoshio Fujitani","Akemi Hara, Yuko Nakagawa, Keiko Nakao, Motoyuki Tamaki, Tetsuya Ikemoto, Mitsuo Shimada, Munehide Matsuhisa, Hiroki Mizukami, Nobuhiro Maruyama, Hirotaka Watada, Yoshio Fujitani","null","Pancreatic polypeptide (PP) is a 36-amino acid peptide encoded by the Ppy gene, which is produced by a small population of cells located in the periphery of the islets of Langerhans. Owing to the high amino acid sequence similarity among neuropeptide Y family members, antibodies against PP that are currently available are not convincingly specific to PP. Here we report the development of mouse monoclonal antibodies that specifically bind to PP. We generated Ppy knockout (Ppy-KO) mice in which the Ppy-coding region was replaced by Cre recombinase. The Ppy-KO mice were immunized with mouse PP peptide, and stable hybridoma cell lines producing anti-PP antibodies were isolated. Firstly, positive clones were selected in an enzyme-linked immunosorbent assay for reactivity with PP coupled to bovine serum albumin. During the screening, hybridoma clones producing antibodies that cross-react to the peptide YY (PYY) were excluded. In the second screening, hybridoma clones in which their culture media produce no signal in Ppy-KO islets but detect specific cells in the peripheral region of wild-type islets, were selected. Further studies demonstrated that the selected monoclonal antibody (23-2D3) specifically recognizes PP-producing cells, not only in mouse, but also in human and rat islets. The monoclonal antibodies with high binding specificity for PP developed in this study will be fundamental for future studies towards elucidating the expression profiles and the physiological roles of PP.","Pancreatic polypeptide (PP) is a 36-amino acid peptide encoded by the Ppy gene, which is produced by a small population of cells located in the periphery of the islets of Langerhans. Owing to the high amino acid sequence similarity among neuropeptide Y family members, antibodies against PP that are currently available are not convincingly specific to PP. Here we report the development of mouse monoclonal antibodies that specifically bind to PP. We generated Ppy knockout (Ppy-KO) mice in which the Ppy-coding region was replaced by Cre recombinase. The Ppy-KO mice were immunized with mouse PP peptide, and stable hybridoma cell lines producing anti-PP antibodies were isolated. Firstly, positive clones were selected in an enzyme-linked immunosorbent assay for reactivity with PP coupled to bovine serum albumin. During the screening, hybridoma clones producing antibodies that cross-react to the peptide YY (PYY) were excluded. In the second screening, hybridoma clones in which their culture media produce no signal in Ppy-KO islets but detect specific cells in the peripheral region of wild-type islets, were selected. Further studies demonstrated that the selected monoclonal antibody (23-2D3) specifically recognizes PP-producing cells, not only in mouse, but also in human and rat islets. The monoclonal antibodies with high binding specificity for PP developed in this study will be fundamental for future studies towards elucidating the expression profiles and the physiological roles of PP.","null","null","2019-03-06","Endocrine Journal","Endocrine Journal","Vol.66","No.5","459","468","eng","true","null","scientific_journal","null","null","10.1507/endocrj.EJ18-0441","1348-4540","null","null","null","null","null" "Development and Validation of the Continuous Subcutaneous Insulin Infusion-related Quality of Life (CSII-QOL) Scale.","Development and Validation of the Continuous Subcutaneous Insulin Infusion-related Quality of Life (CSII-QOL) Scale.","Naoki Sakane, Takashi Murata, Atsuhito Tone, Ken Kato, Moritsugu Kimura, Satoshi Kawashima, Hideaki Sawaki, Yushi Hirota, Akira Okada, Akio Kuroda, Munehide Matsuhisa, Tomokazu Watanabe, Akiko Suganuma, Shinsuke Nirengi, Masao Toyoda","Naoki Sakane, Takashi Murata, Atsuhito Tone, Ken Kato, Moritsugu Kimura, Satoshi Kawashima, Hideaki Sawaki, Yushi Hirota, Akira Okada, Akio Kuroda, Munehide Matsuhisa, Tomokazu Watanabe, Akiko Suganuma, Shinsuke Nirengi, Masao Toyoda","null","The CSII-QOL is the first CSII-related QOL scale for people with T1D. This short, validated, and reliable instrument might potentially be useful in future clinical studies and routine clinical patient care. Further validation is required to confirm these issues because of the small and potentially biased sample. (UMIN-CTR: UMIN000031595).","The CSII-QOL is the first CSII-related QOL scale for people with T1D. This short, validated, and reliable instrument might potentially be useful in future clinical studies and routine clinical patient care. Further validation is required to confirm these issues because of the small and potentially biased sample. (UMIN-CTR: UMIN000031595).","null","null","2019-02-16","Diabetes Technology & Therapeutics","Diabetes Technology & Therapeutics","Vol.22","No.3","216","221","eng","true","null","scientific_journal","null","null","10.1089/dia.2019.0216","1557-8593","null","null","null","null","null" "Association of accumulated advanced glycation end-products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes.","Association of accumulated advanced glycation end-products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes.","Hiroyasu Mori, Akio Kuroda, Masashi Ishizu, Mami Ohishi, Yuichi Takashi, Yinhua Otsuka, Satoshi Taniguchi, Motoyuki Tamaki, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, Yuko Akehi, Munehide Matsuhisa","Hiroyasu Mori, Akio Kuroda, Masashi Ishizu, Mami Ohishi, Yuichi Takashi, Yinhua Otsuka, Satoshi Taniguchi, Motoyuki Tamaki, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, Yuko Akehi, Munehide Matsuhisa","null","Advanced glycation end-products (AGEs), which are a major cause of diabetic vascular complications, accumulate in various tissues under chronic hyperglycemic conditions, as well as with aging in patients with diabetes. The loss of muscle mass and strength, so-called sarcopenia and dynapenia, has recently been recognized as a diabetic complication. However, the influence of accumulated AGEs on muscle mass and strength remains unclear. The present study aimed to evaluate the association of sarcopenia and dynapenia with accumulated AGEs in patients with type 2 diabetes. We recruited 166 patients with type 2 diabetes aged 30 years (mean age 63.2 ± 12.3 years; body mass index 26.3 ± 4.9 kg/m ; glycated hemoglobin 7.1 ± 1.1%). Skin autofluorescence as a marker of AGEs, limb skeletal muscle mass index, grip strength, knee extension strength and gait speed were assessed. Sarcopenia and dynapenia were observed in 7.2 and 13.9% of participants, respectively. Skin autofluorescence was significantly higher in patients with sarcopenia and dynapenia. Skin autofluorescence was the independent determinant for skeletal muscle mass index, grip strength, knee extension strength, sarcopenia and dynapenia. Accumulated AGEs could contribute to reduced muscle mass and strength, leading to sarcopenia and dynapenia in patients with type 2 diabetes.","Advanced glycation end-products (AGEs), which are a major cause of diabetic vascular complications, accumulate in various tissues under chronic hyperglycemic conditions, as well as with aging in patients with diabetes. The loss of muscle mass and strength, so-called sarcopenia and dynapenia, has recently been recognized as a diabetic complication. However, the influence of accumulated AGEs on muscle mass and strength remains unclear. The present study aimed to evaluate the association of sarcopenia and dynapenia with accumulated AGEs in patients with type 2 diabetes. We recruited 166 patients with type 2 diabetes aged 30 years (mean age 63.2 ± 12.3 years; body mass index 26.3 ± 4.9 kg/m ; glycated hemoglobin 7.1 ± 1.1%). Skin autofluorescence as a marker of AGEs, limb skeletal muscle mass index, grip strength, knee extension strength and gait speed were assessed. Sarcopenia and dynapenia were observed in 7.2 and 13.9% of participants, respectively. Skin autofluorescence was significantly higher in patients with sarcopenia and dynapenia. Skin autofluorescence was the independent determinant for skeletal muscle mass index, grip strength, knee extension strength, sarcopenia and dynapenia. Accumulated AGEs could contribute to reduced muscle mass and strength, leading to sarcopenia and dynapenia in patients with type 2 diabetes.","null","null","2019-01-24","Journal of Diabetes Investigation","Journal of Diabetes Investigation","null","null","null","null","eng","true","null","scientific_journal","null","null","10.1111/jdi.13014","2040-1124","null","null","null","null","null" "Safety of the batteries and power units used in insulin pumps: A pilot cross-sectional study by the Association for the Study of Innovative Diabetes Treatment in Japan.","Safety of the batteries and power units used in insulin pumps: A pilot cross-sectional study by the Association for the Study of Innovative Diabetes Treatment in Japan.","Takashi Murata, Shinsuke Nirengi, Naoki Sakane, Akio Kuroda, Yushi Hirota, Munehide Matsuhisa, Mitsuyoshi Namba, Tetsuro Kobayashi","Takashi Murata, Shinsuke Nirengi, Naoki Sakane, Akio Kuroda, Yushi Hirota, Munehide Matsuhisa, Mitsuyoshi Namba, Tetsuro Kobayashi","null","As trouble related to the batteries and power units of insulin pumps was frequent, practical guidance should be provided to respective patients regarding the use of reliable batteries, and to be well prepared for unexpected insulin pump failure.","As trouble related to the batteries and power units of insulin pumps was frequent, practical guidance should be provided to respective patients regarding the use of reliable batteries, and to be well prepared for unexpected insulin pump failure.","null","null","2018","Journal of Diabetes Investigation","Journal of Diabetes Investigation","Vol.9","No.4","903","907","eng","true","null","scientific_journal","null","null","10.1111/jdi.12765","2040-1124","null","null","null","null","null" "New risk factors of severe hypoglycemia.","New risk factors of severe hypoglycemia.","Munehide Matsuhisa, Akio Kuroda","Munehide Matsuhisa, Akio Kuroda","null","null","null","null","null","2018-10-13","Journal of Diabetes Investigation","Journal of Diabetes Investigation","Vol.10","No.2","219","220","eng","true","null","scientific_journal","null","null","10.1111/jdi.12925","2040-1124","null","null","null","null","null" "Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm.","Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm.","Masahiko Miyagi, Hiroshi Uchino, Naoki Kumashiro, Mariko Higa, Koki Shin, Makiko Sasamoto, Hiroji Kitazato, Motoyuki Tamaki, Munehide Matsuhisa, Takahisa Hirose","Masahiko Miyagi, Hiroshi Uchino, Naoki Kumashiro, Mariko Higa, Koki Shin, Makiko Sasamoto, Hiroji Kitazato, Motoyuki Tamaki, Munehide Matsuhisa, Takahisa Hirose","null","HbA1c was significantly lower at week 24 (- 1.0 ± 0.9% in the IGlar group and - 0.6 ± 0.8% in the liraglutide group), but the difference between groups was not significant. Changes in GA were similar (- 2.9 ± 3.2% vs. - 2.6 ± 3.2%) in both groups. Body weight (BW) was significantly lower only in the liraglutide group (+ 0.5 ± 2.6 kg vs. - 2.2 ± 2.0 kg). The rate of minor hypoglycemic episodes was similar for both groups.","Trial Registry (UMIN-CTR) as UMIN000012224.","null","null","2018-08-18","Diabetes Therapy","Diabetes Therapy","Vol.9","No.5","1959","1968","eng","true","null","scientific_journal","null","null","10.1007/s13300-018-0486-1","1869-6953","null","null","null","null","null" "The current status of treatment-related severe hypoglycemia in Japanese patients with diabetes mellitus: A report from the committee on a survey of severe hypoglycemia in the Japan Diabetes Society.","The current status of treatment-related severe hypoglycemia in Japanese patients with diabetes mellitus: A report from the committee on a survey of severe hypoglycemia in the Japan Diabetes Society.","Mitsuyoshi Namba, Toshio Iwakura, Rimei Nishimura, Kohei Akazawa, Munehide Matsuhisa, Yoshihito Atsumi, Jo Satoh, Toshimasa Yamauchi","Mitsuyoshi Namba, Toshio Iwakura, Rimei Nishimura, Kohei Akazawa, Munehide Matsuhisa, Yoshihito Atsumi, Jo Satoh, Toshimasa Yamauchi","null",") (P < 0.001). Again, the median HbA1c value at onset of severe hypoglycemia was shown to be 7.0 (6.3-8.1)% among all patients examined, 7.5 (6.9-8.6)% among those with type 1 diabetes, and 6.8 (6.1-7.6)% among those with type 2 diabetes, with the HbA1c value at onset of hypoglycemia being significantly lower among those with type 2 diabetes (P < 0.001). Antecedent symptoms of severe hypoglycemia were shown to be present, absent and unknown in 35.5, 35.6, and 28.9% of all patients, respectively, with the incidence of symptomatic hypoglycemia being significantly lower among those with type 1 diabetes (41.0%) than among those with type 2 diabetes (56.9%). The antidiabetic agents used in those with type 2 diabetes were insulin preparations (292 patients including 29 receiving concomitant sulfonylureas [SUs]) (60.8%), SUs (159 insulin-naïve patients) (33.1%), and no insulin preparations or SUs (29 patients) (6.0%). Of the 798 patients surveyed, 296 patients (37.2%) were shown to have required emergency transportation services for severe hypoglycemia before. Thus, the survey revealed, for the first time, the current status of treatment-related severe hypoglycemia in Japan and clearly highlights the acute need for implementing preventive measures against hypoglycemia not only through education on hypoglycemia but through optimization of antidiabetic therapy for those at high risk of severe hypoglycemia or those with a history of severe hypoglycemia.",") than among those with type 1 diabetes (73.3 [53.5-91.1] mL/min/1.73 m","null","null","2018-03-02","Journal of Diabetes Investigation","Journal of Diabetes Investigation","null","null","null","null","eng","true","null","scientific_journal","null","null","10.1111/jdi.12790","2040-1124","null","null","null","null","null" "Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus.","Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus.","Shusuke Yagi, Ken-ichi Aihara, Takeshi Kondo, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Daiju Fukuda, Yutaka Nakaya, Kin-Ichiro Suwaki, Takashi Takeji, Toshihiro Wada, Masdan Hotimah Salim, Saori Hama, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Takeshi Tobiume, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Munehide Matsuhisa, Michio Shimabukuro, Masashi Akaike, Masataka Sata","Shusuke Yagi, Ken-ichi Aihara, Takeshi Kondo, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Daiju Fukuda, Yutaka Nakaya, Kin-Ichiro Suwaki, Takashi Takeji, Toshihiro Wada, Masdan Hotimah Salim, Saori Hama, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Takeshi Tobiume, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Munehide Matsuhisa, Michio Shimabukuro, Masashi Akaike, Masataka Sata","null","Predictors for the effect of sodium glucose co-transporter 2 (SGLT2) inhibitors at lowering hemoglobin A1c (HbA1c) levels in type 2 diabetes mellitus patients remain unclear. We therefore aimed to elucidate these predictors in type 2 diabetes patients after 3 months of SGLT2 treatment. A total of 302 consecutive type 2 diabetes patients who had been treated with SGLT2 inhibitors as monotherapy or add-on therapy to existing antidiabetic treatments were enrolled retrospectively. After excluding 27 patients whose HbA1c levels could not be evaluated 3 months after treatment, the glucose-lowering effects of SGLT2 inhibitors were assessed in 275 patients by measuring HbA1c levels before and 3 months after treatment. The predictors for changes in HbA1c levels after 3 months of treatment were evaluated. SGLT2 inhibitor treatment for 3 months decreased HbA1c levels from 7.8 ± 1.2% to 7.4 ± 1.0% (p < 0.0001). A multiple regression analysis showed that the independent determinants for SGLT2 inhibitor treatment effect included decreased HbA1c levels after 1 month of treatment, high baseline HbA1c levels, and a high estimated glomerular filtration rate (eGFR). We show that type 2 diabetes patients who received the greatest glucose-lowering effect with SGLT2 inhibitor treatment were those with preserved renal function (high baseline eGFR) and high baseline HbA1c levels. Moreover, SGLT2 inhibitor treatment efficacy could be predicted by the patients' initial response to treatment.","Predictors for the effect of sodium glucose co-transporter 2 (SGLT2) inhibitors at lowering hemoglobin A1c (HbA1c) levels in type 2 diabetes mellitus patients remain unclear. We therefore aimed to elucidate these predictors in type 2 diabetes patients after 3 months of SGLT2 treatment. A total of 302 consecutive type 2 diabetes patients who had been treated with SGLT2 inhibitors as monotherapy or add-on therapy to existing antidiabetic treatments were enrolled retrospectively. After excluding 27 patients whose HbA1c levels could not be evaluated 3 months after treatment, the glucose-lowering effects of SGLT2 inhibitors were assessed in 275 patients by measuring HbA1c levels before and 3 months after treatment. The predictors for changes in HbA1c levels after 3 months of treatment were evaluated. SGLT2 inhibitor treatment for 3 months decreased HbA1c levels from 7.8 ± 1.2% to 7.4 ± 1.0% (p < 0.0001). A multiple regression analysis showed that the independent determinants for SGLT2 inhibitor treatment effect included decreased HbA1c levels after 1 month of treatment, high baseline HbA1c levels, and a high estimated glomerular filtration rate (eGFR). We show that type 2 diabetes patients who received the greatest glucose-lowering effect with SGLT2 inhibitor treatment were those with preserved renal function (high baseline eGFR) and high baseline HbA1c levels. Moreover, SGLT2 inhibitor treatment efficacy could be predicted by the patients' initial response to treatment.","null","null","2017-11","Advances in Therapy","Advances in Therapy","Vol.35","No.1","124","134","eng","true","null","scientific_journal","null","null","10.1007/s12325-017-0639-z","1865-8652","null","null","null","null","null" "Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.","Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.","Kohjiro Ueki, Takayoshi Sasako, Yukiko Okazaki, Masayuki Kato, Sumie Okahata, Hisayuki Katsuyama, Mikiko Haraguchi, Ai Morita, Ken Ohashi, Kazuo Hara, Atsushi Morise, Kazuo Izumi, Naoki Ishizuka, Yasuo Ohashi, Mitsuhiko Noda, Takashi Kadowaki, Group Study J-DOIT3, Munehide Matsuhisa","Kohjiro Ueki, Takayoshi Sasako, Yukiko Okazaki, Masayuki Kato, Sumie Okahata, Hisayuki Katsuyama, Mikiko Haraguchi, Ai Morita, Ken Ohashi, Kazuo Hara, Atsushi Morise, Kazuo Izumi, Naoki Ishizuka, Yasuo Ohashi, Mitsuhiko Noda, Takashi Kadowaki, Group Study J-DOIT3, Munehide Matsuhisa","null","Ministry of Health, Labour and Welfare of Japan, Asahi Kasei Pharma, Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Kissei Pharmaceutical, Kowa Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Novo Nordisk, Ono Pharmaceutical, Pfizer, Sanwa Kagaku Kenkyusho, Shionogi, Sumitomo Dainippon Pharma, Taisho Toyama Pharmaceutical, and Takeda.","Ministry of Health, Labour and Welfare of Japan, Asahi Kasei Pharma, Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Kissei Pharmaceutical, Kowa Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Novo Nordisk, Ono Pharmaceutical, Pfizer, Sanwa Kagaku Kenkyusho, Shionogi, Sumitomo Dainippon Pharma, Taisho Toyama Pharmaceutical, and Takeda.","null","null","2017-10-24","The Lancet. Diabetes & Endocrinology","The Lancet. Diabetes & Endocrinology","Vol.5","No.12","951","964","eng","true","null","scientific_journal","null","null","10.1016/S2213-8587(17)30327-3","2213-8595","null","null","null","null","null" "Accuracy and Time Delay of Glucose Measurements of Continuous Glucose Monitoring and Bedside Artificial Pancreas During Hyperglycemic and Euglycemic Hyperinsulinemic Glucose Clamp Study.","Accuracy and Time Delay of Glucose Measurements of Continuous Glucose Monitoring and Bedside Artificial Pancreas During Hyperglycemic and Euglycemic Hyperinsulinemic Glucose Clamp Study.","Akio Kuroda, Satoshi Taniguchi, Yuko Akehi, Hiroyasu Mori, Motoyuki Tamaki, Reiko Suzuki, Yinhua Otsuka, Munehide Matsuhisa","Akio Kuroda, Satoshi Taniguchi, Yuko Akehi, Hiroyasu Mori, Motoyuki Tamaki, Reiko Suzuki, Yinhua Otsuka, Munehide Matsuhisa","null","Both CGM and AP failed to follow plasma glucose values during nonphysiologically rapid glucose rising, but indicated accurate values during physiological glucose change.","Both CGM and AP failed to follow plasma glucose values during nonphysiologically rapid glucose rising, but indicated accurate values during physiological glucose change.","null","null","2017-10-09","Journal of Diabetes Science and Technology","Journal of Diabetes Science and Technology","Vol.11","No.6","1096","1100","eng","true","null","scientific_journal","null","null","10.1177/1932296817735122","1932-2968","null","null","null","null","null" "Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.","Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.","Kiyoe Kurahashi, Itsuro Endo, Takeshi Kondo, Kana Morimoto, Sumiko Yoshida, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Kohhei Nakajima, Yoshifumi Mizobuchi, Shinji Nagahiro, Masahiro Abe, Seiji Fukumoto","Kiyoe Kurahashi, Itsuro Endo, Takeshi Kondo, Kana Morimoto, Sumiko Yoshida, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Kohhei Nakajima, Yoshifumi Mizobuchi, Shinji Nagahiro, Masahiro Abe, Seiji Fukumoto","null","Acromegaly is caused by excessive growth hormone secretion, usually from pituitary adenomas. Somoatostatin analogues are widely used as primary or adjunctive therapy in the management of acromegaly. In this report, we present a case with remarkable shrinkage of a tumor after relatively short-term octreotide long-acting release (LAR) administration. During the 30-month follow-up after starting octreotide LAR, there was no recurrence of acromegaly with remarkable shrinkage of the tumor on pituitary magnetic resonance imaging. A literature review of the predictors for tumor shrinkage after the administration of somatostatin analogues in patients with acromegaly is also discussed in relation to this case.","Acromegaly is caused by excessive growth hormone secretion, usually from pituitary adenomas. Somoatostatin analogues are widely used as primary or adjunctive therapy in the management of acromegaly. In this report, we present a case with remarkable shrinkage of a tumor after relatively short-term octreotide long-acting release (LAR) administration. During the 30-month follow-up after starting octreotide LAR, there was no recurrence of acromegaly with remarkable shrinkage of the tumor on pituitary magnetic resonance imaging. A literature review of the predictors for tumor shrinkage after the administration of somatostatin analogues in patients with acromegaly is also discussed in relation to this case.","null","null","2017-08-21","Internal Medicine","Internal Medicine","Vol.56","No.18","2455","2461","eng","true","null","scientific_journal","null","null","10.2169/internalmedicine.8223-16","1349-7235","null","null","null","null","null" "Advanced glycation end products is a risk for muscle weakness in Japanese patients with type 1 diabetes.","Advanced glycation end products is a risk for muscle weakness in Japanese patients with type 1 diabetes.","Hiroyasu Mori, Akio Kuroda, Michiko Araki, Reiko Suzuki, Satoshi Taniguchi, Motoyuki Tamaki, Yuko Akehi, Munehide Matsuhisa","Hiroyasu Mori, Akio Kuroda, Michiko Araki, Reiko Suzuki, Satoshi Taniguchi, Motoyuki Tamaki, Yuko Akehi, Munehide Matsuhisa","null","Accumulation of advanced glycation end products (AGEs) is thought to contribute to muscle weakness in a diabetic animal model. Skin autofluorescence (AF) is a proposed marker for accumulation of AGEs in the skin. We aimed to investigate the relationship between AGEs accumulation, sarcopenia, and muscle function of Japanese patients with type 1 diabetes. Thirty-six patients with type 1 diabetes participated in this cross-sectional study. Sarcopenia parameters (skeletal muscle mass index (SMI) and knee extension strength) were compared with subcutaneous AGEs accumulation using skin AF. The prevalence of sarcopenia and impaired knee extension strength was 16.6% (male: 0.0%, female: 22.2%) and 47.2% (male: 22.2%, female: 55.6%), respectively. Knee extension strength was negatively correlated with skin AF (r²= 0.14, p < 0.05), but not with SMI. In conclusion, the AGEs accumulation might be one of the reasons of impaired lower limb muscle function in Japanese patients with type 1 diabetes. This article is protected by copyright. All rights reserved.","Accumulation of advanced glycation end products (AGEs) is thought to contribute to muscle weakness in a diabetic animal model. Skin autofluorescence (AF) is a proposed marker for accumulation of AGEs in the skin. We aimed to investigate the relationship between AGEs accumulation, sarcopenia, and muscle function of Japanese patients with type 1 diabetes. Thirty-six patients with type 1 diabetes participated in this cross-sectional study. Sarcopenia parameters (skeletal muscle mass index (SMI) and knee extension strength) were compared with subcutaneous AGEs accumulation using skin AF. The prevalence of sarcopenia and impaired knee extension strength was 16.6% (male: 0.0%, female: 22.2%) and 47.2% (male: 22.2%, female: 55.6%), respectively. Knee extension strength was negatively correlated with skin AF (r²= 0.14, p < 0.05), but not with SMI. In conclusion, the AGEs accumulation might be one of the reasons of impaired lower limb muscle function in Japanese patients with type 1 diabetes. This article is protected by copyright. All rights reserved.","null","null","2017-05","Journal of Diabetes Investigation","Journal of Diabetes Investigation","Vol.8","No.3","377","382","eng","true","null","scientific_journal","null","null","10.1111/jdi.12582","2040-1124","null","null","null","null","null" "Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.","Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.","Hirotsugu Yamada, Atsushi Tanaka, Kenya Kusunose, Rie Amano, Munehide Matsuhisa, Hiroyuki Daida, Masaaki Ito, Hiroyuki Tsutsui, Mamoru Nanasato, Haruo Kamiya, K Yasuko Bando, Masato Odawara, Hisako Yoshida, Toyoaki Murohara, Masataka Sata, Koichi Node","Hirotsugu Yamada, Atsushi Tanaka, Kenya Kusunose, Rie Amano, Munehide Matsuhisa, Hiroyuki Daida, Masaaki Ito, Hiroyuki Tsutsui, Mamoru Nanasato, Haruo Kamiya, K Yasuko Bando, Masato Odawara, Hisako Yoshida, Toyoaki Murohara, Masataka Sata, Koichi Node","null","Adding sitagliptin to conventional antidiabetic regimens in patients with T2DM for 24 months attenuated the annual exacerbation in the echocardiographic parameter of diastolic dysfunction (E/e') independent of other clinical variables such as blood pressure and glycemic control. Trial registration UMIN000004490 (University Hospital Medical Information Network Clinical Trials). https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005356 ; registered November 1, 2010.","Diabetes is associated closely with an increased risk of cardiovascular events, including diastolic dysfunction and heart failure that leads to a shortening of life expectancy. It is therefore extremely valuable to evaluate the impact of antidiabetic agents on cardiac function. However, the influence of dipeptidyl peptidase 4 inhibitors on cardiac function is controversial and a major matter of clinical concern. We therefore evaluated the effect of sitagliptin on echocardiographic parameters of diastolic function in patients with type 2 diabetes as a sub-analysis of the PROLOGUE study.","null","null","2017-05-11","Cardiovascular Diabetology","Cardiovascular Diabetology","Vol.16","No.1","63","63","eng","true","null","scientific_journal","null","null","10.1186/s12933-017-0546-2","1475-2840","null","null","null","null","null" "Strict blood glucose control by an artificial endocrine pancreas during hepatectomy may prevent postoperative acute kidney injury","Strict blood glucose control by an artificial endocrine pancreas during hepatectomy may prevent postoperative acute kidney injury","Naoji Mita, Shinji Kawahito, Tomohiro Soga, Kazumi Takaishi, Hiroshi Kitahata, Munehide Matsuhisa, Mitsuo Shimada, Kinoshita Hiroyuki, Yasuo Tsutsumi, Katsuya Tanaka","Naoji Mita, Shinji Kawahito, Tomohiro Soga, Kazumi Takaishi, Hiroshi Kitahata, Munehide Matsuhisa, Mitsuo Shimada, Kinoshita Hiroyuki, Yasuo Tsutsumi, Katsuya Tanaka","null","The aim of the present study was to evaluate the usefulness of a closed-loop system (STG-55; Nikkiso, Tokyo, Japan), a type of artificial endocrine pancreas for the continuous monitoring and control of intraoperative blood glucose, for preventing postoperative acute kidney injury (AKI) in patients undergoing hepatectomy. Thirty-eight patients were enrolled in this study. Glucose concentrations were controlled with either a manual injection of insulin based on a commonly used sliding scale (manual insulin group, n = 19) or the programmed infusion of insulin determined by the control algorithm of the artificial endocrine pancreas (programmed insulin group, n = 19). After the induction of anesthesia, a 20-G intravenous catheter was inserted into the peripheral forearm vein of patients in the programmed insulin group and connected to an artificial endocrine pancreas (STG-55). The target range for glucose concentrations was set to 100-150 mg/dL. The mean serum creatinine concentrations of preoperative, postoperative 24 and 48 h were 0.72, 0.78, and 0.79 mg/dL in the programmed insulin group, and 0.81, 0.95, and 1.03 mg/dL in the manual insulin group, respectively. Elevations in serum creatinine concentrations postoperative 48 h were significantly suppressed in the programmed insulin group. The STG-55 closed-loop system was effective for maintaining strict blood glucose control during hepatectomy with minimal variability in blood glucose concentrations and for suppressing elevations in serum creatinine concentrations. Strict blood glucose control by an artificial endocrine pancreas during hepatectomy may prevent postoperative AKI.","The aim of the present study was to evaluate the usefulness of a closed-loop system (STG-55; Nikkiso, Tokyo, Japan), a type of artificial endocrine pancreas for the continuous monitoring and control of intraoperative blood glucose, for preventing postoperative acute kidney injury (AKI) in patients undergoing hepatectomy. Thirty-eight patients were enrolled in this study. Glucose concentrations were controlled with either a manual injection of insulin based on a commonly used sliding scale (manual insulin group, n = 19) or the programmed infusion of insulin determined by the control algorithm of the artificial endocrine pancreas (programmed insulin group, n = 19). After the induction of anesthesia, a 20-G intravenous catheter was inserted into the peripheral forearm vein of patients in the programmed insulin group and connected to an artificial endocrine pancreas (STG-55). The target range for glucose concentrations was set to 100-150 mg/dL. The mean serum creatinine concentrations of preoperative, postoperative 24 and 48 h were 0.72, 0.78, and 0.79 mg/dL in the programmed insulin group, and 0.81, 0.95, and 1.03 mg/dL in the manual insulin group, respectively. Elevations in serum creatinine concentrations postoperative 48 h were significantly suppressed in the programmed insulin group. The STG-55 closed-loop system was effective for maintaining strict blood glucose control during hepatectomy with minimal variability in blood glucose concentrations and for suppressing elevations in serum creatinine concentrations. Strict blood glucose control by an artificial endocrine pancreas during hepatectomy may prevent postoperative AKI.","null","null","2017-03","Journal of Artificial Organs","Journal of Artificial Organs","Vol.20","No.1","76","83","eng","true","null","scientific_journal","null","null","10.1007/s10047-016-0925-6","1619-0904","null","null","null","null","null" "A Pirot study comparing the CGM-assessed glycemic profiles of patients with type 1 diabetes on insulin degludec and insulin glargine","A Pirot study comparing the CGM-assessed glycemic profiles of patients with type 1 diabetes on insulin degludec and insulin glargine","Akio Kuroda, Tsuruo Miho, Aki Nanako, Takeshi Kondo, Oguro Yukari, Motoyuki Tamaki, Ken-ichi Aihara, Itsuro Endo, Toshio Matsumoto, Masahiro Abe, Munehide Matsuhisa","Akio Kuroda, Tsuruo Miho, Aki Nanako, Takeshi Kondo, Oguro Yukari, Motoyuki Tamaki, Ken-ichi Aihara, Itsuro Endo, Toshio Matsumoto, Masahiro Abe, Munehide Matsuhisa","null","null","null","null","null","2017-03","Diabetology International","Diabetology International","Vol.8","No.1","112","115","eng","true","null","scientific_journal","null","null","10.1007/s13340-016-0289-4","2190-1678","null","null","null","null","null" "糖尿病治療に関連した重症低血糖の調査委員会報告","The Current Status of Treatment-related Severe Hypoglycemia in Japanese Patients with Diabetes Mellitus: A Report from the Committee on a Survey of Severe Hypoglycemia in the Japan Diabetes Society","難波 光義, 岩倉 敏夫, 西村 理明, 赤澤 宏平, 松久 宗英, 渥美 義仁, 佐藤 譲, 山内 敏正, 日本糖尿病学会―糖尿病治療に関連した重症低血糖の調査委員会―","Mitsuyoshi Namba, Toshio Iwakura, Rimei Nishimura, Kohei Akazawa, Munehide Matsuhisa, Yoshihito Atsumi, Jo Satoh, Toshimasa Yamauchi, Mellitus: A Report from the Committee on a Survey of Severe Hypoglycemia in the Japan Diabetes Society","null","
糖尿病に対する薬物治療の進歩の一方で,患者の高齢化などを背景とした低血糖リスクの増大が憂慮されている.このため,わが国の糖尿病実臨床における治療に関連した重症低血糖の調査を行った.日本糖尿病学会学術調査研究等倫理審査委員会の承認のもと,2015年7月に同学会認定教育施設631施設の研修責任者に対して調査への参加を依頼した.参加意思を表明した施設には,倫理審査の必要書類を送付し,各施設の倫理審査委員会での承認後,Web登録システム(症例データは匿名・非連結)を利用してデータ登録を依頼した.本調査研究は,同学会学術調査研究委員会の予算で行った.施設実態調査(施設データ)および,個々の症例から同意取得後に症例調査(症例データ)を実施した.重症低血糖の定義は,『自己のみでは対処できない低血糖症状があり,発症・発見・受診時の静脈血漿血糖値が60 mg/dL未満(毛細管全血50 mg/dL未満)が明らかにされていることが望ましい』とし,調査期間は2014年4月1日から2015年3月31日としたが,施設データは193施設から,症例データはそのうち113施設から総数798症例の登録があった.回答を得た193施設中,149施設(77.2 %)に救急部が併設されており,1施設あたりの同部への年間総救急搬送件数(中央値)は4962件,このうち重症低血糖は17.0件(0.34 %)をしめた.回答施設における重症低血糖による年間受診総数は2237人であり,1施設あたり6.5人であった.重症低血糖による年間入院総数は1171人で,1施設あたり4.0人であり,重症低血糖による年間受診数の52.3 %を占めていた.798例の症例データをまとめると,病型は1型240人,2型480人,その他78人,年齢は1型54.0(41.0-67.0)歳,2型77.0(68.0-83.0)歳であり,2型が有意に高齢で(P < 0.001),BMIは1型では21.3(18.9-24.0)kg/m2,2型では22.0(19.5-24.8)kg/m2で,2型の方が高値であった(P = 0.003).推算糸球体濾過量(eGFR)は1型73.3(53.5-91.1)mL/min/1.73 m2,2型50.6(31.8-71.1)mL/min/1.73 m2となり,2型の方が低値であった(P < 0.001).重症低血糖発生時点のHbA1cは全体で7.0(6.3-8.1)%,1型7.5(6.9-8.6)%,2型6.8(6.1-7.6)%であり2型で低値であった(P < 0.001).重症低血糖の前駆症状の有無に関しては全体で有35.5 %,無35.6 %,不明28.9 %,前駆症状の発現率は1型で41.0 %,2型で56.9 %となり,1型の方が前駆症状の発現率は低かった(P < 0.001).2型の治療薬はインスリン使用群(SU薬併用29人含む)292人(60.8 %),SU薬群(インスリン未使用)159人(33.1 %),インスリン・SU薬未使用群29人(6.0 %)であった.調査対象798例のうち296例(37.2 %)は,過去にも重症低血糖で救急受診した既往を有していた.以上のようにわが国の糖尿病治療に関連する重症低血糖の実態が初めて明らかになった.今後は重症低血糖の高リスク者や既往者に対し,低血糖の教育と治療の適正化による発症予防対策が急務であることが明確となった.
","Despite great strides in pharmacotherapy for diabetes, there is increasing concern over the risk of hypoglycemia in diabetes patients receiving pharmacotherapy as they become older. This has prompted the Japan Diabetes Society (JDS) to initiate a survey on the current status of severe hypoglycemia in the clinical setting. In July 2015, after receiving approval from the JDS Scientific Survey/Research Ethics Committee, the JDS extended an invitation to executive educators, who represented a total of 631 healthcare facilities accredited by the JDS for diabetes education, to participate in the proposed survey. Among these educators, those who expressed their willingness to participate in the survey were sent an application form to obtain ethical approval from their hospitals. After receiving approval, they were asked to enter relevant clinical data (on an unlinked, anonymous basis) into a web-based registry. The current survey was fully funded by the JDS Scientific Survey/Research Committee. A case registry (clinical case database) was launched after collecting facility-specific information (healthcare facility database) from all of the participating facilities and after obtaining informed consent from all of the participating patients. The current survey, which defined severe hypoglycemia as ""the presence of hypoglycemic symptoms requiring assistance from another person to treat and plasma venous glucose levels at the onset/diagnosis of disease or glucose levels that were clearly less than 60 mg/dL at presentation (capillary whole blood glucose, <50 mg/dL) "", was conducted between April 1, 2014 and March 31, 2015, During the study period, facility-specific information was collected from a total of 193 healthcare facilities with a total of 798 case reports collected from 113 facilities. (View PDF for the rest of the abstract.)
","null","null","2017","糖尿病","Journal of the The Japan Diabetes Society","Vol.60","No.12","826","842","jpn","true","null","scientific_journal","null","null","10.11213/tonyobyo.60.826","0021-437X","null","null","null","null","null" "Sequential cleavage of insulin receptor by calpain 2 and -secretase impairs insulin signalling.","Sequential cleavage of insulin receptor by calpain 2 and -secretase impairs insulin signalling.","Tomoyuki Yuasa, Kikuko Amo-Shiinoki, Shuhei Ishikura, Mitsuyoshi Takahara, Takaaki Matsuoka, Hideaki Kaneto, Akio Kuroda, Munehide Matsuhisa, Seiichi Hashida","Tomoyuki Yuasa, Kikuko Amo-Shiinoki, Shuhei Ishikura, Mitsuyoshi Takahara, Takaaki Matsuoka, Hideaki Kaneto, Akio Kuroda, Munehide Matsuhisa, Seiichi Hashida","null","Sequential cleavage of IR by calpain 2 and -secretase may contribute to insulin signalling in cells and its inhibition may be partly responsible for the glucose-lowering effects of metformin. Thus, IR cleavage may offer a new mechanism for the aetiology of insulin resistance.","Sequential cleavage of IR by calpain 2 and -secretase may contribute to insulin signalling in cells and its inhibition may be partly responsible for the glucose-lowering effects of metformin. Thus, IR cleavage may offer a new mechanism for the aetiology of insulin resistance.","null","null","2016-12","Diabetologia","Diabetologia","Vol.59","No.12","2711","2721","eng","true","null","scientific_journal","null","null","10.1007/s00125-016-4102-5","1432-0428","null","null","null","null","null" "Suppression of the Hypothalamic-pituitary-adrenal Axis by Maximum Androgen Blockade in a Patient with Prostate Cancer.","Suppression of the Hypothalamic-pituitary-adrenal Axis by Maximum Androgen Blockade in a Patient with Prostate Cancer.","Takeshi Kondo, Itsuro Endo, Yukari Ooguro, Kana Morimoto, Kiyoe Kurahashi, Sumiko Yoshida, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Masahiro Abe, Seiji Fukumoto","Takeshi Kondo, Itsuro Endo, Yukari Ooguro, Kana Morimoto, Kiyoe Kurahashi, Sumiko Yoshida, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Masahiro Abe, Seiji Fukumoto","null","A 78-year-old Japanese man showed suppression of the hypothalamic-pituitary-adrenal axis during maximum androgen blockade (MAB) therapy including chlormadinone acetate (CMA) for prostate cancer. After stopping the MAB therapy, both the basal ACTH level and the response to CRH recovered. While no reports have indicated that CMA suppresses the hypothalamic-pituitary-adrenal axis in patients with prostate cancer, CMA has been shown to inhibit this axis in animals. These observations suggest that we must monitor the hypothalamic-pituitary-adrenal axis in patients treated with CMA, especially under stressful conditions.","A 78-year-old Japanese man showed suppression of the hypothalamic-pituitary-adrenal axis during maximum androgen blockade (MAB) therapy including chlormadinone acetate (CMA) for prostate cancer. After stopping the MAB therapy, both the basal ACTH level and the response to CRH recovered. While no reports have indicated that CMA suppresses the hypothalamic-pituitary-adrenal axis in patients with prostate cancer, CMA has been shown to inhibit this axis in animals. These observations suggest that we must monitor the hypothalamic-pituitary-adrenal axis in patients treated with CMA, especially under stressful conditions.","null","null","2016-12-15","Internal Medicine","Internal Medicine","Vol.55","No.24","3623","3626","eng","true","null","scientific_journal","null","null","10.2169/internalmedicine.55.7359","1349-7235","null","null","null","null","null" "Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study.","Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study.","Hirofumi Tomiyama, Takashi Miwa, Kenshi Kan, Munehide Matsuhisa, Haruo Kamiya, Mamoru Nanasato, Tomoki Kitano, Hiroaki Sano, Jun Ohno, Masato Iida, Masataka Sata, Hirotsugu Yamada, Koji Maemura, Atsushi Tanaka, Toyoaki Murohara, Koichi Node","Hirofumi Tomiyama, Takashi Miwa, Kenshi Kan, Munehide Matsuhisa, Haruo Kamiya, Mamoru Nanasato, Tomoki Kitano, Hiroaki Sano, Jun Ohno, Masato Iida, Masataka Sata, Hirotsugu Yamada, Koji Maemura, Atsushi Tanaka, Toyoaki Murohara, Koichi Node","null","No conclusive evidence has been obtained yet on the significance of the effects of dipeptidyl peptidase-4 (DPP-4 inhibitor) treatment on the arterial stiffness in clinical settings. In addition, the effects of good glycemic control on the arterial stiffness have also not been clarified yet. As a sub-analysis of the PROLOGUE study, we examined the effect of a DPP-4 inhibitor (sitagliptin) on the 2-year progression of the arterial stiffness and also to determine the effect of good glycemic control on the rate of progression of the arterial stiffness. In the PROLOGUE study, the study participants were either allocated to add-on sitagliptin treatment or to continued treatment with conventional anti-diabetic agents. Among the 463 participants of the PROLOGUE study, we succeeded in measuring the brachial-ankle pulse wave velocity (baPWV) at least two times during the 2-year study period in 96 subjects. The changes in the baPWV during the study period were similar between the both groups (i.e., with/without staglipitin), overall. On the other hand, when the study subjects were divided into two groups according to the glycemic control status during the study period {good glycemic control group (GC) = hemoglobin (Hb)A1c <7.0 at both 12 and 24 months after the treatment randomization; poor glycemic control group (PC) = HbA1c ≥7.0 at either 12 months, 24 months, or both}, the 2-year increase of the baPWV was marginally significantly larger in the PC group (144 ± 235 cm/s) as compared to that the GC group (-10 ± 282 cm/s) (p = 0.036). While the present study could not confirm the beneficial effect of sitagliptin per se on the arterial stiffness, the results suggested that good glycemic control appears to be beneficial for delaying the annual progression of the arterial stiffness. Trial registration University Hospital Medical Information Network Clinical Trials Registry UMIN000004490.","No conclusive evidence has been obtained yet on the significance of the effects of dipeptidyl peptidase-4 (DPP-4 inhibitor) treatment on the arterial stiffness in clinical settings. In addition, the effects of good glycemic control on the arterial stiffness have also not been clarified yet. As a sub-analysis of the PROLOGUE study, we examined the effect of a DPP-4 inhibitor (sitagliptin) on the 2-year progression of the arterial stiffness and also to determine the effect of good glycemic control on the rate of progression of the arterial stiffness. In the PROLOGUE study, the study participants were either allocated to add-on sitagliptin treatment or to continued treatment with conventional anti-diabetic agents. Among the 463 participants of the PROLOGUE study, we succeeded in measuring the brachial-ankle pulse wave velocity (baPWV) at least two times during the 2-year study period in 96 subjects. The changes in the baPWV during the study period were similar between the both groups (i.e., with/without staglipitin), overall. On the other hand, when the study subjects were divided into two groups according to the glycemic control status during the study period {good glycemic control group (GC) = hemoglobin (Hb)A1c <7.0 at both 12 and 24 months after the treatment randomization; poor glycemic control group (PC) = HbA1c ≥7.0 at either 12 months, 24 months, or both}, the 2-year increase of the baPWV was marginally significantly larger in the PC group (144 ± 235 cm/s) as compared to that the GC group (-10 ± 282 cm/s) (p = 0.036). While the present study could not confirm the beneficial effect of sitagliptin per se on the arterial stiffness, the results suggested that good glycemic control appears to be beneficial for delaying the annual progression of the arterial stiffness. Trial registration University Hospital Medical Information Network Clinical Trials Registry UMIN000004490.","null","null","2016-11-03","Cardiovascular Diabetology","Cardiovascular Diabetology","Vol.15","No.1","150","150","eng","true","null","scientific_journal","null","null","10.1186/s12933-016-0472-8","1475-2840","null","null","null","null","null" "Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension).","Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension).","Munehide Matsuhisa, Masayoshi Koyama, Xi Cheng, Mariko Sumi, C Matthew Riddle, B Geremia Bolli, Takahisa Hirose","Munehide Matsuhisa, Masayoshi Koyama, Xi Cheng, Mariko Sumi, C Matthew Riddle, B Geremia Bolli, Takahisa Hirose","null","Over 12months' treatment, participants with type 1 diabetes receiving Gla-300 achieved sustained glycaemic control and experienced less nocturnal hypoglycaemia that was confirmed (<3.0mmol/L [<54mg/dL]) or severe compared with Gla-100, supporting the 6-month results.","Over 12months' treatment, participants with type 1 diabetes receiving Gla-300 achieved sustained glycaemic control and experienced less nocturnal hypoglycaemia that was confirmed (<3.0mmol/L [<54mg/dL]) or severe compared with Gla-100, supporting the 6-month results.","null","null","2016-10-13","Diabetes Research and Clinical Practice","Diabetes Research and Clinical Practice","Vol.122","null","133","140","eng","true","null","scientific_journal","null","null","10.1016/j.diabres.2016.10.002","1872-8227","null","null","null","null","null" "Somatic cell reprogramming-free generation of genetically modified pigs.","Somatic cell reprogramming-free generation of genetically modified pigs.","Fuminori Tanihara, Tatsuya Takemoto, Eri Kitagawa, Shengbin Rao, Kim Lanh Thi Do, Akira Onishi, Yukiko Yamashita, Chisato Kosugi, Hitomi Suzuki, Shoichiro Sembon, Shunichi Suzuki, Michiko Nakai, Masakazu Hashimoto, Akihiro Yasue, Munehide Matsuhisa, Sumihare Noji, Tatsuya Fujimura, Dai-Ichiro Fuchimoto, Takeshige Otoi","Fuminori Tanihara, Tatsuya Takemoto, Eri Kitagawa, Shengbin Rao, Kim Lanh Thi Do, Akira Onishi, Yukiko Yamashita, Chisato Kosugi, Hitomi Suzuki, Shoichiro Sembon, Shunichi Suzuki, Michiko Nakai, Masakazu Hashimoto, Akihiro Yasue, Munehide Matsuhisa, Sumihare Noji, Tatsuya Fujimura, Dai-Ichiro Fuchimoto, Takeshige Otoi","null","Genetically modified pigs for biomedical applications have been mainly generated using the somatic cell nuclear transfer technique; however, this approach requires complex micromanipulation techniques and sometimes increases the risks of both prenatal and postnatal death by faulty epigenetic reprogramming of a donor somatic cell nucleus. As a result, the production of genetically modified pigs has not been widely applied. We provide a simple method for CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 gene editing in pigs that involves the introduction of Cas9 protein and single-guide RNA into in vitro fertilized zygotes by electroporation. The use of gene editing by electroporation of Cas9 protein (GEEP) resulted in highly efficient targeted gene disruption and was validated by the efficient production of Myostatin mutant pigs. Because GEEP does not require the complex methods associated with micromanipulation for somatic reprogramming, it has the potential for facilitating the genetic modification of pigs.","Genetically modified pigs for biomedical applications have been mainly generated using the somatic cell nuclear transfer technique; however, this approach requires complex micromanipulation techniques and sometimes increases the risks of both prenatal and postnatal death by faulty epigenetic reprogramming of a donor somatic cell nucleus. As a result, the production of genetically modified pigs has not been widely applied. We provide a simple method for CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 gene editing in pigs that involves the introduction of Cas9 protein and single-guide RNA into in vitro fertilized zygotes by electroporation. The use of gene editing by electroporation of Cas9 protein (GEEP) resulted in highly efficient targeted gene disruption and was validated by the efficient production of Myostatin mutant pigs. Because GEEP does not require the complex methods associated with micromanipulation for somatic reprogramming, it has the potential for facilitating the genetic modification of pigs.","null","null","2016-09-14","Science Advances","Science Advances","Vol.2","No.9","null","null","eng","true","null","scientific_journal","null","null","10.1126/sciadv.1600803","2375-2548","null","null","null","null","null" "Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.","Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.","A Tanaka, T Murohara, I Taguchi, K Eguchi, M Suzuki, M Kitakaze, Y Sato, T Ishizu, Y Higashi, Hirotsugu Yamada, M Nanasato, Michio Shimabukuro, H Teragawa, S Ueda, S Kodera, Munehide Matsuhisa, T Kadokami, K Kario, Y Nishio, T Inoue, K Maemura, J Oyama, M Ohishi, Masataka Sata, H Tomiyama, K Node, Investigators Study PROTECT","A Tanaka, T Murohara, I Taguchi, K Eguchi, M Suzuki, M Kitakaze, Y Sato, T Ishizu, Y Higashi, Hirotsugu Yamada, M Nanasato, Michio Shimabukuro, H Teragawa, S Ueda, S Kodera, Munehide Matsuhisa, T Kadokami, K Kario, Y Nishio, T Inoue, K Maemura, J Oyama, M Ohishi, Masataka Sata, H Tomiyama, K Node, Investigators Study PROTECT","null","BACKGROUND: Type 2 diabetes mellitus is associated strongly with an increased risk of micro- and macro-vascular complications, leading to impaired quality of life and shortened life expectancy. In addition to appropriate glycemic control, multi-factorial intervention for a wide range of risk factors, such as hypertension and dyslipidemia, is crucial for management of diabetes. A recent cardiovascular outcome trial in diabetes patients with higher cardiovascular risk demonstrated that a SGLT2 inhibitor markedly reduced mortality, but not macro-vascular events. However, to date there is no clinical evidence regarding the therapeutic effects of SGLT2 inhibitors on arteriosclerosis. The ongoing PROTECT trial was designed to assess whether the SGLT2 inhibitors, ipragliflozin, prevented progression of carotid intima-media thickness in Japanese patients with type 2 diabetes mellitus.METHODS: A total of 480 participants with type 2 diabetes mellitus with a HbA1c between 6 and 10 % despite receiving diet/exercise therapy and/or standard anti-diabetic agents for at least 3 months, will be randomized systematically (1:1) into either ipragliflozin or control (continuation of conventional therapy) groups. After randomization, ipragliflozin (50-100 mg once daily) will be added on to the background therapy in participants assigned to the ipragliflozin group. The primary endpoint of the study is the change in mean intima-media thickness of the common carotid artery from baseline to 24 months. Images of carotid intima-media thickness will be analyzed at a central core laboratory in a blinded manner. The key secondary endpoints include the change from baseline in other parameters of carotid intima-media thickness, various metabolic parameters, and renal function. Other cardiovascular functional tests are also planned for several sub-studies.DISCUSSION: The PROTECT study is the first to assess the preventive effect of ipragliflozin on progression of carotid atherosclerosis using carotid intima-media thickness as a surrogate marker. The study has potential to clarify the protective effects of ipragliflozin on atherosclerosis. Trial registration Unique Trial Number, UMIN000018440 ( https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021348 ).","BACKGROUND: Type 2 diabetes mellitus is associated strongly with an increased risk of micro- and macro-vascular complications, leading to impaired quality of life and shortened life expectancy. In addition to appropriate glycemic control, multi-factorial intervention for a wide range of risk factors, such as hypertension and dyslipidemia, is crucial for management of diabetes. A recent cardiovascular outcome trial in diabetes patients with higher cardiovascular risk demonstrated that a SGLT2 inhibitor markedly reduced mortality, but not macro-vascular events. However, to date there is no clinical evidence regarding the therapeutic effects of SGLT2 inhibitors on arteriosclerosis. The ongoing PROTECT trial was designed to assess whether the SGLT2 inhibitors, ipragliflozin, prevented progression of carotid intima-media thickness in Japanese patients with type 2 diabetes mellitus.METHODS: A total of 480 participants with type 2 diabetes mellitus with a HbA1c between 6 and 10 % despite receiving diet/exercise therapy and/or standard anti-diabetic agents for at least 3 months, will be randomized systematically (1:1) into either ipragliflozin or control (continuation of conventional therapy) groups. After randomization, ipragliflozin (50-100 mg once daily) will be added on to the background therapy in participants assigned to the ipragliflozin group. The primary endpoint of the study is the change in mean intima-media thickness of the common carotid artery from baseline to 24 months. Images of carotid intima-media thickness will be analyzed at a central core laboratory in a blinded manner. The key secondary endpoints include the change from baseline in other parameters of carotid intima-media thickness, various metabolic parameters, and renal function. Other cardiovascular functional tests are also planned for several sub-studies.DISCUSSION: The PROTECT study is the first to assess the preventive effect of ipragliflozin on progression of carotid atherosclerosis using carotid intima-media thickness as a surrogate marker. The study has potential to clarify the protective effects of ipragliflozin on atherosclerosis. Trial registration Unique Trial Number, UMIN000018440 ( https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021348 ).","null","null","2016-09-13","Cardiovascular Diabetology","Cardiovascular Diabetology","Vol.15","No.1","133","133","eng","true","null","scientific_journal","null","null","10.1186/s12933-016-0449-7","1475-2840","null","null","null","null","null" "Skin Autofluorescence is Associated with Early-stage Atherosclerosis in Patients with Type 1 Diabetes.","Skin Autofluorescence is Associated with Early-stage Atherosclerosis in Patients with Type 1 Diabetes.","Saeko Osawa, Naoto Katakami, Akio Kuroda, Mitsuyoshi Takahara, Fumie Sakamoto, Dan Kawamori, Takaaki Matsuoka, Munehide Matsuhisa, Iichiro Shimomura","Saeko Osawa, Naoto Katakami, Akio Kuroda, Mitsuyoshi Takahara, Fumie Sakamoto, Dan Kawamori, Takaaki Matsuoka, Munehide Matsuhisa, Iichiro Shimomura","null","Skin AF values were significantly higher in type 1 diabetic patients than in healthy controls (2.07±0.50 (mean±SD) and 1.90±0.26, respectively, p=0.024). Skin AF was associated with carotid IMT (r=0.446, p<0.001) and baPWV (r=0.450, p<0.001), but not with ABI (r=-0.019, p=0.8488). Notably, skin AF was an independent risk factor for IMT thickening. Similarly, skin AF was associated with log (UACR) (r=0.194, p=0.049) and was an independent risk factor for UACR. Furthermore, skin AF values were significantly higher in patients with diabetic retinopathy than in those without (2.21±0.08 and 1.97±0.06, respectively, p=0.020).","Skin AF was significantly associated with the presence and/or severity of diabetic complications and was an independent risk factor for carotid atherosclerosis.","null","null","2016-09-02","Journal of Atherosclerosis and Thrombosis","Journal of Atherosclerosis and Thrombosis","null","null","null","null","eng","true","null","scientific_journal","null","null","10.5551/jat.35592","1880-3873","null","null","null","null","null" "A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes.","A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes.","B Allen King, Akio Kuroda, Munehide Matsuhisa, Todd Hobbs","B Allen King, Akio Kuroda, Munehide Matsuhisa, Todd Hobbs","null","Dosing guidelines for patients with type 1 diabetes using continuous subcutaneous insulin infusion (CSII), which are historically based on clinical experience and retrospective studies of patients consuming an American diet, recommend that basal insulin should represent approximately 50 % of the total daily dose (TDD). Recent prospective studies in the USA and Japan conclude that the more appropriate proportion is closer to 30-40 % of TDD. In addition, currently used formulas for calculating the carbohydrate-to-insulin ratio (CIR) and correction factor (CF) may lead to underdosing of bolus insulin by as much as 12.8-50 % for a hypothetical patient. The discrepancies between traditional formulas and data from newer studies can be accounted for by the more rigorous design of the newer studies (e.g., prospective design, controlled diets, meal omission, and frequent glucose monitoring). International differences in diet composition may also be important to consider when developing dosing recommendations for CSII.","Dosing guidelines for patients with type 1 diabetes using continuous subcutaneous insulin infusion (CSII), which are historically based on clinical experience and retrospective studies of patients consuming an American diet, recommend that basal insulin should represent approximately 50 % of the total daily dose (TDD). Recent prospective studies in the USA and Japan conclude that the more appropriate proportion is closer to 30-40 % of TDD. In addition, currently used formulas for calculating the carbohydrate-to-insulin ratio (CIR) and correction factor (CF) may lead to underdosing of bolus insulin by as much as 12.8-50 % for a hypothetical patient. The discrepancies between traditional formulas and data from newer studies can be accounted for by the more rigorous design of the newer studies (e.g., prospective design, controlled diets, meal omission, and frequent glucose monitoring). International differences in diet composition may also be important to consider when developing dosing recommendations for CSII.","null","null","2016-09","Current Diabetes Reports","Current Diabetes Reports","Vol.16","No.9","null","null","eng","true","null","scientific_journal","null","null","10.1007/s11892-016-0772-0","1539-0829","null","null","null","null","null" "The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial.","The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial.","J Oyama, T Murohara, M Kitakaze, T Ishizu, Y Sato, K Kitagawa, H Kamiya, M Ajioka, M Ishiara, K Dai, M Nanasato, Masataka Sata, K Maemura, H Tomiyama, Y Higashi, K Kaku, Hirotsugu Yamada, Munehide Matsuhisa, K Yamashita, YK Bando, N Kashihara, S Ueda, T Inoue, K Node, Investigators Study PROLOGUE","J Oyama, T Murohara, M Kitakaze, T Ishizu, Y Sato, K Kitagawa, H Kamiya, M Ajioka, M Ishiara, K Dai, M Nanasato, Masataka Sata, K Maemura, H Tomiyama, Y Higashi, K Kaku, Hirotsugu Yamada, Munehide Matsuhisa, K Yamashita, YK Bando, N Kashihara, S Ueda, T Inoue, K Node, Investigators Study PROLOGUE","null","BACKGROUND: Experimental studies have suggested that dipeptidyl peptidase-4 (DPP-4) inhibitors provide cardiovascular protective effects. We performed a randomized study to evaluate the effects of sitagliptin added on to the conventional therapy compared with conventional therapy alone (diet, exercise, and/or drugs, except for incretin-related agents) on the intima-media thickness (IMT) of the carotid artery, a surrogate marker for the evaluation of atherosclerotic cardiovascular disease, in people with type 2 diabetes mellitus (T2DM).METHODS AND FINDINGS: We used a multicenter PROBE (prospective, randomized, open label, blinded endpoint) design. Individuals aged 30 y with T2DM (6.2% HbA1c < 9.4%) were randomly allocated to receive either sitagliptin (25 to 100 mg/d) or conventional therapy. Carotid ultrasound was performed at participating medical centers, and all parameters were measured in a core laboratory. Of the 463 enrolled participants with T2DM, 442 were included in the primary analysis (sitagliptin group, 222; conventional therapy group, 220). Estimated mean (± standard error) common carotid artery IMT at 24 mo of follow-up in the sitagliptin and conventional therapy groups was 0.827 ± 0.007 mm and 0.837 ± 0.007 mm, respectively, with a mean difference of -0.009 mm (97.2% CI -0.028 to 0.011, p = 0.309). HbA1c level at 24 mo was significantly lower with sitagliptin than with conventional therapy (6.56% ± 0.05% versus 6.72% ± 0.05%, p = 0.008; group mean difference -0.159, 95% CI -0.278 to -0.041). Episodes of serious hypoglycemia were recorded only in the conventional therapy group, and the rate of other adverse events was not different between the two groups. As it was not a placebo-controlled trial and carotid IMT was measured as a surrogate marker of atherosclerosis, there were some limitations of interpretation.CONCLUSIONS: In the PROLOGUE study, there was no evidence that treatment with sitagliptin had an additional effect on the progression of carotid IMT in participants with T2DM beyond that achieved with conventional treatment.TRIAL REGISTRATION: University Hospital Medical Information Network Clinical Trials Registry UMIN000004490.","BACKGROUND: Experimental studies have suggested that dipeptidyl peptidase-4 (DPP-4) inhibitors provide cardiovascular protective effects. We performed a randomized study to evaluate the effects of sitagliptin added on to the conventional therapy compared with conventional therapy alone (diet, exercise, and/or drugs, except for incretin-related agents) on the intima-media thickness (IMT) of the carotid artery, a surrogate marker for the evaluation of atherosclerotic cardiovascular disease, in people with type 2 diabetes mellitus (T2DM).METHODS AND FINDINGS: We used a multicenter PROBE (prospective, randomized, open label, blinded endpoint) design. Individuals aged 30 y with T2DM (6.2% HbA1c < 9.4%) were randomly allocated to receive either sitagliptin (25 to 100 mg/d) or conventional therapy. Carotid ultrasound was performed at participating medical centers, and all parameters were measured in a core laboratory. Of the 463 enrolled participants with T2DM, 442 were included in the primary analysis (sitagliptin group, 222; conventional therapy group, 220). Estimated mean (± standard error) common carotid artery IMT at 24 mo of follow-up in the sitagliptin and conventional therapy groups was 0.827 ± 0.007 mm and 0.837 ± 0.007 mm, respectively, with a mean difference of -0.009 mm (97.2% CI -0.028 to 0.011, p = 0.309). HbA1c level at 24 mo was significantly lower with sitagliptin than with conventional therapy (6.56% ± 0.05% versus 6.72% ± 0.05%, p = 0.008; group mean difference -0.159, 95% CI -0.278 to -0.041). Episodes of serious hypoglycemia were recorded only in the conventional therapy group, and the rate of other adverse events was not different between the two groups. As it was not a placebo-controlled trial and carotid IMT was measured as a surrogate marker of atherosclerosis, there were some limitations of interpretation.CONCLUSIONS: In the PROLOGUE study, there was no evidence that treatment with sitagliptin had an additional effect on the progression of carotid IMT in participants with T2DM beyond that achieved with conventional treatment.TRIAL REGISTRATION: University Hospital Medical Information Network Clinical Trials Registry UMIN000004490.","null","null","2016-06-28","PLoS Medicine","PLoS Medicine","Vol.13","No.6","e1002051","e1002051","eng","true","null","scientific_journal","null","null","10.1371/journal.pmed.1002051","1549-1676","null","null","null","null","null" "New insulin glargine 300 U/mL versus glargine 100 U/mL in Japanese adults with type 1 diabetes using basal and mealtime insulinglucose control and hypoglycaemia in a randomized controlled trial","New insulin glargine 300 U/mL versus glargine 100 U/mL in Japanese adults with type 1 diabetes using basal and mealtime insulinglucose control and hypoglycaemia in a randomized controlled trial","Munehide Matsuhisa, M. Koyama, X Cheng, Y Takahashi, M C Riiddle, G B Boli, T Hirose, on behalf of the Edition JP 1 study group","Munehide Matsuhisa, M. Koyama, X Cheng, Y Takahashi, M C Riiddle, G B Boli, T Hirose, on behalf of the Edition JP 1 study group","null","To compare efficacy and safety of new insulin glargine 300 U/ml (Gla-300) with that of insulin glargine 100 U/ml (Gla-100) in Japanese adults with type 1 diabetes. The EDITION JP 1 study (NCT01689129) was a 6-month, multicentre, open-label, phase III study. Participants (n = 243) were randomized to Gla-300 or Gla-100 while continuing mealtime insulin. Basal insulin was titrated with the aim of achieving a fasting self-monitored plasma glucose target of 4.4-7.2 mmol/l. The primary endpoint was change in glycated haemoglobin (HbA1c) over 6 months. Safety measures included hypoglycaemia and change in body weight. Gla-300 was non-inferior to Gla-100 for the primary endpoint of HbA1c change over the 6-month period {least squares [LS] mean difference 0.13 % [95 % confidence interval (CI) -0.03 to 0.29]}. The annualized rate of confirmed (≤3.9 mmol/l) or severe hypoglycaemic events was 34 % lower with Gla-300 than with Gla-100 at night [rate ratio 0.66 (95 % CI 0.48-0.92)] and 20 % lower at any time of day [24 h; rate ratio 0.80 (95 % CI 0.65-0.98)]; this difference was most pronounced during the first 8 weeks of treatment. Severe hypoglycaemia was infrequent. The basal insulin dose increased in both groups (month 6 dose: Gla-300 0.35 U/kg/day, Gla-100 0.29 U/kg/day). A between-treatment difference in body weight change over 6 months favouring Gla-300 was observed [LS mean difference -0.6 kg (95 % CI -1.1 to -0.0); p = 0.035]. Adverse event rates were comparable between the groups. In Japanese adults with type 1 diabetes using basal plus mealtime insulin, less hypoglycaemia was observed with Gla-300 than with Gla-100, particularly during the night, while glycaemic control did not differ.","To compare efficacy and safety of new insulin glargine 300 U/ml (Gla-300) with that of insulin glargine 100 U/ml (Gla-100) in Japanese adults with type 1 diabetes. The EDITION JP 1 study (NCT01689129) was a 6-month, multicentre, open-label, phase III study. Participants (n = 243) were randomized to Gla-300 or Gla-100 while continuing mealtime insulin. Basal insulin was titrated with the aim of achieving a fasting self-monitored plasma glucose target of 4.4-7.2 mmol/l. The primary endpoint was change in glycated haemoglobin (HbA1c) over 6 months. Safety measures included hypoglycaemia and change in body weight. Gla-300 was non-inferior to Gla-100 for the primary endpoint of HbA1c change over the 6-month period {least squares [LS] mean difference 0.13 % [95 % confidence interval (CI) -0.03 to 0.29]}. The annualized rate of confirmed (≤3.9 mmol/l) or severe hypoglycaemic events was 34 % lower with Gla-300 than with Gla-100 at night [rate ratio 0.66 (95 % CI 0.48-0.92)] and 20 % lower at any time of day [24 h; rate ratio 0.80 (95 % CI 0.65-0.98)]; this difference was most pronounced during the first 8 weeks of treatment. Severe hypoglycaemia was infrequent. The basal insulin dose increased in both groups (month 6 dose: Gla-300 0.35 U/kg/day, Gla-100 0.29 U/kg/day). A between-treatment difference in body weight change over 6 months favouring Gla-300 was observed [LS mean difference -0.6 kg (95 % CI -1.1 to -0.0); p = 0.035]. Adverse event rates were comparable between the groups. In Japanese adults with type 1 diabetes using basal plus mealtime insulin, less hypoglycaemia was observed with Gla-300 than with Gla-100, particularly during the night, while glycaemic control did not differ.","null","null","2016-04","Diabetes, Obesity & Metabolism","Diabetes, Obesity & Metabolism","Vol.18","No.4","375","383","eng","true","null","scientific_journal","null","null","10.1111/dom.12619","1463-1326","null","null","null","null","null" "Serum carboxy-terminal telopeptide of type I collagen levels are associated with carotid atherosclerosis in patients with cardiovascular risk factors.","Serum carboxy-terminal telopeptide of type I collagen levels are associated with carotid atherosclerosis in patients with cardiovascular risk factors.","Takeshi Kondo, Itsuro Endo, Ken-ichi Aihara, Ohnishi Yukiyo, Dong Bingzi, Oguro Yukari, Kiyoe Kurahashi, Sumiko Yoshida, Yuichi Fujinaka, Akio Kuroda, Munehide Matsuhisa, Seiji Fukumoto, Toshio Matsumoto, Masahiro Abe","Takeshi Kondo, Itsuro Endo, Ken-ichi Aihara, Ohnishi Yukiyo, Dong Bingzi, Oguro Yukari, Kiyoe Kurahashi, Sumiko Yoshida, Yuichi Fujinaka, Akio Kuroda, Munehide Matsuhisa, Seiji Fukumoto, Toshio Matsumoto, Masahiro Abe","null","Carboxy-terminal telopeptide of type I collagen (ICTP) is generated through matrix metalloproteinase (MMP)-dependent type I collagen digestion, and has been widely utilized as a biomarker for bone turnover. The fact that atherosclerotic lesions are rich in both type I collagen and MMP-producing macrophages led to the hypothesis that serum ICTP concentrations may serve as a non-invasive clinical biomarker for atherosclerosis. Therefore, the association of serum ICTP concentrations with the maximum intima-media thickness (IMT) of carotid arteries, a surrogate index of systemic atherosclerosis, or brachial-ankle pulse wave velocity (baPWV) in patients with atherosclerotic risk factors was evaluated. A total of 52 male and 65 female (mean age: 62.8 yrs) patients without renal failure, malignancies or bone diseases known to affect serum ICTP concentrations were recruited. Patients with max IMTs ≥1.1 mm showed significantly higher serum ICTP concentrations compared with patients with max IMTs <1.1 mm (3.33 ± 0.97 vs 2.82 ± 0.65 ng/mL, p<0.05). Serum ICTP concentration was also positively correlated with max IMT (p<0.001) or baPWV values (p<0.05). Multivariate analyses also revealed that serum ICTP concentrations were correlated with max IMT (p<0.001; 95% CI 0.200 to 0.454). These results suggest that serum ICTP concentrations can be used as a non-invasive biomarker for systemic atherosclerosis.","Carboxy-terminal telopeptide of type I collagen (ICTP) is generated through matrix metalloproteinase (MMP)-dependent type I collagen digestion, and has been widely utilized as a biomarker for bone turnover. The fact that atherosclerotic lesions are rich in both type I collagen and MMP-producing macrophages led to the hypothesis that serum ICTP concentrations may serve as a non-invasive clinical biomarker for atherosclerosis. Therefore, the association of serum ICTP concentrations with the maximum intima-media thickness (IMT) of carotid arteries, a surrogate index of systemic atherosclerosis, or brachial-ankle pulse wave velocity (baPWV) in patients with atherosclerotic risk factors was evaluated. A total of 52 male and 65 female (mean age: 62.8 yrs) patients without renal failure, malignancies or bone diseases known to affect serum ICTP concentrations were recruited. Patients with max IMTs ≥1.1 mm showed significantly higher serum ICTP concentrations compared with patients with max IMTs <1.1 mm (3.33 ± 0.97 vs 2.82 ± 0.65 ng/mL, p<0.05). Serum ICTP concentration was also positively correlated with max IMT (p<0.001) or baPWV values (p<0.05). Multivariate analyses also revealed that serum ICTP concentrations were correlated with max IMT (p<0.001; 95% CI 0.200 to 0.454). These results suggest that serum ICTP concentrations can be used as a non-invasive biomarker for systemic atherosclerosis.","null","null","2016-02-17","Endocrine Journal","Endocrine Journal","Vol.63","No.4","397","404","eng","true","null","scientific_journal","null","null","10.1507/endocrj.EJ15-0589","1348-4540","null","null","null","null","null" "カーボカウントと糖質摂取","Carbohydrate Counting and Its Consumption","黒田 暁生, 松久 宗英","Akio Kuroda, Munehide Matsuhisa","null","null","null","null","null","2016-02-04","糖尿病","Journal of the The Japan Diabetes Society","Vol.59","No.1","24","26","jpn","true","null","scientific_journal","null","null","10.11213/tonyobyo.59.24","0021-437X","null","http://ci.nii.ac.jp/naid/130005125023/","null","null","null" "糖尿病地域医療連携のIT化の試み∼その現状と課題∼","糖尿病地域医療連携のIT化の試み∼その現状と課題∼","松久 宗英","Munehide Matsuhisa","null","null","null","null","null","2016-01-29","NPO法人日本糖尿病情報学会誌","NPO法人日本糖尿病情報学会誌","Vol.14","null","null","null","jpn","true","null","scientific_journal","null","null","null","null","null","null","null","null","null" "Significant elevation of serum dipeptidyl peptidase-4 activity in young-adult type 1 diabetes.","Significant elevation of serum dipeptidyl peptidase-4 activity in young-adult type 1 diabetes.","Saeko Osawa, Dan Kawamori, Naoto Katakami, Mitsuyoshi Takahara, Fumie Sakamoto, Takashi Katsura, Tetsuyuki Yasuda, Hideaki Kaneto, Munehide Matsuhisa, Taka-Aki Matsuoka, Iichiro Shimomura","Saeko Osawa, Dan Kawamori, Naoto Katakami, Mitsuyoshi Takahara, Fumie Sakamoto, Takashi Katsura, Tetsuyuki Yasuda, Hideaki Kaneto, Munehide Matsuhisa, Taka-Aki Matsuoka, Iichiro Shimomura","null","Serum DPP-4 activity is significantly elevated in Japanese type 1 diabetes, suggesting pathophysiological significance of the enzyme in type 1 diabetes.","Serum DPP-4 activity is significantly elevated in Japanese type 1 diabetes, suggesting pathophysiological significance of the enzyme in type 1 diabetes.","null","null","2016-01-14","Diabetes Research and Clinical Practice","Diabetes Research and Clinical Practice","Vol.113","null","135","142","eng","true","null","scientific_journal","null","null","10.1016/j.diabres.2015.12.022","1872-8227","null","null","null","null","null" "Development of the Diabetes Oral Health Assessment Tool © for Nurses","Development of the Diabetes Oral Health Assessment Tool © for Nurses","Yumi Kuwamura, Sumikawa Masuko, Tetsuya Tanioka, Toshihiko Nagata, Eijiro Sakamoto, Hiromi Murata, Munehide Matsuhisa, Ken-ichi Aihara, Daisuke Hinode, Hirokazu Uemura, Hirokazu Ito, Yuko Yasuhara, Rozzano De Castro Locsin","Yumi Kuwamura, Sumikawa Masuko, Tetsuya Tanioka, Toshihiko Nagata, Eijiro Sakamoto, Hiromi Murata, Munehide Matsuhisa, Ken-ichi Aihara, Daisuke Hinode, Hirokazu Uemura, Hirokazu Ito, Yuko Yasuhara, Rozzano De Castro Locsin","null","null","null","null","null","2015-12-28","Health","Health","Vol.7","No.12","1710","1720","eng","true","null","scientific_journal","null","null","10.4236/health.2015.712186","1949-4998","null","null","null","null","null" "Non-invasive Measurement of Skin Autofluorescence as a Beneficial Surrogate Marker for Atherosclerosis in Patients with Type 2 Diabetes","Non-invasive Measurement of Skin Autofluorescence as a Beneficial Surrogate Marker for Atherosclerosis in Patients with Type 2 Diabetes","Jin Temma, Munehide Matsuhisa, Toru Horie, Akio Kuroda, Hiroyasu Mori, Motoyuki Tamaki, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe, Toshio Matsumoto","Jin Temma, Munehide Matsuhisa, Toru Horie, Akio Kuroda, Hiroyasu Mori, Motoyuki Tamaki, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe, Toshio Matsumoto","null","Advanced glycation end-products (AGEs) are thought to play a major role in the pathogenesis of diabetic vascular complications. Skin autofluorescence (AF) was recently reported to represent tissue AGEs accumulation with a non-invasive method. The aim of the present study was to evaluate association between AF value and diabetic vascular complications, such as retinopathy, nephropathy and cervical atherosclerosis using the carotid intima-media thickness (IMT), an established marker of cardiovascular disease in patients with type 2 diabetes. A total of 68 patients with type 2 diabetes were enrolled in a cross-sectional manner. AGEs accumulation was measured with AF reader. Clinical parameters were collected at the time of AF and IMT measurement. Max-IMT was correlated with age and AF (r=0.407, p=0.001), but not with HbA1c, GA, and pentosidine. Also, AF was not correlated with HbA1c, GA and pentosidine, but was correlated with age (r=0.560, p<0.001), duration of diabetes (r=0.256, p<0.05). Multivariate regression analysis revealed that AF, but not age, was an independent determinant of max-IMT. In conclusion, AF might be a beneficial surrogate marker for evaluating carotid atherosclerosis in patients with type 2 diabetes non-invasively. J. Med. Invest. 62: 126-129, August, 2015.","Advanced glycation end-products (AGEs) are thought to play a major role in the pathogenesis of diabetic vascular complications. Skin autofluorescence (AF) was recently reported to represent tissue AGEs accumulation with a non-invasive method. The aim of the present study was to evaluate association between AF value and diabetic vascular complications, such as retinopathy, nephropathy and cervical atherosclerosis using the carotid intima-media thickness (IMT), an established marker of cardiovascular disease in patients with type 2 diabetes. A total of 68 patients with type 2 diabetes were enrolled in a cross-sectional manner. AGEs accumulation was measured with AF reader. Clinical parameters were collected at the time of AF and IMT measurement. Max-IMT was correlated with age and AF (r=0.407, p=0.001), but not with HbA1c, GA, and pentosidine. Also, AF was not correlated with HbA1c, GA and pentosidine, but was correlated with age (r=0.560, p<0.001), duration of diabetes (r=0.256, p<0.05). Multivariate regression analysis revealed that AF, but not age, was an independent determinant of max-IMT. In conclusion, AF might be a beneficial surrogate marker for evaluating carotid atherosclerosis in patients with type 2 diabetes non-invasively. J. Med. Invest. 62: 126-129, August, 2015.","null","null","2015-07","The Journal of Medical Investigation : JMI","The Journal of Medical Investigation : JMI","Vol.62","No.3-4","126","129","eng","true","null","scientific_journal","null","null","10.2152/jmi.62.126","1349-6867","null","null","null","null","null" "Acute effect of fast walking on postprandial blood glucose control in type 2 diabetes","Acute effect of fast walking on postprandial blood glucose control in type 2 diabetes","Kenichi Deguchi, Tetsuya Enishi, Nori Sato, Hajime Miura, Yuichi Fujinaka, Munehide Matsuhisa, Shinsuke Katoh","Kenichi Deguchi, Tetsuya Enishi, Nori Sato, Hajime Miura, Yuichi Fujinaka, Munehide Matsuhisa, Shinsuke Katoh","null","null","null","null","null","2015-06","Diabetology International","Diabetology International","null","null","null","null","eng","true","null","scientific_journal","null","null","10.1007/s13340-015-0217-z","2190-1678","null","null","null","null","null" "インスリン治療による低血糖と日常生活への影響に関するアンケート調査","インスリン治療による低血糖と日常生活への影響に関するアンケート調査","寺内 康夫, 池田 勧夫, 弘世 貴久, 松久 宗英, 小田原 雅人","寺内 康夫, 池田 勧夫, 弘世 貴久, Munehide Matsuhisa, 小田原 雅人","null","null","null","null","null","2015-05","医学と薬学","Japanese Journal of Medicine and Pharmaceutical Science","Vol.72","No.6","1059","1074","jpn","true","null","scientific_journal","null","null","null","0389-3898","null","null","null","null","null" "Impact of newly developed, next-generation artificial endocrine pancreas","Impact of newly developed, next-generation artificial endocrine pancreas","Noriko Kambe, Shinji Kawahito, Naoji Mita, Kazumi Takaishi, Tosiko Katayama, Yoko Sakai, Tomohiro Soga, Hiroaki Kawano, Munehide Matsuhisa, Mitsuo Shimada, Tetsuya Kitagawa, Hiroshi Kitahata","Noriko Kambe, Shinji Kawahito, Naoji Mita, Kazumi Takaishi, Tosiko Katayama, Yoko Sakai, Tomohiro Soga, Hiroaki Kawano, Munehide Matsuhisa, Mitsuo Shimada, Tetsuya Kitagawa, Hiroshi Kitahata","null","Recent studies have shown that strict perioperative blood glucose management may reduce mortality and morbidity in critically ill adult patients. The purpose of this study was to assess the accuracy and efficacy of the intraoperative application of a newly developed, next-generation artificial endocrine pancreas (STG-55, Nikkiso Co., Ltd., Tokyo, Japan). Twenty patients scheduled to undergo surgery were enrolled in this study. The STG-55 is designed to be more user-friendly than its conventional counterpart (STG-22) while maintaining the latter's fundamental functions, such as a closed-loop system using algorithms for insulin and glucose infusion. After anesthetic induction, a 20G intravenous catheter was inserted into a peripheral forearm vein and connected to a continuous blood glucose monitor. The resultant 105 scores for paired blood glucose values were compared by Bland-Altman analysis. Stable blood glucose values were maintained automatically, and there were no complications related to use of the STG-55. A close correlation (r=0.96) was observed between continuous glucose measurements using the STG-55 and conventional intermittent glucose measurements. The difficulty of manipulation using this system was decreased by improved preparation procedures. The glycemic control system using the STG-55 could provide an alternative way to achieve effective and safe perioperative glycemic control.","Recent studies have shown that strict perioperative blood glucose management may reduce mortality and morbidity in critically ill adult patients. The purpose of this study was to assess the accuracy and efficacy of the intraoperative application of a newly developed, next-generation artificial endocrine pancreas (STG-55, Nikkiso Co., Ltd., Tokyo, Japan). Twenty patients scheduled to undergo surgery were enrolled in this study. The STG-55 is designed to be more user-friendly than its conventional counterpart (STG-22) while maintaining the latter's fundamental functions, such as a closed-loop system using algorithms for insulin and glucose infusion. After anesthetic induction, a 20G intravenous catheter was inserted into a peripheral forearm vein and connected to a continuous blood glucose monitor. The resultant 105 scores for paired blood glucose values were compared by Bland-Altman analysis. Stable blood glucose values were maintained automatically, and there were no complications related to use of the STG-55. A close correlation (r=0.96) was observed between continuous glucose measurements using the STG-55 and conventional intermittent glucose measurements. The difficulty of manipulation using this system was decreased by improved preparation procedures. The glycemic control system using the STG-55 could provide an alternative way to achieve effective and safe perioperative glycemic control.","null","null","2015-02","The Journal of Medical Investigation : JMI","The Journal of Medical Investigation : JMI","Vol.62","No.1-2","41","44","eng","true","null","scientific_journal","null","null","10.2152/jmi.62.41","1349-6867","null","null","null","null","null" "NFC通信歩数計を活用した健康データの可視化による生活習慣の行動変容","The Behavior Modification to the Lifestyle by Healthy Condition Visualization which Utilized NFC Communication Pedometer","田木 真和, 玉木 悠, 森川 富昭, 松久 宗英, 森口 博基","Masato Tagi, Yuu Tamaki, Tomiaki Morikawa, Munehide Matsuhisa, Hiroki Moriguchi","null","健康データの登録の自動化と可視化ができるシステムを利用することで,計測者が健康改善に向けての意識変化や行動変容が起こるかどうか,健康管理を継続することにより健康データに変化が起こるかどうかについて検証することを目的としている.日常の健康管理を行う際に体重や運動の記録が自動で登録・グラフ化できるように,PCとNFC通信歩数計・体組成計・血圧計などの健康機器を連携したシステムを構築した.このシステムを利用し,健康データを日々計測することによってデータの可視化を図り,計測者が健康改善に向けての行動変容が起きるかについて検証を行った.利用期間が1年を経過している企業3社226名の利用者について,2011年10月から2013年3月までに得られたデータで分析を行った.歩数計の計測を2013年3月まで継続し続けたのは167名(73.9%)となった.歩数は「1カ月∼3カ月」の平均と「4カ月∼6カ月」の平均を比べると,7,299±3,731歩から7,515±4,629歩(p=0.075)へと増加傾向があった.血圧は収縮期が129.2±13.2 mmHgから127.1±13.5 mmHg(p=0.028)へ有意に減少し,拡張期も78.6±9.8 mmHgから76.0±9.9 mmHg(p=0.00016)へと有意に減少しており,BMIについても,23.3±2.9 kg/m2から23.2±2.8 kg/m2(p=0.029)へと有意に減少していた.これらの結果より,システムを利用することで開始当初に健康データが改善し,その後も血圧に関しては継続効果が認められ,健康改善に向けての行動変容が生じたと考えられた.","To record individual body weight and physical activity has been shown to be beneficial for maintaining personal health. We, therefore, established a system which connects a personal computer and health appliances to record body weight, daily step, and blood pressure. We applied this system to 226 employees in 3 companies during the period of October, 2011-March, 2013 and evaluated whether this system could improve individual behavioral modification. One hundred sixty seven persons (73.9%) had continuously recorded the measurement of the pedometer for at least one year. We compared the average of the first three months with the average of the next three months. As a result, the number of steps tended to increase to 7,515±4,629 steps from 7,299±3,731steps (p=0.075). As for blood pressure, the systolic phase significantly decreased from 129.2±13.2 mmHg to 127.1±13.5 mmHg (p=0.028), and diastolic phase decreased from 78.6±9.8 mmHg to 76.0±9.9 mmHg (p=0.00016). BMI also significantly decreased from 23.3±2.9 kg/m2 to 23.2±2.8 kg/m2(p=0.029). In conclusion, to record daily step, body weight and blood pressure by using newly established system improved individual behavior towards a healthy condition.","null","null","2015-02","医療情報学","Japan Journal of Medical Informatics","Vol.34","No.6","281","291","jpn","true","null","scientific_journal","null","null","10.14948/jami.34.281","0289-8055","null","http://ci.nii.ac.jp/naid/130005148401/","null","null","null" "ICTを活用した徳島県糖尿病医療連携システムの構築 (多職種協働で支える高齢化社会 医療と介護の壁を破る)","Establishment of the Local Medical Care System for Diabetes Using by ICT Network in Tokushima","松久 宗英, 黒田 暁生, 玉木 悠","Munehide Matsuhisa, Akio Kuroda, Yuu Tamaki","null","null","null","null","null","2014","日本糖尿病情報学会誌 = Journal of the Japan Association of Diabetes Informatics","日本糖尿病情報学会誌 = Journal of the Japan Association of Diabetes Informatics","null","No.12","12","20","jpn","true","null","scientific_journal","null","null","null","null","null","null","null","null","null" "Short- and long-term effect of sitagliptin after near normalization of glycemic control with insulin in poorly controlled Japanese type 2 diabetic patients.","Short- and long-term effect of sitagliptin after near normalization of glycemic control with insulin in poorly controlled Japanese type 2 diabetic patients.","Keiko Fujisawa, Tetsuyuki Yasuda, Hideaki Kaneto, Naoto Katakami, Mayumi Tsuji, Fumiyo Kubo, Shugo Sasaki, Kazuyuki Miyashita, Toyoko Naka, Ryuuichi Kasami, Akio Kuroda, Munehide Matsuhisa, Iichiro Shimomura","Keiko Fujisawa, Tetsuyuki Yasuda, Hideaki Kaneto, Naoto Katakami, Mayumi Tsuji, Fumiyo Kubo, Shugo Sasaki, Kazuyuki Miyashita, Toyoko Naka, Ryuuichi Kasami, Akio Kuroda, Munehide Matsuhisa, Iichiro Shimomura","null","These findings suggest that near normalization of glycemic control with insulin improves the clinical response to sitagliptin in poorly controlled type 2 diabetic patients.","These findings suggest that near normalization of glycemic control with insulin improves the clinical response to sitagliptin in poorly controlled type 2 diabetic patients.","null","null","2014","Journal of Diabetes Investigation","Journal of Diabetes Investigation","Vol.5","No.5","548","553","eng","true","null","scientific_journal","null","null","10.1111/jdi.12176","2040-1116","null","null","null","null","null" "Vitamin D deficiency is significantly associated with retinopathy in young Japanese type 1 diabetic patients.","Vitamin D deficiency is significantly associated with retinopathy in young Japanese type 1 diabetic patients.","Naoki Shimo, Tetsuyuki Yasuda, Hideaki Kaneto, Naoto Katakami, Akio Kuroda, Fumie Sakamoto, Mitsuyoshi Takahara, Yoko Irie, Keiko Horikawa, Kazuyuki Miyashita, Takeshi Miyatsuka, Kazutomi Yoshiuchi, Dan Kawamori, Ken'ya Sakamoto, Taka-aki Matsuoka, Keisuke Kosugi, Iichiro Shimomura, Munehide Matsuhisa","Naoki Shimo, Tetsuyuki Yasuda, Hideaki Kaneto, Naoto Katakami, Akio Kuroda, Fumie Sakamoto, Mitsuyoshi Takahara, Yoko Irie, Keiko Horikawa, Kazuyuki Miyashita, Takeshi Miyatsuka, Kazutomi Yoshiuchi, Dan Kawamori, Ken'ya Sakamoto, Taka-aki Matsuoka, Keisuke Kosugi, Iichiro Shimomura, Munehide Matsuhisa","null","The aim of this study was to examine the possible association of vitamin D deficiency with diabetic retinopathy in 75 young Japanese type 1 diabetic patients. A multivariate regression analysis, duration of diabetes and vitamin D deficiency were independent determinants of diabetic retinopathy.","The aim of this study was to examine the possible association of vitamin D deficiency with diabetic retinopathy in 75 young Japanese type 1 diabetic patients. A multivariate regression analysis, duration of diabetes and vitamin D deficiency were independent determinants of diabetic retinopathy.","null","null","2014-08-12","Diabetes Research and Clinical Practice","Diabetes Research and Clinical Practice","Vol.106","No.2","e41","3","eng","true","null","scientific_journal","null","null","10.1016/j.diabres.2014.08.005","1872-8227","null","null","null","null","null" "Usefulness of artificial endocrine pancreas during resection of insulinoma.","Usefulness of artificial endocrine pancreas during resection of insulinoma.","Kayo Hirose, Shinji Kawahito, Naoji Mita, Kazumi Takaishi, Tomiya Kawahara, Tomohiro Soga, Toshiko Katayama, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Mitsuo Shimada, Munehide Matsuhisa, Hiroshi Kitahata","Kayo Hirose, Shinji Kawahito, Naoji Mita, Kazumi Takaishi, Tomiya Kawahara, Tomohiro Soga, Toshiko Katayama, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Mitsuo Shimada, Munehide Matsuhisa, Hiroshi Kitahata","null","A 71-year-old woman had an episode of syncope due to hypoglycemia of 27 mg/dl. She was diagnosed with insulinoma and scheduled for laparoscopic enucleation along with the use of an artificial endocrine pancreas (STG-22, Nikkiso Co., Ltd., Tokyo, Japan). Anesthesia was maintained with sevoflurane and remifentanil. Her blood glucose level was controlled using the artificial endocrine pancreas, which enabled continuous blood glucose monitoring and computer-operated glucose and insulin infusion to maintain the blood glucose level at a steady state. The target concentration of blood glucose was set at 80-120 mg/dl during surgery. Until removal of the tumor, the blood glucose level was kept at around 80-100 mg/dl. After removal of the tumor, the blood glucose level gradually increased, but it was kept in the normal range by the artificial endocrine pancreas. The artificial endocrine pancreas was useful to monitor and maintain blood glucose levels during and after the removal of insulinoma, without any hyper- or hypoglycemia. J. Med. Invest. 61: 421-425, August, 2014.","A 71-year-old woman had an episode of syncope due to hypoglycemia of 27 mg/dl. She was diagnosed with insulinoma and scheduled for laparoscopic enucleation along with the use of an artificial endocrine pancreas (STG-22, Nikkiso Co., Ltd., Tokyo, Japan). Anesthesia was maintained with sevoflurane and remifentanil. Her blood glucose level was controlled using the artificial endocrine pancreas, which enabled continuous blood glucose monitoring and computer-operated glucose and insulin infusion to maintain the blood glucose level at a steady state. The target concentration of blood glucose was set at 80-120 mg/dl during surgery. Until removal of the tumor, the blood glucose level was kept at around 80-100 mg/dl. After removal of the tumor, the blood glucose level gradually increased, but it was kept in the normal range by the artificial endocrine pancreas. The artificial endocrine pancreas was useful to monitor and maintain blood glucose levels during and after the removal of insulinoma, without any hyper- or hypoglycemia. J. Med. Invest. 61: 421-425, August, 2014.","null","null","2014-08","The Journal of Medical Investigation : JMI","The Journal of Medical Investigation : JMI","Vol.61","No.3-4","421","425","eng","true","null","scientific_journal","null","null","10.2152/jmi.61.421","1349-6867","null","null","null","null","null" "Ectopic fat accumulation and distant organ-specific insulin resistance in Japanese people with nonalcoholic fatty liver disease.","Ectopic fat accumulation and distant organ-specific insulin resistance in Japanese people with nonalcoholic fatty liver disease.","Ken-ichiro Kato, Toshinari Takamura, Yumie Takeshita, Yasuji Ryu, Hirofumi Misu, Tsuguhito Ota, Kumpei Tokuyama, Shoichiro Nagasaka, Munehide Matsuhisa, Osamu Matsui, Shuichi Kaneko","Ken-ichiro Kato, Toshinari Takamura, Yumie Takeshita, Yasuji Ryu, Hirofumi Misu, Tsuguhito Ota, Kumpei Tokuyama, Shoichiro Nagasaka, Munehide Matsuhisa, Osamu Matsui, Shuichi Kaneko","null","HGP × FPI was significantly correlated with Rd (r = -0.57, P<0.001), %HGP with %FFA (r = 0.38, P<0.01), and Rd with %FFA (r = 0.27, P<0.05). Liver steatosis score was negatively associated with Rd (r = -0.47, P<0.001) as well as with HGP × FPI (r = 0.43, P<0.001). Similarly, intrahepatic lipid was negatively associated with Rd (r = -0.32, P<0.05). IMCL was not associated with Rd (r = -0.16, P = 0.26). Fat mass and its percentage were associated with HGP × FPI (r = 0.50, P<0.001; r = 0.48, P<0.001, respectively) and Rd (r = -0.59, P<0.001; r = -0.52, P<0.001, respectively), but not with %FFA (r = -0.21, P = 0.10; r = -0.001, P = 0.99, respectively).","Unexpectedly, fat accumulation in the skeletal muscle and adipose tissue was not associated with organ-specific IR. Instead, liver fat was associated not only with hepatic IR but also with skeletal muscle IR, suggesting a central role of fatty liver in systemic IR and that a network exists between liver and skeletal muscle.","null","null","2014-03-20","PLoS ONE","PLoS ONE","Vol.9","No.3","e92170","e92170","eng","true","null","scientific_journal","null","null","10.1371/journal.pone.0092170","1932-6203","null","http://ci.nii.ac.jp/naid/120005440398/","null","null","null" "Effects of Pioglitazone on Macrovascular Events in Patients with Type 2 Diabetes Mellitus at High Risk of Stroke: The PROFIT-J Study.","Effects of Pioglitazone on Macrovascular Events in Patients with Type 2 Diabetes Mellitus at High Risk of Stroke: The PROFIT-J Study.","Hidenori Yoshii, Tomio Onuma, Tsutomu Yamazaki, Hirotaka Watada, Munehide Matsuhisa, Masayasu Matsumoto, Kazuo Kitagawa, Masafumi Kitakaze, Yoshimitsu Yamasaki, Ryuzo Kawamori","Hidenori Yoshii, Tomio Onuma, Tsutomu Yamazaki, Hirotaka Watada, Munehide Matsuhisa, Masayasu Matsumoto, Kazuo Kitagawa, Masafumi Kitakaze, Yoshimitsu Yamasaki, Ryuzo Kawamori","null","Aim: The present study evaluated the effects of pioglitazone treatment on the incidence of primary cardiovascular events in Japanese subjects with type 2 diabetes mellitus at high risk of stroke. Methods: A prospective, multicenter, randomized, open label, comparative study was conducted among diabetic patients recruited from 50 medical institutions nationwide. A total of 522 patients with hypertension and/or dyslipidemia who had one or more silent cerebral infarcts, advanced carotid atherosclerosis or microalbuminuria at baseline were randomly treated with (n=254) or without pioglitazone (n=268) and observed for a medium of 672 days. The hypertension and dyslipidemia were concurrently treated according to the respective treatment guidelines. The primary outcome was the time to the first occurrence of a composite of all-cause death, nonfatal cerebral infarction and nonfatal myocardial infarction. Results: Treatment with pioglitazone resulted in significant reductions in the levels of HbA1c, diastolic blood pressure and LDL-cholesterol and a significant increase in the levels of HDL-cholesterol. The pioglitazone non-users exhibited a significant reduction in the LDL-cholesterol levels alone. Primary events were registered during the study period in nine patients in the pioglitazone group and 10 patients in the non-pioglitazone group. The difference in the cumulative incidence of the primary outcome was not significant between the two groups(1.8% per year). Conclusions: Pioglitazone therapy produces immediate and effective improvements in glycemic control, diastolic blood pressure and lipid profiles. While this study was too underpowered to determine the effects of pioglitazone on the incidence of cardiovascular events, the results indicated that two years of pioglitazone treatment did not produce any statistically significant reductions in the rate of primary cardiovascular events.","Aim: The present study evaluated the effects of pioglitazone treatment on the incidence of primary cardiovascular events in Japanese subjects with type 2 diabetes mellitus at high risk of stroke. Methods: A prospective, multicenter, randomized, open label, comparative study was conducted among diabetic patients recruited from 50 medical institutions nationwide. A total of 522 patients with hypertension and/or dyslipidemia who had one or more silent cerebral infarcts, advanced carotid atherosclerosis or microalbuminuria at baseline were randomly treated with (n=254) or without pioglitazone (n=268) and observed for a medium of 672 days. The hypertension and dyslipidemia were concurrently treated according to the respective treatment guidelines. The primary outcome was the time to the first occurrence of a composite of all-cause death, nonfatal cerebral infarction and nonfatal myocardial infarction. Results: Treatment with pioglitazone resulted in significant reductions in the levels of HbA1c, diastolic blood pressure and LDL-cholesterol and a significant increase in the levels of HDL-cholesterol. The pioglitazone non-users exhibited a significant reduction in the LDL-cholesterol levels alone. Primary events were registered during the study period in nine patients in the pioglitazone group and 10 patients in the non-pioglitazone group. The difference in the cumulative incidence of the primary outcome was not significant between the two groups(1.8% per year). Conclusions: Pioglitazone therapy produces immediate and effective improvements in glycemic control, diastolic blood pressure and lipid profiles. While this study was too underpowered to determine the effects of pioglitazone on the incidence of cardiovascular events, the results indicated that two years of pioglitazone treatment did not produce any statistically significant reductions in the rate of primary cardiovascular events.","null","null","2014-01-29","Journal of Atherosclerosis and Thrombosis","Journal of Atherosclerosis and Thrombosis","Vol.21","No.6","563","573","eng","true","null","scientific_journal","null","null","10.5551/jat.21626","1880-3873","null","http://ci.nii.ac.jp/naid/130004444748/","null","null","null" "Diabetic conditions differentially affect the endothelial function, arterial stiffness and carotid atherosclerosis.","Diabetic conditions differentially affect the endothelial function, arterial stiffness and carotid atherosclerosis.","Mizuho Kinouchi, Ken-ichi Aihara, Yuichi Fujinaka, Sumiko Yoshida, Yukari Ooguro, Kiyoe Kurahashi, Takeshi Kondo, Nanako Aki, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Toshio Matsumoto","Mizuho Kinouchi, Ken-ichi Aihara, Yuichi Fujinaka, Sumiko Yoshida, Yukari Ooguro, Kiyoe Kurahashi, Takeshi Kondo, Nanako Aki, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Toshio Matsumoto","null","Aim: The levels of fasting and postprandial plasma glucose, HbA1c and other risk factors for atherosclerosis have distinct effects in patients with and those without diabetes mellitus. The aim of this study was to determine the impact of diabetic surrogate markers on the endothelial function, arterial stiffness and carotid atherosclerosis in individuals with and without diabetes. Methods: A total of 320 Japanese subjects(mean age: 61.2±12.1 years) were recruited in this study. Demographic, clinical and laboratory parameters, including 75 g OGTT(155 subjects) results, were examined. The endothelial function was evaluated according to the flow-mediated vasodilation of the brachial artery(%FMD). In addition, arterial stiffness was evaluated according to the brachial-ankle pulse wave velocity(baPWV), and carotid atherosclerotic changes were estimated according to the maximum intima-media thickness(max-IMT) and resistive index of the common carotid artery(CCA-RI). A multiple regression analysis was performed to identify independent determinants of these vascular surrogate markers. Results: None of the glucose-related parameters were associated with the %FMD. In contrast, the presence of T2DM, the HbA1c level and an increased plasma glucose level at 60 minutes during 75 g OGTT were associated with an increased baPWV. The HbA1c level was also correlated with an increased max-IMT. The fasting plasma glucose(FPG) level and the presence of T2DM correlated with an increased CCA-RI. In the subjects with T2DM, the protective effects of high-density lipoprotein cholesterol(HDL-C) on the %FMD and baPWV were abolished. Conclusions: Various glucose metabolism parameters have different effects the degree of arterial stiffness and presence of carotid atherosclerosis, but not the endothelial function, suggesting that pharmacological intervention has the potential to preserve the endothelial function in diabetic individuals. In addition, the presence of T2DM blunts the vascular protective effects of HDL-C on the endothelial function and progression of arterial stiffness.","Aim: The levels of fasting and postprandial plasma glucose, HbA1c and other risk factors for atherosclerosis have distinct effects in patients with and those without diabetes mellitus. The aim of this study was to determine the impact of diabetic surrogate markers on the endothelial function, arterial stiffness and carotid atherosclerosis in individuals with and without diabetes. Methods: A total of 320 Japanese subjects(mean age: 61.2±12.1 years) were recruited in this study. Demographic, clinical and laboratory parameters, including 75 g OGTT(155 subjects) results, were examined. The endothelial function was evaluated according to the flow-mediated vasodilation of the brachial artery(%FMD). In addition, arterial stiffness was evaluated according to the brachial-ankle pulse wave velocity(baPWV), and carotid atherosclerotic changes were estimated according to the maximum intima-media thickness(max-IMT) and resistive index of the common carotid artery(CCA-RI). A multiple regression analysis was performed to identify independent determinants of these vascular surrogate markers. Results: None of the glucose-related parameters were associated with the %FMD. In contrast, the presence of T2DM, the HbA1c level and an increased plasma glucose level at 60 minutes during 75 g OGTT were associated with an increased baPWV. The HbA1c level was also correlated with an increased max-IMT. The fasting plasma glucose(FPG) level and the presence of T2DM correlated with an increased CCA-RI. In the subjects with T2DM, the protective effects of high-density lipoprotein cholesterol(HDL-C) on the %FMD and baPWV were abolished. Conclusions: Various glucose metabolism parameters have different effects the degree of arterial stiffness and presence of carotid atherosclerosis, but not the endothelial function, suggesting that pharmacological intervention has the potential to preserve the endothelial function in diabetic individuals. In addition, the presence of T2DM blunts the vascular protective effects of HDL-C on the endothelial function and progression of arterial stiffness.","null","null","2014-01-08","Journal of Atherosclerosis and Thrombosis","Journal of Atherosclerosis and Thrombosis","Vol.21","No.5","486","500","eng","true","null","scientific_journal","null","null","10.5551/jat.20834","1880-3873","null","http://ci.nii.ac.jp/naid/130004444734/","null","null","null" "第7版食品交換表に基づいた炭水化物50~60%での主食以外の炭水化物含有量","Carbohydrate Content in Dishes Other than Staple Foods Based on the Food Exchange Lists (7th edition) Allowing for a 50-60 % Energy Intake from Carbohydrates","黒田 暁生, 丸山 千寿子, 松久 宗英","Akio Kuroda, 丸山 千寿子, Munehide Matsuhisa","null","null","null","null","null","2014","糖尿病","Journal of the The Japan Diabetes Society","Vol.57","No.12","921","922","jpn","true","null","scientific_journal","null","null","10.11213/tonyobyo.57.921","0021-437X","null","http://ci.nii.ac.jp/naid/130004905435/","null","null","null" "術前後で持続血糖モニター(CGM)を比較しえたアドレナリン優位褐色細胞腫の1例","Comparison of Continuous Glucose Monitoring (CGM) Values before and after Adrenalectomy in a Case of Adrenaline-producing Pheochromocytoma","近藤 剛史, 黒田 暁生, 曽我部 公子, 大黒 由加里, 倉橋 清衛, 田蒔 基行, 木内 美瑞穂, 吉田 守美子, 安芸 菜奈子, 遠藤 逸朗, 粟飯原 賢一, 藤中 雄一, 松久 宗英, 松本 俊夫","Takeshi Kondo, Akio Kuroda, 曽我部 公子, 大黒 由加里, 倉橋 清衛, Motoyuki Tamaki, Mizuho Kinouchi, Sumiko Yoshida, 安芸 菜奈子, Itsuro Endo, Ken-ichi Aihara, Yuichi Fujinaka, Munehide Matsuhisa, Toshio Matsumoto","null","症例は78歳女性.2012年1月,25 mm大の左副腎腫瘍,尿メタネフリン高値,MIBGシンチからアドレナリン優位型褐色細胞腫と診断され,5月当科を紹介された.罹病期間9年の糖尿病があり内服加療をうけるも2010年頃よりHbA1cは悪化し,初診時8.5 %で,褐色細胞腫の周術期管理および血糖管理目的で当科入院した.入院後速やかにインスリン導入を行い,目標血糖値に達した際の持続血糖モニター(以下CGMと略す)の標準偏差(SD)は54であった.腹腔鏡下腫瘍摘除後は,一日総インスリン量が術前50単位から術後14単位に減少し,術後CGMでSDが24に改善した.また退院時はグリメピリド0.5 mg,シタグリプチン50 mgで管理可能となった.本例は,家族歴がなくやせ型で術後の血糖管理の改善からアドレナリン過剰が術前の病態の中心と考えられた.","A 77-year-old woman was incidentally found to have a left adrenal mass measuring 2.5 cm in January 2012. The urine metanephrine concentration was 3.0 mg/day (normal range, 0.04-0.19 mg/day), and an iodine-131 metaiodobenzylguanidine (MIBG) scan showed uptake in the area of the left adrenal gland, leading to a diagnosis of pheochromocytoma. In addition, the patient had a history of diabetes mellitus for nine years, with gradually worsening blood glucose control since 2010. The patient was subsequently admitted to our hospital for perioperative care. On admission, her fasting blood glucose level was 121 mg/dl and her HbA1c level was 8.5 %. She was treated with basal-bolus insulin therapy during hospitalization and underwent adrenalectomy at the urology department after her glycemic control had improved. The total daily insulin dose was immediately decreased from 50 to 14 units after the adrenalectomy procedure. In addition, the mean glucose level on preoperative continuous glucose monitoring (CGM) had been 141 mg/dl with a standard deviation (SD) of 54. However, after the operation, the mean glucose level increased to 153 mg/dl while the SD decreased to 24; thus, the range of glycemic fluctuation markedly decreased after surgery. Therefore, excess endogenous adrenalin primarily contributed to the glycemic fluctuations observed in this patient with pheochromocytoma.","null","null","2014","糖尿病","Journal of the The Japan Diabetes Society","Vol.57","No.9","729","735","jpn","true","null","scientific_journal","null","null","10.11213/tonyobyo.57.729","0021-437X","null","http://ci.nii.ac.jp/naid/130004696304/","null","null","null" "日本先進糖尿病治療研究会によるCSⅡおよびCGMに関するステートメント","Consensus Statement on Continuous Subcutaneous Insulin Infusion and Continuous Glucose Monitoring","小林 哲郎, 難波 光義, 黒田 暁生, 松久 宗英, 山田 研太郎, 今村 洋一, 金重 勝博, 浜口 朋也, 川村 智行, 佐藤 譲, 高橋 和眞, 丸山 太郎, 西村 理明, 勝野 朋幸, 楠 宜樹, 清水 一紀, 柳澤 克之, 粟田 卓也, 雨宮 伸","小林 哲郎, 難波 光義, Akio Kuroda, Munehide Matsuhisa, 山田 研太郎, 今村 洋一, 金重 勝博, 浜口 朋也, 川村 智行, 佐藤 譲, 高橋 和眞, 丸山 太郎, 西村 理明, 勝野 朋幸, 楠 宜樹, 清水 一紀, 柳澤 克之, 粟田 卓也, 雨宮 伸","null","最近,持続インスリン皮下注入療法(Continuous subcutaneous insulin infusion:以下CSII)と持続血糖モニタリング(Continuous glucose monitoring:以下CGM)が糖尿病の治療機器として普及しつつある.我々はCSIIおよびCGMに関する科学的根拠をもとに,これをコンセンサスステートメントとしてまとめた.CSIIでは適応,臨床効果,リスク管理など,さらに,運用法の実際的な要点,シックデイ,妊娠,食事・運動などに関する注意などについて述べた.CGMに関してもその適応と効果,糖尿病治療への活用法,注意点を述べた.CSIIおよびCGMは1型糖尿病,2型糖尿病の一部や妊娠中の糖尿病症例にも重要な臨床機器であり,このステートメントをもとに内科および小児科領域の患者教育に適応できる具体的なガイドラインの作成が望まれる.","The use of continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) in clinical practice is increasing in Japan. Against this background, the Association for the Study of Innovative Diabetes Treatment in Japan (ASINDTJ) arranged a Consensus Statement of opinions for the optimal and safe routine use of CSII and CGM. The Consensus Statement on the routine use of CSII and CGM includes patient selection and indications for clinical outcomes as well as risk management for routine use. The development of patient educational programs conducted by diabetologists in association with certified diabetes educators (CDEs) regarding the use of pumps and/or CGM is a prerequisite for clinical use. In addition, items associated with CSII and CGM, such as insulin dose adjustment, application methods for use in daily life, diet and exercise, risk management of pump difficulties, "" sick day"" occasions and skin problems, are included in the Consensus Statement. Our consensus opinion and suggestions also emphasize the usefulness of CSII and CGM in adult diabetic patients as well as children with type 1 and type 2 diabetes and pregnant diabetic patients. According to the Consensus Statement, the development of detailed educational guidelines for the use of CSII and CGM is needed.","null","null","2014","糖尿病","Journal of the The Japan Diabetes Society","Vol.57","No.6","403","415","jpn","true","null","scientific_journal","null","null","10.11213/tonyobyo.57.403","0021-437X","null","http://ci.nii.ac.jp/naid/130004905446/","null","null","null" "糖尿病患者に対する血糖平坦化を目指したミグリトールとインスリン併用療法の有用性の検討ー血糖自己測定(SMBG)を用いた評価ー","Effectiveness of miglitol combined with various types of insulin therapy for reducing the daily glycemic fluctuation on Japanese type 2 diabetic patients: Evaluation with self-monitoring blood glucose (SMBG)","弘世 貴久, 渡邉 隆宏, 綿田 裕孝, 安孫子 亜津子, 羽田 勝計, 武部 典子, 佐藤 譲, 山口 賢, 石原 寿光, 前田 朝美, 江藤 一弘, 太田 明雄, 田中 逸, 武田 貞二, 駒津 光久, 卯木 智, 前川 聡, 伊藤 裕進, 能宗 伸輔, 廣峰 義久, 川畑 由美子, 池上 博司, 寺前 純吾, 花房 俊昭, 富永 貴元, 井上 康, 谷澤 幸生, 松本 俊夫, 黒田 暁生, 松久 宗英, 野見山 崇, 柳瀬 敏彦, 小林 邦久, 近藤 龍也, 荒木 栄一, 石井 則夫, 井形 元雄, 久木留 大介, 本島 寛之, 河盛 隆造","弘世 貴久, 渡邉 隆宏, 綿田 裕孝, 安孫子 亜津子, 羽田 勝計, 武部 典子, 佐藤 譲, 山口 賢, 石原 寿光, 前田 朝美, 江藤 一弘, 太田 明雄, 田中 逸, 武田 貞二, 駒津 光久, 卯木 智, 前川 聡, 伊藤 裕進, 能宗 伸輔, 廣峰 義久, 川畑 由美子, 池上 博司, 寺前 純吾, 花房 俊昭, 富永 貴元, 井上 康, 谷澤 幸生, Toshio Matsumoto, Akio Kuroda, Munehide Matsuhisa, 野見山 崇, 柳瀬 敏彦, 小林 邦久, 近藤 龍也, 荒木 栄一, 石井 則夫, 井形 元雄, 久木留 大介, 本島 寛之, 河盛 隆造","null","null","null","null","null","2013-12","Therapeutic Research","Therapeutic Research","Vol.34","No.12","1503","1511","jpn","true","null","scientific_journal","null","null","null","0289-8020","null","null","null","null","null" "Usefulness of a novel system for measuring glucose area under the curve while screening for glucose intolerance in outpatients.","Usefulness of a novel system for measuring glucose area under the curve while screening for glucose intolerance in outpatients.","Kenya Sakamoto, Fumiyo Kubo, Kazutomi Yoshiuchi, Akemi Ono, Toshiyuki Sato, Koji Tomita, Kazuhiko Sakaguchi, Munehide Matsuhisa, Hideaki Kaneto, Hiroshi Maegawa, Hiromu Nakajima, Atsunori Kashiwagi, Keisuke Kosugi","Kenya Sakamoto, Fumiyo Kubo, Kazutomi Yoshiuchi, Akemi Ono, Toshiyuki Sato, Koji Tomita, Kazuhiko Sakaguchi, Munehide Matsuhisa, Hideaki Kaneto, Hiroshi Maegawa, Hiromu Nakajima, Atsunori Kashiwagi, Keisuke Kosugi","null","Good correlation between MIET-predicted and reference AUCs obtained using PG levels was confirmed for a wide AUC range. By introducing a threshold level for AUC to separate glucose intolerance with peak glucose ≥180 mg/dL from normal glucose tolerance, the system was demonstrated to provide better screening accuracy compared with conventional methods that use HbA1c and fasting PG levels. The results of a questionnaire-based survey administered to the subjects suggested that this system was readily accepted by the majority as a painless monitoring method.","The findings suggest that our glucose AUC measurement system using MIET would be useful for screening of glucose intolerance. In the future, this system may prove to be a useful aid as a screen for glucose intolerance before performing an OGTT for diagnosis.","null","null","2013-05-08","Journal of Diabetes Investigation","Journal of Diabetes Investigation","Vol.4","No.6","552","559","eng","true","null","scientific_journal","null","null","10.1111/jdi.12096","2040-1116","null","null","null","null","null" "Evaluation of a minimally invasive system for measuring glucose area under the curve during oral glucose tolerance tests: usefulness of sweat monitoring for precise measurement.","Evaluation of a minimally invasive system for measuring glucose area under the curve during oral glucose tolerance tests: usefulness of sweat monitoring for precise measurement.","Kazuhiko Sakaguchi, Yushi Hirota, Naoko Hashimoto, Wataru Ogawa, Tomoya Hamaguchi, Toshihiro Matsuo, Jun-ichiro Miyagawa, Mitsuyoshi Namba, Toshiyuki Sato, Seiki Okada, Koji Tomita, Munehide Matsuhisa, Hideaki Kaneto, Keisuke Kosugi, Hiroshi Maegawa, Hiromu Nakajima, Atsunori Kashiwagi","Kazuhiko Sakaguchi, Yushi Hirota, Naoko Hashimoto, Wataru Ogawa, Tomoya Hamaguchi, Toshihiro Matsuo, Jun-ichiro Miyagawa, Mitsuyoshi Namba, Toshiyuki Sato, Seiki Okada, Koji Tomita, Munehide Matsuhisa, Hideaki Kaneto, Keisuke Kosugi, Hiroshi Maegawa, Hiromu Nakajima, Atsunori Kashiwagi","null","We confirmed the effectiveness of a sweat monitoring patch for precise AUC measurement using MIET. This novel, easy-to-use system has potential for glucose excursion evaluation in daily clinical practice.","We confirmed the effectiveness of a sweat monitoring patch for precise AUC measurement using MIET. This novel, easy-to-use system has potential for glucose excursion evaluation in daily clinical practice.","null","null","2013-05-01","Journal of Diabetes Science and Technology","Journal of Diabetes Science and Technology","Vol.7","No.3","678","688","eng","true","null","scientific_journal","null","null","10.1177/193229681300700313","1932-2968","null","null","null","null","null" "A Case of Hypocalcemia with Severe Vitamin D Deficiency following Treatment for Graves' Disease with Methimazole.","A Case of Hypocalcemia with Severe Vitamin D Deficiency following Treatment for Graves' Disease with Methimazole.","Kazuyuki Miyashita, Tetsuyuki Yasuda, Hideaki Kaneto, Akio Kuroda, Tetsuhiro Kitamura, Michio Otsuki, Yasuyuki Okamoto, Noboru Hamada, Munehide Matsuhisa, Iichiro Shimomura","Kazuyuki Miyashita, Tetsuyuki Yasuda, Hideaki Kaneto, Akio Kuroda, Tetsuhiro Kitamura, Michio Otsuki, Yasuyuki Okamoto, Noboru Hamada, Munehide Matsuhisa, Iichiro Shimomura","null","We herein report the case of a 41-year-old Japanese female office worker who developed symptomatic hypocalcemia with severe vitamin D deficiency following treatment for Graves' disease with methimazole. The patient's hypocalcemia was mainly caused by vitamin D deficiency due to unbalanced diets and inadequate exposure to sunlight in addition to the resolution of hyperthyroidism. Vitamin D deficiency is increasing worldwide, and it has been more recently shown to relate to the pathogenesis of Graves' disease. However, vitamin D deficiency as a cause of hypocalcemia has received little attention. Taken together, this case suggests that we should take more care in calcium kinetics and vitamin D status during treatment for Graves' disease with antithyroid drugs.","We herein report the case of a 41-year-old Japanese female office worker who developed symptomatic hypocalcemia with severe vitamin D deficiency following treatment for Graves' disease with methimazole. The patient's hypocalcemia was mainly caused by vitamin D deficiency due to unbalanced diets and inadequate exposure to sunlight in addition to the resolution of hyperthyroidism. Vitamin D deficiency is increasing worldwide, and it has been more recently shown to relate to the pathogenesis of Graves' disease. However, vitamin D deficiency as a cause of hypocalcemia has received little attention. Taken together, this case suggests that we should take more care in calcium kinetics and vitamin D status during treatment for Graves' disease with antithyroid drugs.","null","null","2013-04-24","Case Reports in Endocrinology","Case Reports in Endocrinology","Vol.2013","null","null","null","eng","true","null","scientific_journal","null","null","10.1155/2013/512671","2090-6501","null","null","null","null","null" "新たなインスリンポンプParadigm 722によりカーボカウントのみで血糖管理が可能となった1型糖尿病の1例","The New Paradigm 722 Insulin Pump Can Achieve Good Glycemic Control with Carbohydrate Counting Alone : A Case Report of Type 1 Diabetes Mellitus","吉田 守美子, 黒田 暁生, 新居 沙央里, 松本 友里, 近藤 絵里, 安藝 菜奈子, 遠藤 逸朗, 粟飯原 賢一, 鈴木 麗子, 松本 俊夫, 松久 宗英","Sumiko Yoshida, Akio Kuroda, 新居 沙央里, 松本 友里, 近藤 絵里, 安藝 菜奈子, Itsuro Endo, Ken-ichi Aihara, 鈴木 麗子, Toshio Matsumoto, Munehide Matsuhisa","null","インスリンポンプParadigm712は,インスリン作用時間(AIT)が8時間の設定のため,十分な食後血糖補正インスリン投与を提案しないが,新しいParadigm 722はAITを2~8時間に設定できる.そこで,Paradigm 722の食後血糖補正インスリン量の妥当性を検証した.症例は1型糖尿病の50歳代女性.入院の上インスリンリスプロでParadigm 722を導入,食事スキップで基礎インスリンを設定し,糖質/インスリン比を各食前(11,15,13)g/Uとしたカーボカウントのもと,AITを3時間,インスリン効果値を60mg/dl/Uと設定した.退院前1週間の食後2時間血糖補正の際,150mg/dlを目標にインスリン効果値を用いた補正による自己算出インスリン量とポンプでの自動算出インスリン量とを比較した.食後高血糖に対する補正インスリンは,14回中7回で自己算出量よりも自動算出量が適切であった.Paradigm 722による食後補正インスリン自動算出法は,自己算出法と同等で,これを用いることで良好な血糖管理が簡便になった.(著者抄録)","インスリンポンプParadigm712は,インスリン作用時間(AIT)が8時間の設定のため,十分な食後血糖補正インスリン投与を提案しないが,新しいParadigm 722はAITを2~8時間に設定できる.そこで,Paradigm 722の食後血糖補正インスリン量の妥当性を検証した.症例は1型糖尿病の50歳代女性.入院の上インスリンリスプロでParadigm 722を導入,食事スキップで基礎インスリンを設定し,糖質/インスリン比を各食前(11,15,13)g/Uとしたカーボカウントのもと,AITを3時間,インスリン効果値を60mg/dl/Uと設定した.退院前1週間の食後2時間血糖補正の際,150mg/dlを目標にインスリン効果値を用いた補正による自己算出インスリン量とポンプでの自動算出インスリン量とを比較した.食後高血糖に対する補正インスリンは,14回中7回で自己算出量よりも自動算出量が適切であった.Paradigm 722による食後補正インスリン自動算出法は,自己算出法と同等で,これを用いることで良好な血糖管理が簡便になった.(著者抄録)","null","null","2013-04","糖尿病","Journal of the The Japan Diabetes Society","Vol.56","No.4","240","245","jpn","true","null","scientific_journal","null","null","10.11213/tonyobyo.56.240","0021-437X","null","http://ci.nii.ac.jp/naid/40019683974/","null","null","null" "Outcomes of 6 years of activities by the Tokushima Medical Associations Steering Committee for Diabetes prevention to prevent type 2 diabetes in the general population of Tokushima Prefecture.","Outcomes of 6 years of activities by the Tokushima Medical Associations Steering Committee for Diabetes prevention to prevent type 2 diabetes in the general population of Tokushima Prefecture.","K Shima, H Ishimoto, N Hari, Y Shintani, Y Fukushima, Y Noma, Munehide Matsuhisa, A Otsuka, M Saito, I Imoto, T Okabe, Y Nakagawa, H Fujiwara, Y Fujinaka, M Sei, A Shirakami, M Komatsu, M Tsuruo, K Matsumoto, T Tanaka, M Miyamoto, H Ogawa, Y Furuta","K Shima, H Ishimoto, N Hari, Y Shintani, Y Fukushima, Y Noma, Munehide Matsuhisa, A Otsuka, M Saito, I Imoto, T Okabe, Y Nakagawa, H Fujiwara, Y Fujinaka, M Sei, A Shirakami, M Komatsu, M Tsuruo, K Matsumoto, T Tanaka, M Miyamoto, H Ogawa, Y Furuta","null","null","null","null","null","2013-03","Diabetology International","Diabetology International","Vol.4","No.1","23","33","eng","true","null","scientific_journal","null","null","10.1007/s13340-012-0089-4","2190-1678","null","null","null","null","null" "Plasma pentraxin 3 levels are associated with carotid IMT in type 1 diabetic patients.","Plasma pentraxin 3 levels are associated with carotid IMT in type 1 diabetic patients.","Naoto Katakami, Hideaki Kaneto, Fumie Sakamoto, Mitsuyoshi Takahara, Yoko Irie, Keiko Fujisawa, Kazuyuki Miyashita, Tetsuyuki Yasuda, Taka-Aki Matsuoka, Kazutomi Yoshiuchi, Ken'ya Sakamoto, Akio Kuroda, Munehide Matsuhisa, Keisuke Kosugi, Iichiro Shimomura","Naoto Katakami, Hideaki Kaneto, Fumie Sakamoto, Mitsuyoshi Takahara, Yoko Irie, Keiko Fujisawa, Kazuyuki Miyashita, Tetsuyuki Yasuda, Taka-Aki Matsuoka, Kazutomi Yoshiuchi, Ken'ya Sakamoto, Akio Kuroda, Munehide Matsuhisa, Keisuke Kosugi, Iichiro Shimomura","null","AIMS: Pentraxin3 (PTX3), a recently discovered inflammatory mediator, is produced abundantly in various cells in atherosclerotic lesions, and therefore, its plasma level could reflect local inflammation at the site of atherosclerotic lesion. The present study evaluated whether plasma PTX3 levels are associated with subclinical atherosclerosis in young subjects with type 1 diabetes. METHODS: Plasma PTX3 levels, urinary albumin excretion, diabetic retinopathy, and carotid intima-media thickness (IMT) were examined in 78 Japanese type 1 diabetic patients (30 men and 48 women, aged 28.5±5.3 years (±SD), duration of diabetes 19.7±6.5 years). RESULTS: There was statistically significant association between plasma PTX3 levels and Max-IMT (r=0.363, p=0.001). A stepwise multivariate regression analysis including conventional coronary risk factors as independent variables revealed that plasma PTX3 levels (=0.389, p<0.001), duration of diabetes (=0.256, p=0.035), and serum triglyceride levels (=0.371, p<0.001) were independent determinants of Max-IMT. In addition, plasma PTX3 levels was an independent determinant of urinary albumin excretion, an indicator of diabetic nephropathy (=0.258, p=0.018). However, there was no significant association between plasma PTX3 levels and diabetic retinopathy. CONCLUSIONS: Increased levels of plasma PTX3 are associated with accelerated atherosclerotic change and increased albuminuria in young patients with type 1 diabetes.","AIMS: Pentraxin3 (PTX3), a recently discovered inflammatory mediator, is produced abundantly in various cells in atherosclerotic lesions, and therefore, its plasma level could reflect local inflammation at the site of atherosclerotic lesion. The present study evaluated whether plasma PTX3 levels are associated with subclinical atherosclerosis in young subjects with type 1 diabetes. METHODS: Plasma PTX3 levels, urinary albumin excretion, diabetic retinopathy, and carotid intima-media thickness (IMT) were examined in 78 Japanese type 1 diabetic patients (30 men and 48 women, aged 28.5±5.3 years (±SD), duration of diabetes 19.7±6.5 years). RESULTS: There was statistically significant association between plasma PTX3 levels and Max-IMT (r=0.363, p=0.001). A stepwise multivariate regression analysis including conventional coronary risk factors as independent variables revealed that plasma PTX3 levels (=0.389, p<0.001), duration of diabetes (=0.256, p=0.035), and serum triglyceride levels (=0.371, p<0.001) were independent determinants of Max-IMT. In addition, plasma PTX3 levels was an independent determinant of urinary albumin excretion, an indicator of diabetic nephropathy (=0.258, p=0.018). However, there was no significant association between plasma PTX3 levels and diabetic retinopathy. CONCLUSIONS: Increased levels of plasma PTX3 are associated with accelerated atherosclerotic change and increased albuminuria in young patients with type 1 diabetes.","null","null","2013-02","Diabetes Research and Clinical Practice","Diabetes Research and Clinical Practice","Vol.99","No.2","185","91","eng","true","null","scientific_journal","null","null","10.1016/j.diabres.2012.11.020","1872-8227","null","null","null","null","null" "Regular insulin, rather than rapid-acting insulin, is a suitable choice for premeal bolus insulin in lean patients with type 2 diabetes mellitus.","Regular insulin, rather than rapid-acting insulin, is a suitable choice for premeal bolus insulin in lean patients with type 2 diabetes mellitus.","Akio Kuroda, Hideaki Kaneto, Satoshi Kawashima, Kenya Sakamoto, Mitsuyoshi Takahara, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Naoto Katakami, Taka-Aki Matsuoka, Iichiro Shimomura, Munehide Matsuhisa","Akio Kuroda, Hideaki Kaneto, Satoshi Kawashima, Kenya Sakamoto, Mitsuyoshi Takahara, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Naoto Katakami, Taka-Aki Matsuoka, Iichiro Shimomura, Munehide Matsuhisa","null","The aim of the present study was to compare the usefulness of premeal rapid-acting and regular insulin in type 2 diabetes patients. A total of 56 type 2 diabetic patients were investigated during hospitalization. Premeal rapid-acting insulin was applied instead of other medications. Premeal insulin was titrated to adjust premeal and bedtime blood glucose levels to 81-120 mg/dL. Premeal rapid-acting insulin was changed to regular insulin just before a meal at the same dosage if the postmeal blood glucose level was lower than the premeal blood glucose level. A total of 15 patients changed to regular insulin, and 41 patients continued rapid-acting insulin. The blood glucose level was comparable between these two groups. Body mass index was significantly lower in the patients using regular insulin. According to the multivariate logistic regression analysis, low body mass index was an independent variable accounting for the usefulness of regular insulin. Regular insulin, rather than rapid-acting insulin, is a suitable choice for premeal insulin in lean type 2 diabetic patients.","The aim of the present study was to compare the usefulness of premeal rapid-acting and regular insulin in type 2 diabetes patients. A total of 56 type 2 diabetic patients were investigated during hospitalization. Premeal rapid-acting insulin was applied instead of other medications. Premeal insulin was titrated to adjust premeal and bedtime blood glucose levels to 81-120 mg/dL. Premeal rapid-acting insulin was changed to regular insulin just before a meal at the same dosage if the postmeal blood glucose level was lower than the premeal blood glucose level. A total of 15 patients changed to regular insulin, and 41 patients continued rapid-acting insulin. The blood glucose level was comparable between these two groups. Body mass index was significantly lower in the patients using regular insulin. According to the multivariate logistic regression analysis, low body mass index was an independent variable accounting for the usefulness of regular insulin. Regular insulin, rather than rapid-acting insulin, is a suitable choice for premeal insulin in lean type 2 diabetic patients.","null","null","2013-01","Journal of Diabetes Investigation","Journal of Diabetes Investigation","Vol.4","No.1","78","81","eng","true","null","scientific_journal","null","null","10.1111/j.2040-1124.2012.00231.x","2040-1116","null","null","null","null","null" "Association of serum YKL-40 levels with urinary albumin excretion rate in young Japanese patients with type 1 diabetes mellitus.","Association of serum YKL-40 levels with urinary albumin excretion rate in young Japanese patients with type 1 diabetes mellitus.","Fumie Sakamoto, Naoto Katakami, Hideaki Kaneto, Tetsuyuki Yasuda, Mitsuyoshi Takahara, Kazuyuki Miyashita, Akio Kuroda, Munehide Matsuhisa, Keisuke Kosugi, Iichiro Shimomura","Fumie Sakamoto, Naoto Katakami, Hideaki Kaneto, Tetsuyuki Yasuda, Mitsuyoshi Takahara, Kazuyuki Miyashita, Akio Kuroda, Munehide Matsuhisa, Keisuke Kosugi, Iichiro Shimomura","null","YKL-40 is a marker of inflammation and endothelial dysfunction, both of which play important roles in the progression of diabetic complications. However, little information has been obtained about serum YKL-40 levels in type 1 diabetic patients. We evaluated YKL-40 levels and its association with diabetic micro- and macroandgiopathy in 131 young Japanese type 1 diabetic patients without advanced diabetic complications (aged 24.7±5.9 years) and 97 age- and gender-matched healthy controls. YKL-40 levels were significantly elevated in type 1 diabetic patients than in healthy controls (median (range) 46.4 (20.3-136.7) and 52.3 (21.4-274.1) ng/ml, respectively, p = 0.006). There was a significant positive association between YKL-40 levels and urinary albumin creatinine ratio (UACR) (r = 0.226, p = 0.013). Furthermore, a multivariate regression analysis demonstrated that YKL-40 levels were a determinant of UACR independently of conventional risk factors. In addition, YKL-40 levels were significantly higher in participants with diabetic retinopathy compared to those without it (median (range) 55.5 (23.3-274.1) and 50.3 (21.4-237.4) ng/ml, respectively, p = 0.039). Serum YKL-40 levels were elevated in type 1 diabetic patients and associated with increasing level of albuminuria. YKL-40 could be a predictor to assess the risk of diabetic microangiopathy in the early stage in type 1 diabetic patients.","YKL-40 is a marker of inflammation and endothelial dysfunction, both of which play important roles in the progression of diabetic complications. However, little information has been obtained about serum YKL-40 levels in type 1 diabetic patients. We evaluated YKL-40 levels and its association with diabetic micro- and macroandgiopathy in 131 young Japanese type 1 diabetic patients without advanced diabetic complications (aged 24.7±5.9 years) and 97 age- and gender-matched healthy controls. YKL-40 levels were significantly elevated in type 1 diabetic patients than in healthy controls (median (range) 46.4 (20.3-136.7) and 52.3 (21.4-274.1) ng/ml, respectively, p = 0.006). There was a significant positive association between YKL-40 levels and urinary albumin creatinine ratio (UACR) (r = 0.226, p = 0.013). Furthermore, a multivariate regression analysis demonstrated that YKL-40 levels were a determinant of UACR independently of conventional risk factors. In addition, YKL-40 levels were significantly higher in participants with diabetic retinopathy compared to those without it (median (range) 55.5 (23.3-274.1) and 50.3 (21.4-237.4) ng/ml, respectively, p = 0.039). Serum YKL-40 levels were elevated in type 1 diabetic patients and associated with increasing level of albuminuria. YKL-40 could be a predictor to assess the risk of diabetic microangiopathy in the early stage in type 1 diabetic patients.","null","null","2013-01","Endocrine Journal","Endocrine Journal","Vol.60","No.1","73","79","eng","true","null","scientific_journal","null","null","10.1507/endocrj.EJ12-0238","1348-4540","null","null","null","null","null" "Basal insulin requirements after progesterone treatment in a type 1 diabetic pregnant woman.","Basal insulin requirements after progesterone treatment in a type 1 diabetic pregnant woman.","Shugo Sasaki, Tetsuyuki Yasuda, Hideaki Kaneto, Akio Kuroda, Yukari Fujita, Keiko Fujisawa, Yukiko Tabuchi, Ryuichi Kasami, Taka-Aki Matsuoka, Munehide Matsuhisa, Iichiro Shimomura","Shugo Sasaki, Tetsuyuki Yasuda, Hideaki Kaneto, Akio Kuroda, Yukari Fujita, Keiko Fujisawa, Yukiko Tabuchi, Ryuichi Kasami, Taka-Aki Matsuoka, Munehide Matsuhisa, Iichiro Shimomura","null","We herein report the case of a 37-year-old type 1 diabetic pregnant woman treated with an insulin pump. Although the patient's glycemic control deteriorated following progesterone treatment for the prevention of preterm delivery and miscarriage, it was improved by adjusting the basal insulin rate on the days of progesterone treatment. Excess progesterone is known to impair both insulin sensitivity and secretion. The present case is the first report to evaluate deterioration of glycemic control induced by progesterone treatment and to determine the dose of insulin required in a type 1 diabetic pregnant woman whose insulin secretion was completely depleted.","We herein report the case of a 37-year-old type 1 diabetic pregnant woman treated with an insulin pump. Although the patient's glycemic control deteriorated following progesterone treatment for the prevention of preterm delivery and miscarriage, it was improved by adjusting the basal insulin rate on the days of progesterone treatment. Excess progesterone is known to impair both insulin sensitivity and secretion. The present case is the first report to evaluate deterioration of glycemic control induced by progesterone treatment and to determine the dose of insulin required in a type 1 diabetic pregnant woman whose insulin secretion was completely depleted.","null","null","2013-01-15","Internal Medicine","Internal Medicine","Vol.52","No.2","259","262","eng","true","null","scientific_journal","null","null","10.2169/internalmedicine.52.8675","1349-7235","null","null","null","null","null" "Usefulness of continuous blood glucose monitoring and control for patients undergoing liver transplantation.","Usefulness of continuous blood glucose monitoring and control for patients undergoing liver transplantation.","Tsuyoshi Okada, Shinji Kawahito, Naoji Mita, Munehide Matsuhisa, Hiroshi Kitahata, Mitsuo Shimada, Shuzo Oshita","Tsuyoshi Okada, Shinji Kawahito, Naoji Mita, Munehide Matsuhisa, Hiroshi Kitahata, Mitsuo Shimada, Shuzo Oshita","null","The STG-22 closed-loop system is effective for maintaining strict blood glucose control during liver transplantation with minimal variability in blood glucose concentration.","The STG-22 closed-loop system is effective for maintaining strict blood glucose control during liver transplantation with minimal variability in blood glucose concentration.","null","null","2013","The Journal of Medical Investigation : JMI","The Journal of Medical Investigation : JMI","Vol.60","No.3-4","205","212","eng","true","null","scientific_journal","null","null","10.2152/jmi.60.205","1349-6867","null","null","null","null","null" "小学校給食の副食に含まれる糖質量の検討","Evaluation of the Sugar Content in the Side Dishes Served in Elementary School Lunches","山口 美輪, 黒田 暁生, 小谷 裕美子, 松村 晃子, 釜野 桜子, 上村 浩一, 横田 一郎, 香美 祥二, 有澤 孝吉, 松久 宗英","Miwa Yamaguchi, Akio Kuroda, Yumiko Kotani, Akiko Matsumura, Sakurako Kamano, Hirokazu Uemura, Ichiro Yokota, Shoji Kagami, Kokichi Arisawa, Munehide Matsuhisa","null","「食品交換表に基づく新たなカーボカウント法」(黒田ら,糖尿病2010)に基づいて糖尿病食1食に含まれる糖質量を算出する場合,1食を主食と副食にわけ,副食は一律20 gと概算する.しかし,小児期は必要エネルギー量や栄養素バランスが食品交換表とは異なる.よって本研究では,小児期の副食糖質量を検討することを目的とした.学校給食摂取基準に基づく学校給食42食分を小学校の学年別に検討した.その結果,1食のエネルギーは670±44∼752±50(平均値±標準偏差)kcalと学年が上がるに従い増加したが,副食糖質量は29.7±7.5∼31.2±8.1 gであり,エネルギー量にかかわらず副食糖質量を約30 gに概算できた.学校給食では糖質約10 gの牛乳が毎食提供されるため糖尿病食や病院普通食に比較して副食糖質量が10 g増加すると考えられた.以上より,小学校給食では副食糖質量を30 gとしてカーボカウントを指導できることが明らかとなった.Development of highly sensitive enzyme immunoassay (ICT-EIA) for IA-2 autoantibody and application for detection of three islet-specific autoantibodies ( GADA, IA-2A and IAA) in type I diabetes mellitus Tomoharu Kawano, Satoshi Numata, Yuki Fujimoto, Akio Kuroda, Tetsuyuki Yasuda,Kazuyuki Miyashita, Fumie Sakamoto, Naoto Katakami, Taka-aki Matsuoka, Munehide Matsuhisa and Seiichi Hashida Summary Detection of pancreatic islet-related autoantibodies( insulin antibody [IAA]; glutamic acid decarboxylase antibody [GADA]; and islet antigen-2 antibody [IA-2A], is essential for the diagnosis and prediction of the onset of type I diabetes mellitus. Depending on the disease duration, the detection rate of each autoantibody is different, and using only one kind of autoantibody detection risks overlooking a positive result. The detection precision of type I diabetes mellitus would thus be improved by measuring all three kinds of autoantibodies. We developed a highly sensitive enzyme immunoassay( ICT-EIA) for IA-2 autoantibody. ICT-EIAs for IAA and GADA have already been developed. Using three ICT-EIAs, we attempted to measure autoantibodies in sera from patients with type I diabetes mellitus. Patients comprised 25 males and 51 females( mean age, 33.3±5.7 years; disease duration, 23.9±6.7 years) with type I diabetes mellitus who had been undergoing treatment with insulin for between 11 and 40 years. Among these patients, urinary C-peptide-positive results were seen in three patients. IAA, GADA and IA-2A in sera were measured by ICT-EIA. The newly developed ICT-EIA for IA-2 antibodies was approximately 100-times more sensitive than the conventional ELISA. The positive ratio was 77.6%, representing a high rate of detection. In addition, even in patients with a disease duration >30 years, the positive rate was 64.3%. ICT-EIA was thus suggested to be useful in combination assays for pancreatic islet-related autoantibodies (IAA, GADA and IA-2A).
","
Development of highly sensitive enzyme immunoassay (ICT-EIA) for IA-2 autoantibody and application for detection of three islet-specific autoantibodies ( GADA, IA-2A and IAA) in type I diabetes mellitus Tomoharu Kawano, Satoshi Numata, Yuki Fujimoto, Akio Kuroda, Tetsuyuki Yasuda,Kazuyuki Miyashita, Fumie Sakamoto, Naoto Katakami, Taka-aki Matsuoka, Munehide Matsuhisa and Seiichi Hashida Summary Detection of pancreatic islet-related autoantibodies( insulin antibody [IAA]; glutamic acid decarboxylase antibody [GADA]; and islet antigen-2 antibody [IA-2A], is essential for the diagnosis and prediction of the onset of type I diabetes mellitus. Depending on the disease duration, the detection rate of each autoantibody is different, and using only one kind of autoantibody detection risks overlooking a positive result. The detection precision of type I diabetes mellitus would thus be improved by measuring all three kinds of autoantibodies. We developed a highly sensitive enzyme immunoassay( ICT-EIA) for IA-2 autoantibody. ICT-EIAs for IAA and GADA have already been developed. Using three ICT-EIAs, we attempted to measure autoantibodies in sera from patients with type I diabetes mellitus. Patients comprised 25 males and 51 females( mean age, 33.3±5.7 years; disease duration, 23.9±6.7 years) with type I diabetes mellitus who had been undergoing treatment with insulin for between 11 and 40 years. Among these patients, urinary C-peptide-positive results were seen in three patients. IAA, GADA and IA-2A in sera were measured by ICT-EIA. The newly developed ICT-EIA for IA-2 antibodies was approximately 100-times more sensitive than the conventional ELISA. The positive ratio was 77.6%, representing a high rate of detection. In addition, even in patients with a disease duration >30 years, the positive rate was 64.3%. ICT-EIA was thus suggested to be useful in combination assays for pancreatic islet-related autoantibodies (IAA, GADA and IA-2A).
","null","null","2018-09","徳島文理大学研究紀要","Research bulletin of Tokushima Bunri University","Vol.96","null","35","44","jpn","null","null","research_institution","null","null","10.24596/tokusimabunriu.96.0_35","0286-9829","null","https://ci.nii.ac.jp/naid/130007602165/","null","null","null"